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Acute myeloid leukemia (AML) cells rely on phospho-signaling pathways to gain 
unlimited proliferation potential. A tightly regulated balance between phosphorylation and 
dephosphorylation, sustained by coordinated and competing activities of phosphatases and 
kinases, lies at the basis of cellular signaling. Given the advances of the past two decades in 
designing potent and selective inhibitors against phosphatases and kinases, these phospho-
signaling enzymes present some of the priority targets in AML.  
Here, we used domain-focused CRISPR screening to identify the nuclear 
phosphatase SCP4 as a dependency in AML. We provide evidence that this enzyme is likely 
dispensable in normal hematopoietic progenitor cells and could constitute a novel 
therapeutic target in leukemia. Using CRISPR exon scanning and gene complementation 
assays, we showed that the catalytic function of SCP4 was essential in AML. Our work, for 
the first time, elucidates a link between SCP4 and human cancer and provides a context for a 
deeper understanding of the molecular functions of this poorly studied phosphatase. 
Through mass spectrometry analysis of the SCP4 interactome, we identify the kinase 
paralogs STK35 and PDIK1L as binding partners and substrates of the SCP4 phosphatase 
domain. STK35/PDIK1L signaling roles and biochemical interactions are largely unknown, 
and this study sheds light on their involvement in leukemogenesis. We showed that STK35 
and PDIK1L catalytic activity was required in AML. Moreover, these kinases function 
redundantly in the same pathway as SCP4 to maintain leukemia cell proliferation.  
We found that SCP4 regulated STK35/PDIK1L through two distinct mechanisms: 
promoting kinase stability and kinase catalytic activity. Our study provides the first genetic 
evidence that the conserved serine residue at the DFG+2 position could serve as the site of 
inhibitory phosphorylation at the kinases activation loop. Overall, our findings reveal a 
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1.1. Acute Myeloid Leukemia 
This dissertation has uncovered a novel dependency in a deadly cancer of the blood and bone 
marrow called Acute Myeloid Leukemia. The following chapter outlines our current understanding of 
this disease and the rationale for focusing our research efforts on the enzymes involved in cell 
signaling.  
Acute Myeloid Leukemia (AML) is an aggressive hematologic malignancy caused by 
the impaired differentiation of myeloid progenitor cells, which results in the unrestrained 
proliferation of early immature clones, called myeloblasts, or leukemic blasts (Fig. A). 20% 
blasts in the complete blood count or bone marrow differential is generally required for 
AML diagnosis. The accumulation of aberrant myeloblasts in the bone marrow prevents its 
normal functions, leading to the associated clinical presentations, such as bleeding, anemia, 
and infections.  
1.1.1. Epidemiology 
There are about 20,000 new AML cases diagnosed in the United States every year — 
this is around 1% of all the estimated new cancer cases, according to the National Cancer 
Institute Surveillance, Epidemiology, and End Results (SEER) Program (Fig. B). AML has 
one of the lowest 5-year relative survival rates of 29.5% (2011–2017), fifth after the pancreas 
(10.8%), esophagus (19.9%), liver (20.3%), and lung (21.7%) cancers. AML is more common 
in older adults, with incidence rates dramatically increasing after the age of 45 and the 
median age at diagnosis of 68 years old. There are considerable differences in AML survival 
by age that, together with the prevalence of AML in older patients, contribute to the low 
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five-year overall survival rate. Additionally, AML incidence is modestly (1.2 – 1.6) higher in 
males than in females, with the difference first detectable after 50 and increasing with age 
(Shallis et al. 2019). 
Most commonly used AML therapies, including intensive chemotherapy and stem 
cell transplant, are more likely to benefit a minority of younger and otherwise fit patients, 
whereas most older patients exhibit poor prognoses. Population-based statistics from the 
SEER program report 5-year relative survival of 63%, 39.6%, 15.5%, and 3.7% for patients 
aged below 39, 40 – 64, 65 – 74, and 75 or older, respectively (2011–2017). There are several 
reasons for this disparity in disease outcomes. First, older patients are more likely to have 
secondary AML (see below), linked with lower complete remission rates and decreased 
disease-free survival (Lazarevic 2021). Second, AML in older patients is commonly 
associated with unfavorable cytogenetic and molecular abnormalities that cause resistance 
to standard chemotherapy and poor recovery of normal hematopoiesis (Lazarevic 2021). 
Lastly, older patients are generally presented with more comorbidities and organ 
dysfunctions that could increase treatment-related mortality and non-receipt of any anti-
leukemic therapy (Medeiros et al. 2015). The differences between AML biology and 
pathophysiology in older and younger patients illustrate the notion of AML as an umbrella 
diagnosis comprising different subtypes with their respective prognostic features and 
treatment options, which are being continuously optimized as we enter the era of precision 
medicine (Kantarjian et al. 2021).  
1.1.2. Etiology 
AML can be classified into de novo AML and secondary AML. Secondary AML can 
evolve from untreated or treated antecedent hematological disorders (AHDs) that are often 
undiagnosed, or be therapy-related (t-AML), accounting for 7–15% of all AML cases. 
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1.1.2.1. De novo AML 
De novo AML is referred to any case of AML not arising from germline 
predisposition, prior treatment, or prior myeloid malignancy. While as many as two-thirds 
of all diagnosed AML cases are described as de novo AML, this concept fails to account for 
poor diagnosis for AHDs and non-therapeutic exposures such as tobacco smoking and 
ambient presence of carcinogens, including benzene, formaldehyde, and pesticides (Shallis 
et al. 2020). Noteworthily, a gene mutations profiling study showed differences between de 
novo AML and t-AML. De novo AML was characterized by higher frequencies of mutations 
in FLT3 and NPM1 and lower in TP53 and PTPN11, compared to t-AML (Ok et al. 2015). 
Although some of these observations did not reach statistical significance, this and similar 
studies provide the rationale for further research concerned with differences in clonal 
representation between de novo and secondary AML. 
1.1.2.2. Inherited predisposition 
The incidence of AML is increased in patients with specific genetic syndromes such 
as Fanconi’s anemia, Down syndrome, Bloom syndrome, and others (Alter 2014; Caldwell et 
al. 2014; Bochtler et al. 2015). Physicians also distinguish genetically defined hereditary 
myeloid malignancy syndromes (HMMSs). One of the first HMMSs was discovered in 1999 
by the presence of inherited mutations in RUNX1 (Song et al. 1999). It was closely followed 
by the report on the incidence of familial AML with CEBPA mutation in 2004 (Smith et al. 
2004). The accessibility of next-generation sequencing led to the discoveries of other AML 
heritable predispositions, including mutations in GATA2 (Ostergaard et al. 2011) and ETV6 
(Topka et al. 2015). Early identification of genetic predisposition to AML could benefit 
patients via implementation of preventive therapies aimed at the currently present 




The first reports of the increased leukemogenesis risk following primary cancer 
regimens appeared in the literature in the 1960s for patients treated with alkylating agents 
(such as nitrogen mustard). Old combination chemotherapies generally posed a higher risk 
for t-AML development, and this risk sometimes declined with the introduction of new 
regimens (Schonfeld et al. 2006). 
t-AML is about twice as likely to be associated with poor-risk cytogenetics than de 
novo AML (Ok et al. 2015). While initially it was thought that t-AML was rooted in DNA 
damage induced by prior exposure to chemotherapy or radiotherapy, another possibility is 
that the exposure to these regimens promotes the selection of pre-existing mutant clones 
rather than leading to new mutations (McNerney et al. 2017). One argument in favor of this 
hypothesis would be the statistically significant increase in the rate of clonal hematopoiesis 
in solid tumor patients post-radiotherapy as compared to the general population (Coombs 
et al. 2017). Additionally, immunosuppressive therapies for organ transplant recipients were 
shown to allow t-AML development in the absence of direct DNA damage, supporting the 
model in which clonal expansion may arise due to abnormal cells escaping weakened 
immune surveillance (Offman et al. 2004). 
1.1.2.4. Secondary AML 
Secondary AML is diagnosed in conjunction with an AHD, either myelodysplastic 
syndrome (MDS) or myeloproliferative neoplasm (MPN) (Genovese et al. 2014; Jaiswal et al. 
2014). AHDs can arise from age-related clonal hematopoiesis disorders (ACHD). More than 
75% of ACHDs are characterized by recurrent somatic mutations in one of the three genes, 
DNMT3a, ASXL1, or TET2 (Genovese et al. 2014). Additionally, mutations in TP53, JAK2, or 
genes of the spliceosome machinery (SF3B1, SRSF2, and U2AF1) were also linked to an 
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increased risk of developing AML (Jaiswal and Ebert 2019). The abnormal clones still have 
the differentiation capacity but acquire a proliferative advantage leading to their expansion.  
The persistence of mutant clones may be conducive to accumulating additional 
mutations over time, explaining why clonal hematopoiesis is associated with an elevated 
risk of developing hematologic malignancies. The prevalence of clonal hematopoiesis 
conditions increases with age, and about 10% of the population above 70 years old is 
estimated to carry leukemia-related somatic mutations (Jaiswal et al. 2014). It is important to 
note that most people with clonal hematopoiesis never develop hematologic cancer 
(Steensma 2018). 
1.1.3. Ontogeny 
1.1.3.1. Cytogenetic abnormalities 
Clinical practice guidelines in oncology usually involve cytogenetic/molecular 
classification of AML (Table A) and its associated risks. The karyotype  and cytogenetic  1 2
abnormalities are present in 50–60% of AML cases and strongly correlate with response to 
therapies and overall survival. For example, t(15;17) (PML-RARA) is considered better risk 
cytogenetics due to the discovery of effective targeted therapy for it. 
Patients above 60 years old are reported to have a higher proportion of poor-risk 
associated cytogenetics such as most MLL translocations (translocations involving 11q23) 
and inv(3) (EVI1 induction), and adverse karyotypes including deletions of chromosomes 
5q, 7q, and 17p (TP53 deletion) (Lazarevic 2021). Low-risk cytogenetic abnormalities such as 
t(8;21) (RUNX1T1-RUNX1) or inv(16) (CBFB-MYH11) are more common in younger patients 
(Tsai et al. 2016). Notably, the prognostic value of these genetic events depends on both age 
 The number and visual appearance of the chromosomes in the cell nuclei of an organism or species.1
 Here: changes in chromosomes, including deletions, duplications, insertions, inversions, and translocations.2
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and etiology. For example, single translocation (9;11)(p22;q23) (KMT2A-MLLT3) may pose 
an intermediate risk in younger patients with de novo AML (Bill et al. 2020).  
1.1.3.2. Molecular abnormalities 
While AML prognosis is defined mainly by the cytogenetic abnormalities among the 
favorable and unfavorable karyotype subsets, in the normal karyotype (i.e., diploid), 
somatic mutations are considered prognostic (Pastore et al. 2014). At a minimum, recent 
experts’ recommendations include testing for FLT3-ITD, FLT3-TKD, TP53, NPM1, RUNX1, 
ASXL1, and CEBPA mutations (Dohner et al. 2017). Among frequently mutated genes (>5%) 
in AML, mutations in FLT3, TP53, RUNX1, and ASXL1 are associated with poor outcomes 
identifying a molecular subgroup of high-risk AML. AML with NPM1 or biallelic CEBPA 
mutations and normal karyotype are considered a better risk (Table A). 
Similarly to PML-RARA, the predictive value of mutations in AML is altered with the 
advances in diagnosis and treatment. The normal karyotype AML with mutations in NPM1 
(50%) generally responds well to cytarabine-based regimens and to regimens containing the 
hypomethylating agents (HMAs) and venetoclax (Kantarjian et al. 2021). FLT3 inhibitors 
midostaurin and gilteritinib have been approved by FDA and now became standard practice 
in FLT3-mutated AML. Since FDA approval of IDH1/2 inhibitors, screening for IDH1/2 
mutations is now being considered in clinical practice, particularly at the time of relapse. 
1.1.4. The two-hit hypothesis of leukemogenesis 
Although AML etiological and cytogenetic/molecular classification is broadly used 
in clinical practice to inform treatment strategies and prognoses as well as case studies, 
considerable heterogeneity exists within every recognized subgroup. AML genetic 
alterations exhibit complex co-occurrence patterns or mutual exclusivity that result in 
17
INTRODUCTION 
enormous combinatorial diversity in phenotypes and clinical outcomes. The continuous 
accumulation of mutations and subsequent clonal expansions dramatically increase AML 
clonal representation. The stepwise acquisition of mutations and association with clonal 
disorders consolidated the notion of AML as an excellent model for studying the principles 
of cancer evolution, especially with the single-cell sequencing technologies becoming more 
widely available (Grove and Vassiliou 2014; van Galen et al. 2019; Potter et al. 2019). 
Understanding AML pathways of clonal dominance and shifts will guide precision 
medicine and diagnosis, for example, at the level of the minimal residual disease (Moffitt et 
al. 2020). There is also a considerable need for identifying general principles utilized by 
AML cells for proliferation and targeted therapies resistance. 
In 2002, with several co-authors, Gilliland proposed a so-called “two-hit” model of 
leukemogenesis, which still serves as a useful conceptual framework (Gilliland and Griffin 
2002; Kelly and Gilliland 2002). They noticed that while the commonly mutated in AML 
constitutively activated kinases such as  FLT3,  BCR-ABL1, and  JAK2  are necessary and 
sufficient to cause the myeloproliferative clonal expansion phenotype, they are not enough 
for the differentiation block characteristic for AML. Additional mutations in transcription 
factors and epigenetic regulators are required for full-blown AML development. Gilliland 
and co-authors suggested the term “class I” mutations for the mutations conferring 
proliferative advantage to cells and “class II” for the mutations rewiring myeloid 
differentiation program. One of the arguments in favor of this hypothesis was the relatively 
low likelihood of two mutations from the same class co-existing together in the same cell, 
such as FLT3 and RAS (class I) or KMT2A (MLL) and DNMT3A (class II) (Gilliland and 
Griffin 2002; Wang et al. 2017). Other recurrent mutation groups in AML discovered later 
(spliceosome genes, epigenetic modifiers, cohesins) are likely to synergistically produce 
similar results (Table B) (Grove and Vassiliou 2014).  
18
INTRODUCTION 
Aberrant activation of cellular signaling pathways commonly results in increased 
proliferation; hence these mutations are frequently considered class I. Out of AML patients 
in the Cancer Genome Atlas (TCGA) cohort (median age, 55 years), 59% carry mutations in 
the genes involved in signal transduction pathways, which makes them the most commonly 
mutated group in AML (Table B) (Bullinger et al. 2017). Moreover, acquisition or enrichment 
of clones with activation of specific signaling pathways can result in the primary and 
adaptive resistance to the existing therapies (DiNardo et al. 2020b). A tightly regulated 
balance between phosphorylation and dephosphorylation, sustained by coordinated and 
competing activities of kinases and phosphatases, lies at the basis of cellular signaling. 
Given the advances of the past two decades in designing potent and selective inhibitors 
against kinases and phosphatases, these phospho-signaling enzymes present some of the 
priority targets in AML. 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Figure A. Simplified hematopoiesis and AML origin.  





Figure B. AML statistics.  
(A) The proportion of AML among all cancer cases diagnosed in the US in 2019. Data from the 
American Cancer Society, 2020. (B) Schematic representation of the incidence rate of AML by age 
groups at diagnosis. Data from the SEER, 2014–2018. (C) 5-Year relative survival rates by age groups 
at diagnosis. Data from the SEER, 2011–2017.  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Table A. National Comprehensive Cancer Network (NCCN) 
cytogenetic/molecular classification of AML 
NCCN 
Classification Cytogenetics Gene fusion Molecular Abnormalities








Normal cytogenetics;  
NPM1 mutation without FLT3-ITD;  
isolated biallelic CEBPα mutation
Intermediate 
risk
t(9;11)(p22;q23)  MLLT3-MLL t(8;21), inv(16), t(16;16) with c-KIT 
mutations;  
NPM1 mutation with FLT3-ITDhigh; 
NPM1 wt without FLT3-ITD;  
NPM1 wt and FLT3-ITDlow
or normal cytogenetics;  
+8 alone;  
other undefined










TP53 mutation;  
RUNX1 mutation;  
ASXL1 mutation;  
NPM1 wt and FLT3-ITDhigh
or complex karyotype  
(≥ 3 clonal chromosomal 
abnormalities); 
monosomal karyotype; 
-5 or del(5q) 
-7 or del(7q) 
abn(17p)
inv, inversion; t, translocation; wt, wild-type; low, low allelic ratio (<0.5); high, high allelic ratio (≥0.5). 
Table adapted from Kantarjian et al. 2021.
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Table B. Functional Categories of Genes Commonly Affected in AML 
(according to the TCGA dataset)  
Functional Category Selected Gene Members Role in Leukemogenesis TCGA Cohort (%)*
Signaling genes
Kinases (e.g., FLT3, c-KIT), 
phosphatases (e.g., 
PTPN11), or RAS family 
members (e.g., KRAS, 
NRAS)
Activated signaling confers a 
proliferative advantage through 




associated genes DNMT3A, TET2, IDH1/2
Deregulated DNA methylation 




Myeloid TF gene 
fusions or mutations
TF fusions Aberrant TF function results in 








Mutations (e.g., ASXL1, 
EZH2) or KMT2A fusions
Deregulation of histone marks 










genes TP53, WT1, PHF6 Loss of tumor suppressors 16
Spliceosome-
complex genes
SRSF2, SF3B1, U2AF1, 
ZRSR2
Impaired spliceosome functions 
and deregulated RNA 





Mutations may lead to impaired 
accurate chromosome 
segregation and impact 
transcriptional regulation.
13
TF, transcription factor. 
*, a dataset from TCGA was selected for younger patients (median age, 55 years); thus, the respective data 
might be biased, and incidences could vary if additional older patients were included.  
Table adapted from Bullinger et al. 2017 with modifications based on Grove and Vassiliou 2014.
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1.2. Kinases and phosphatases in AML 
Aberrant signaling in AML is dependent on net substrates phosphorylation levels regulated 
by kinases and phosphatases. This chapter introduces the reader to these enzymes, commonly hijacked 
by AML cells, and describes several prominent examples of molecular mechanisms employing kinases 
or phosphatases to support leukemia cell proliferation.  
1.2.1. Brief introduction to kinases and phosphatases 
Phosphorylation is an addition of a phosphate group to a given substrate by a 
kinase, whereas dephosphorylation is a removal of a phosphate group from a substrate by a 
phosphatase. Phosphorylation and dephosphorylation are some of the most prominent 
substrate modifications due to the chemical properties of the phosphate group, the chemical 
stability of phosphate esters in aqueous solutions at physiological pH, and the favorable 
kinetics of these reactions in the presence of ATP (for phosphorylation) and appropriate 
enzyme catalysts. The unique interactions of the phosphate group with the solvent (ionic 
shell) and its negative charge allow new physicochemical properties for the biomolecular 
surfaces gaining or losing the covalently bound phosphate groups (Hunter 2012). The 
predominant protein residues undergoing phosphorylation/dephosphorylation in 
eukaryotes are serine (86.4% of proteins), threonine (11.8%), and tyrosine (1.8%) (Olsen et al. 
2006), with many of these sites playing critical regulatory roles. 
In the field of tyrosine phosphorylation, a preconception was born where tyrosine 
kinases were thought of as “switch on,” or “writers,” with predominantly active roles in cell 
signaling, allowing for the “reader” function by proteins recognizing the phosphorylation at 
the specific target tyrosine residues. Protein tyrosine phosphatases in this “three-part 
toolkit” were reduced to the role of “erasers,” merely counteracting the function of kinases 
by “switching off” their substrates (Lim and Pawson 2010). However, both phosphorylation 
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and dephosphorylation can activate or deactivate proteins, and the whole signaling cascades 
through the changes in protein conformation and the creation or ablation of binding 
surfaces, affecting protein functions, protein-protein interactions, localization, and stability 
(Nishi et al. 2014). Moreover, the activity of some phosphatases can result in an increase in 
phosphorylation of downstream targets (see Introduction §1.2.2.9). Along these lines, the 
preconception that protein kinases act as an “on switch” in cancer, whereas phosphatases 
only serve as tumor suppressors, is now refuted by a growing body of evidence 
demonstrating that some phosphatases are dominant oncogenes, or “on switches,” in a 
number of contexts with several remarkable examples in leukemia discussed below (SHP2, 
PPM1D, and others) (Elson 2018). 
The potency of phosphorylation/dephosphorylation in regulating the functions of 
their substrates made these processes central in cell signaling. Phosphorylation signaling 
networks are cellular information processing systems. Signal recipients at the cell surface, 
such as receptor tyrosine kinases and phosphatases, detect an extracellular stimulus and 
pass it to the downstream network of signal transducers (RAS, Src, SHP2, and many others). 
The signal gets amplified or dampened via numerous positive and negative feedback loops 
in the complex signaling networks. Multiple upstream signal transduction pathways can 
converge on signal integrators and processors (such as mTOR or p53). At the final step of the 
simplified signal transduction pathway, phosphorylation regulates signal effectors, such as 
transcription factors, mediating the cell response to the stimulus. At every level of signal 
transduction, the signaling output defined as net protein phosphorylation is controlled by a 
dynamic equilibrium between kinases and phosphatases. The cooperation between these 
classes of enzymes is especially crucial in the space and time-sensitive processes that require 
highly coordinated activities of all players, such as cell division (Szomolay and Shahrezaei 
2012; Nasa and Kettenbach 2018; Gelens et al. 2018). 
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1.2.1.1. Classification of kinases and phosphatases 
By latest estimates, there are ~768 protein-coding genes with known and predicted 
kinase domains (616 protein kinases, ~152 non-protein and pseudokinases; Table C) and 264 
genes with known and predicted phosphatase domains (~128 protein phosphatases, ~136 
non-protein and pseudophosphatases; Table D) (Klingbeil, unpublished; Tweedie et al. 2021; 
Chen et al. 2017). This imbalance in the absolute numbers of protein kinases and 
phosphatases, as well as the seeming lack of specificity exhibited by some serine/threonine 
phosphatases in vitro, — even though for the tyrosine phosphatases both observations were 
simply not true (Tonks 2013), — served some of the arguments for the initial dismissal of the 
phosphatases as “housekeeping enzymes,” maintaining the basal unphosphorylated state 
rather than regulating signaling. The latter notion was at least in part responsible for the 
lack of interest in the careful studies of phosphatases and the development of specific 
inhibitors. However, by the end of the 1990s, powerful models emerged from the field of 
tyrosine phosphatases, proving that together with the substrate specificity in vitro, 
phosphatase deletion in vivo could drive a “fabulously specific phenotype” (Elchebly et al. 
1999; Klaman et al. 2000; Cheng et al. 2002). Moreover, further studies of serine/threonine 
phosphatases, such as Protein Phosphatase 1 (PP1) and 2A (PP2A), uncovered the 
combinatorial complexity driven by these enzymes forming multimeric competes 
(holoenzymes) with non-catalytic subunits that determine their distinct cellular localization, 
substrate specificity, and precise regulation (Brautigan 2013).  
In terms of classification, kinases and phosphatases can be divided on the basis of 
acting on protein versus non-protein substrates (Table C; Table D). With the availability of 
the human genome sequence, researchers could easily identify a large number of protein 
kinases (581) that belong to a single superfamily containing a eukaryotic protein kinase 
catalytic domain (Manning et al. 2002). However, the discovery of kinases lacking this 
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sequence similarity (atypical) has been lagging. There are now 43 atypical protein kinases 
and ~144 genes with predicted kinase activity against non-protein and yet unknown 
substrates in the Human Kinome project. 
In contrast to kinases, even protein phosphatases are a highly diverse group of 
enzymes comprising many different protein structural folds and catalytic mechanisms (see 
Table D; curated from Chen et al. 2017). Moreover, phosphatases with the same fold can act 
on protein and non-protein substrates, and a given function may not be limited to a single 
fold. Around 40% of all the 264 human protein phosphatases belong to the CC1 (Cys-based 
class I) fold superfamily. The next largest group (16%) is HAD phosphatases (discussed in 
more detail below). Phosphatases with the PPM (metal-dependent protein phosphatase) and 
PPPL (phosphoprotein phosphatase-like) folds are responsible for the majority of phospho-
serine/phospho-threonine dephosphorylation and account for ~14% of all phosphatases. 
The remaining folds are less common. 
1.2.1.2. Evolution of kinases and phosphatases 
The reason for a striking overtake of the protein kinases by a single protein structural 
fold is that the majority of them originate from a common ancestor through genetic 
duplications. The characteristic kinase fold is shared between eukaryotes and bacteria, 
archaea, and viruses (Jin and Pawson 2012). The expansion and functional differentiation of 
the kinome went hand in hand with the development of multicellularity and cellular 
specialization. For example, the number of kinase subfamilies more than doubled in basal 
metazoa. The increase in the numbers and specialization of RTKs in humans, with some 
families unique to this clade, has been associated with the advancement of multiple organ 
systems and processes (Manning et al. 2002).  
True to the complexity of their classification, phosphatases are thought to have 
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distinct ancestry with complex evolution, including both divergent and convergent 
pathways. Moreover, some motifs and catalytic mechanisms are thought to arise 
independently several times during evolution, as exemplified by the three classes of dual-
specificity and tyrosine phosphatases containing the same catalytic core motif (CX5R). 
Similar to kinases, big radiation of the phosphatases subfamilies started at the transition 
from unicellular to multicellular organisms. This included the divergent spread of the CC1 
and PPM folds (Chen et al. 2017). The sequences for the characteristic folds of serine/
threonine phosphatases (PPM and PPPL) are unrelated, yet, at the structure level, they 
converged to the high similarity in their catalytic centers (Moorhead et al. 2009). Many 
phosphatases co-evolved with their regulatory subunits that guide their substrate specificity 
and subcellular localization. The latter is true both for the complex network of docking 
interactions observed for the PPP members and the genetic fusions of catalytic domains to 
their regulatory sequences (PTP, PPM, HAD), with PTP phosphatases serving notable 






























































Table D. Classification of human phosphatases (2/2)
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1.2.2. Notable kinases and phosphatases in AML 
1.2.2.1. FLT3 
Activating mutations in the FMS-related tyrosine kinase 3 (FLT3) are present in one-
third of adult AML patients (Dohner et al. 2010). Most health organizations, including the 
World Health Organization, NCCN, and European LeukemiaNet, consider mutations in 
FLT3 poorly affecting the clinical outcomes (Table A). Commonly observed FLT3 mutations 
include FLT3 internal tandem duplications (FLT3-ITD) and tyrosine kinase domain (TKD) 
point mutations (Grafone et al. 2012).  
FLT3 is a cell membrane protein that belongs to the class III receptor tyrosine kinases, 
characterized by an extracellular ligand-binding domain (ED) with five immunoglobulin-
like modules, a transmembrane domain, and a cytoplasmic region consisting of a 
juxtamembrane domain (JMD) and two highly conserved TKDs (Matsumura et al. 2008). In 
the inactive state, FLT3 is auto-inhibited by the JMD. Upon cytokine binding to the ED, FLT3 
receptors oligomerize and undergo activating transphosphorylation on their JMD and TKD 
domains. Activated FLT3 phosphorylates downstream signaling effectors in the RAS/RAF, 
JAK/STAT, and PI3K/AKT pathways, regulating cellular proliferation, inhibition of 
apoptosis, and differentiation. ITD mutations are in-frame mutations in the JMD region that 
result in the multiplication of its coding sequence and the subsequent loss of the JMD auto-
inhibitory activity. Point mutations in the TKD stabilize the active kinase confirmation and 
also result in the aberrant activation of downstream targets and the cytokine-independent 
growth of hematopoietic cells, though their role in leukemogenesis and prognostic values 
are less defined (Schnittger et al. 2012).  
FLT3 is specifically expressed in early CD34+ hematopoietic stem/progenitor cells 
(HSPCs) and absent from more mature blood cell populations (Grafone et al. 2012). Early 
knockout mouse models showed that Flt3-/- mice developed normally with the only 
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recorded deficiencies in early B cell progenitors and reduced repopulation capacity upon 
bone marrow transplantation (Mackarehtschian et al. 1995). However, it is important to note 
that murine Flt3 expression is restricted to common lymphoid progenitors and leads to the 
loss of self-renewal ability (Mackarehtschian et al. 1995). Flt3 ligand (FL) also fails to 
promote the survival of mouse hematopoietic stem cells and is dispensable for myeloid 
development (Sitnicka et al. 2002). In contrast, human CD34+FLT3+ cells can efficiently and 
continuously reconstitute both lymphoid and myeloid lineages, may have erythroid 
differentiation potential, and FL promotes their viability, underlining the differences in 
mouse and human roles for FLT3 (Kikushige et al. 2008). Additionally, PI3K activation by 
human FLT3 is different to mice since human FLT3 does not directly bind the p85α subunit 
of PI3K (Zhang and Broxmeyer 1999). 
FLT3-ITD is a potent driver of leukemogenesis in humans, as shown by its frequent 
presence at baseline and relapse (Kronke et al. 2013) and the emergence of on-target FLT3 
mutations upon the use of potent inhibitors (Smith et al. 2012). Flt3-ITD knock-in mice 
develop myeloproliferative and lymphoid disorders and overt AML in synergy with other 
common AML oncogenes (reviewed in Muller and Schmidt-Arras 2020). 
FLT3wt in human hematopoietic stem cells was reported to support cell survival 
through multiple mechanisms, including upregulation of MCL-1 — an anti-apoptotic 
protein (Kikushige et al. 2008). This and other functions of FLT3wt could be exploited by its 
constitutive activation in cancer cells (Yoshimoto et al. 2009). Among FLT3-ITD mutant 
specific effectors are transcription factor STAT5 (Choudhary et al. 2007) and protein tyrosine 
phosphatase SHP2 (Chen et al. 2016). Apart from aberrant proliferation, FLT3-ITD was 
shown to induce differentiation block through inhibiting several myeloid transcription 




c-KIT is another class III receptor tyrosine kinase essential for the early 
hematopoietic stem cells self-renewal and differentiation and having a recognized role in 
leukemogenesis. It has a similar overall structure to FLT3 (see above). While mutations in 
the  c-KIT  gene in AML happen in ~5% of cases (Badr et al. 2018), it is often aberrantly 
expressed in AML blasts. In a subset of AML characterized by t(8:21) and inv(16)/t(16;16) 
translocations (core-binding factor, or CBF-AML) frequency of c-KIT mutations reaches 30% 
and is associated with worse prognoses in this otherwise better risk group (Table A) 
(Ayatollahi et al. 2017). However, c-KIT mutations prognostic values vary between reports 
depending on the type of the translocation and the specific c-KIT variant, age of patients, 
and mutation allele burden (Tarlock et al. 2019). 
c-KITwt activates similar downstream pathways to FLT3: PI3K/AKT (through p85α 
PI3K subunit), RAS/RAF, JAK/STAT, and other. c-KIT mutations are gain-of-function and 
lead to ligand-independent constitutive kinase activity.  
c-KIT mutations promote cell growth and radiation resistance through aberrant 
signaling (Malaise et al. 2009). Among mutant-specific effectors of c-KIT were reported the 
increased PI3K and STAT3 activation (Chian et al. 2001; Ning et al. 2001), possibly due to c-
KITmut mislocalization to the intracellular membranes (Schmidt-Arras and Bohmer 2020). 
Other interesting mechanisms reported for c-KITD816V were circumventing the requirement 
for phosphorylation by the Src family of protein tyrosine kinases (SFKs) for downstream 
signaling (Sun et al. 2009) and degradation of its negative regulator src homology 2 domain 
(SH2)-containing protein tyrosine phosphatase SHP1 (Piao et al. 1996). 
Although there are no selective c-KIT inhibitors available yet, the addition of 
multikinase inhibitors, such as midostaurin or dasatinib, to chemotherapy has shown 




The translocation between chromosomes 9 and 22 [t(9;22)(q34.1;q11.2)] was the first 
identified cytogenetic abnormality in leukemia. It was discovered in 1960 in two chronic 
myelogenous leukemia (CML) patient samples and named after the place of its discovery, 
the Philadelphia chromosome (Nowell 1962). Later studies clarified that the translocation 
involved the protein tyrosine kinase ABL1 (Abelson Murine Leukemia Viral Oncogene 
Homolog 1) and the gene breakpoint on the breakpoint cluster region (BCR) of chromosome 
22. The fusion transcript renders a constitutively activated non-receptor tyrosine kinase (de 
Klein et al. 1982; Shtivelman et al. 1985). Like the tyrosine kinases above, it controls many 
cellular processes associated with cell proliferation, differentiation, and stress response.  
Constitutive activation of BCR-ABL1 is achieved through several mechanisms, 
including loss of auto-inhibitory myristoylation at the N-terminus of ABL1 (Hantschel 2012). 
It is a powerful driver of leukemogenesis shown to cause myeloproliferative disorders in 
syngeneic mouse models. One of the critical effectors of BCR-ABL1 is the adapter GAB2, 
required for its downstream signaling to PI3K and SHP2-mediated signaling pathways (Gu 
et al. 2016).  
Various BCR-ABL1 isoforms are present in most CML patients (0.5% of all yearly 
cancer cases), ~25% of adult B-cell ALL patients, and rarely in AML, lymphoma, and 
myeloma (Zhou et al. 2018). Imatinib mesylate (Gleevec) was one of the first rationally 
designed selective anticancer drugs and received the FDA approval for CML patients in 
2001, just two and a half years after its development (Iqbal and Iqbal 2014), and many more 
effective tyrosine kinase inhibitors (TKIs) followed.  
The introduction of imatinib and second- and third-generation TKIs dramatically 
improved survival outcomes in CML patients, with their life expectancy in the chronic phase 
approaching 98% of that in the general population (Bower et al. 2016). Most patients with 
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CML take TKIs for life, even though there have been cases of successful discontinuation 
(Hughes and Ross 2016). TKIs immediate and long-term side effects are some of the 
standing challenges in BCR-ABL1-positive patients, adversely affecting their quality of life 
and treatment adherence. There are also multiple mechanisms of drug resistance and the 
lack of options for the patients with advanced disease in accelerated and blast phases (Shah 
2008). 
One potential explanation for the high likelihood of relapse upon TKI withdrawal is 
the presence of the minimal residual disease presented by leukemia stem cells (LSCs) that 
are intrinsically resistant to BCR-ABL1 inactivation (Morotti et al. 2014). Understanding the 
biology of LSCs is essential to eradicate this population and prevent future disease 
reoccurrences. Another explanation for the high relapse rate — not mutually exclusive with 
the first one — is that the BCR-ABL1 protein itself has a structural role in supporting 
leukemia cell and LSC proliferation regardless of its kinase activity (whereas TKIs 
selectively block only its kinase function) (Neviani et al. 2013). 
1.2.2.4. JAK2 
Approximately 90% of patients with BCR-ABL1-negative MPNs bear mutations in 
the Janus-Associated Kinase/Signal Transducers and Activators of Transcription (JAK/
STAT) signaling pathway (Venugopal and Mascarenhas 2020). Between 5 and 10% of these 
patients develop AML with poor prognoses (Kennedy et al. 2013). 
JAKs have two kinase domains: catalytically active C-terminal tyrosine kinase 
domain and N-terminal pseudokinase domain. Almost 70% of patients with MPNs harbor 
V617F mutation in the JAK2 pseudokinase domain, which results in its cytokine-
independent activation, potentially through disrupting its inhibitory cellular interactions 
(Liau et al. 2019). 
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JAKs regulate survival, proliferation, and differentiation of hematopoietic cells in 
response to cytokines, serving as essential catalytic counterparts of the cytokine receptors. 
Upon activation, JAK2 initiates downstream signaling through STATs nuclear localization, 
RAS/RAF, and PI3K/AKT signaling pathways.  
STAT5 is one of the main effectors of JAK2V617F, and Stat5 deletion impaired Jak2V617F 
driven pathogenesis in mice (Walz et al. 2012). Besides, JAK2V617F catalytic function has been 
implicated in epigenetic regulation. Dawson et al. showed that JAK2V617F is present in the 
nucleus and phosphorylates histone H3Y41, protecting the associated chromatin from 
epigenetic silencing (Dawson et al. 2009). Jeong et al. reported that JAK2V617F activates Ten-
Eleven-Translocase 2 (TET2) — an enzyme that removes cytosine methyl marks from DNA 
— leading to upregulation of HOXA9 and MEIS1 (Jeong et al. 2019).  
Data from our group points to potential cooperativity between JAK2V617F and a dual-
specificity tyrosine-regulated kinase 1A (DYRK1A) (Tarumoto et al. 2018). This phenomenon 
could be mediated by the converging signaling of JAK2 and DYRK1A on STAT3, 
constitutively activated in hematologic malignancies. Maximum transcriptional activity of 
STAT3 is achieved through JAK2-mediated phosphorylation of its Y705 residue and 
DYRK1A mediated phosphorylation of S727 residue (Wen et al. 1995; Matsuo et al. 2001). 
However, inhibition of DYRK1A has not yet been carefully explored in JAK2V617F AML, to 
our knowledge. 
1.2.2.5. CDK6 
Characteristic AML translocations involving chromosome 11q23, the locus for MLL1, 
are associated with poor prognosis (Table A) and account for ~10% of adult leukemias and 
~60% of infant leukemias (Grigsby et al. 2021). MLL1 encodes histone 3 lysine N-
methyltransferase 2A (KMT2A). KMT2A is an epigenetic regulator controlling the 
37
INTRODUCTION 
transcription of many genes important in normal development and hematopoiesis (Hsieh et 
al. 2003). MLL1 locus contains a breakpoint region after the DNA-binding portion of 
KMT2A, which is involved in recurrent chromosomal translocations generating KMT2A-
fusion proteins with over 80 different partners (Meyer et al. 2009). A characteristic 
transcriptional signature in MLL-fusion AML is the upregulation of HOX genes (Armstrong 
et al. 2002). MLL-fusions exploit various epigenetic regulators for the aberrant activation of 
their targets, such as Disrupter of Telomeric silencing 1-Like (DOT1L) (Okada et al. 2005), 
alone or in a complex with the nuclear scaffold protein menin (MEN1) (Jin et al. 2010). Both 
of these MLL-fusion partners have been explored as therapeutic avenues for MLL-fusion-
positive leukemias in pre-clinical and clinical studies (Grieselhuber and Mims 2021).  
Functional genomics studies from Fröhling group (RNAi) and later ours (CRISPR-
Cas9) provided evidence for the cell division protein kinase 6 (CDK6) being specifically 
essential for the survival of MLL-fusion-positive human leukemia cell lines (Placke et al. 
2014; Tarumoto et al. 2018). CDK6 role in these cells was independent of its control of cell-
cycle G1/S progression but instead supported the myeloid differentiation arrest through its 
catalytic activity. CDK6 was shown to be a direct transcriptional target of MLL-AF9, and 
CDK6 inhibition impaired colony formation and promoted differentiation of MLL-fusion-
positive cell lines in a dose-dependent manner, and conferred significant survival benefits in 
mouse models.  
Later reports suggested a more broad role for CDK6 in leukemogenesis, including 
supporting transformation by JAK2V617F and FLT3-ITD. CDK6 gene is frequently 
upregulated in human leukemias. Among CDK6 potential downstream effectors were 
named transcription factors STATs and activator protein 1 (AP-1), and negative regulation of 
p53. CDK6 inhibitors clinical trials in AML are currently ongoing (Uras et al. 2020). 
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1.2.2.6. SIK2/3 and MARKs 
Another transcription factor exploited by MLL-fusions is the myocyte enhancer 
factor 2C (MEF2C), critical for AML proliferation (Krivtsov et al. 2006; Schwieger et al. 2009) 
and dispensable for the establishment or maintenance of the myeloid lineage in vivo albeit 
slight monocyte deficiency (Schuler et al. 2008). One way to target this transcription factor 
through a phospho-signaling pathway emerged in our laboratory from an unbiased 
exploration of the specific AML-promoting roles of all human kinases (Tarumoto et al. 2018). 
Human leukemia cell lines with MLL-fusion showed increased sensitivity to LKB1 
knockout and SIK3/SIK2 double knockout. In a series of genetic and biochemical 
experiments, Tarumoto et al. showed that this effect, at least in part, was explained by LKB1 
activating phosphorylation on SIK3, which in turn phosphorylated HDAC4. HDAC4 
phosphorylation by SIK3 results in its nuclear exclusion (Walkinshaw et al. 2013), therefore 
inhibiting its function. Thus, LKB1-SIK2/3 signaling was essential in the AML context to 
prevent HDAC4 from counteracting MEF2C functions on chromatin. SIK3 early stage 
development inhibitors are available and showed promise in vivo in two different mouse 
models of MLL-fusion driven leukemias while somewhat lacking in efficacy as compared 
with the direct gene inactivation (Tarumoto et al. 2020).  
MEF2C can also be directly phosphorylated and activated by MARK kinases, which 
results in increased AML pathogenesis and worse prognoses, at least in part due to the 
MEF2C aberrant phosphorylation being specifically associated with LSCs maintenance 
(Brown et al. 2018). In a series of elegant experiments, Brown et al. showed that mice with 
homozygous S222A MEF2C mutation were resistant to MLL-AF9-induced leukemogenesis 
due to significantly reduced MEF2C transcriptional activity. A dual selective MARK/SIK 
inhibitor MRT199665 effectively induced apoptosis in AML cells and could potentially 




SH2 domain-containing phosphatase 2 (SHP2) is a non-receptor protein tyrosine 
phosphatase encoded by the PTPN11 gene. It is a major signaling node transmitting the 
information from upstream tyrosine kinases to the central cellular signaling highways, such 
as RAS/RAF, JAK/STAT, and PI3K/AKT pathways (Frankson et al. 2017). SHP2 contains 
two substrate-binding SH2 domains at the N-terminus, a protein tyrosine phosphatase 
(PTP) domain, and a C-terminal domain with two tyrosine phosphorylation sites. Upon 
substrate binding, SHP2 undergoes a conformational change that results in its activation 
through enabling access to the PTP domain catalytic site (Barford and Neel 1998). This 
mechanism became the basis for the later discovery of potent and specific SHP2 allosteric 
inhibitors locking it in its inactive conformation (Chen et al. 2016). 
SHP2 is necessary for normal hematopoiesis (Qu et al. 1998). Activating mutations 
in PTPN11 were initially described for the RASopathies, rare congenital conditions leading 
to multiple developmental abnormalities and an increased risk of leukemias (Rauen 2013). 
Approximately 35% of patients with juvenile myelomonocytic leukemia carry somatic 
mutations in  PTPN11 associated with worse outcomes and increased risk for relapse 
(Niemeyer and Flotho 2019). Large cohorts genomic studies reported PTPN11 mutations in 
4–8% of adult AML patients, also associated with worse prognoses (Alfayez et al. 2021). The 
common SHP2 mutations include D61V and E76K at the interface between the N-terminal 
SH2 domain and the PTP domain, which weaken SHP2 auto-inhibitory conformation 
(Padua et al. 2018).  
One of the major effectors of SHP2 is RAS, another well-established oncogene in 
AML (Chan et al. 2004). SHP2 was reported to interact with directly and dephosphorylate 
RAS, promoting the RAS GTPase cycle (Bunda et al. 2015). Besides, SHP2 downstream 
targets (Sprouty, GRB2/SOS, and RAS-GAP) also regulate RAS activity. Many pre-clinical 
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and clinical studies evaluated SHP2 inhibitors alone or in combination with MEK inhibitors, 
and several clinical trials are still ongoing. 
Mutations in RAS and PTPN11 were shown to be largely mutually exclusive 
(Paulsson et al. 2008), suggesting their combination disadvantageous to the cell or simply 
redundant for providing any additional selective benefit. Notably, several research groups 
reported that tumors with RAS mutations were resistant to SHP2 inhibition, consistent with 
the hypothesis that these mutations confer biochemical properties to RAS, enabling its 
function in the absence of upstream RTK/SHP2 signaling (Chen et al. 2016; Ahmed et al. 
2019; Valencia-Sama et al. 2020). This was challenged in a 2019 study providing evidence for 
KRASmut cells being sensitive to the SHP2 inhibitor SHP099 in 3D multicellular spheroids 
but not in a 2D monolayer (Hao et al. 2019). Of note, most leukemia cell lines grow in 
suspension. Further dissection of SHP2 dependent and independent RAS signaling in 
different cancer contexts is necessary for the clinical development of SHP2 inhibitors as a 
reasonable treatment strategy. One potential resistance prevention approach could be to 
combine SHP2 inhibitors with RASmut specific inhibitors (Ryan et al. 2020).  
SHP2 inhibitor SHP099 screening showed a correlation between human cell lines’ 
sensitivity to SHP2 inactivation and the dependence on RTK signaling, such as activating 
FLT3 mutations and BCR-ABL1. Wild type FLT3 engages SHP2 through GRB2 and GAB1/2 
(Zhang and Broxmeyer 2000). Knockdown of Shp2 was shown to significantly reduce the 
proliferation of the murine pro-B cell line Ba/F3 constitutively expressing human FLT3-ITD 
whereas having little effect on the cells expressing wild-type FLT3 (Nabinger et al. 2013). 
SHP099 eliminated tumor burden in the primary-tumor-derived FLT3-ITD AML xenograft 
setting (Chen et al. 2016). It was also shown to be one of the critical downstream effectors of 
BCR-ABL1, allowing its leukemogenic functions. A 2018 study from Gu et al. reported that 




Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase with numerous 
functions in the cell possible by forming up to 60 distinct holoenzymes with diverse 
substrate specificities and subcellular localizations (Fowle et al. 2019). PP2A activity is 
tightly regulated at every level, including post-transcriptional via interactions with various 
endogenous inhibitors of its functions (such as SET and cancerous inhibitor of PP2A, 
CIP2A). Endogenous PP2A inhibitors were shown to be overexpressed in many leukemias 
and other cancer contexts, whereas the mutations in PP2A itself are relatively rare (Kauko 
and Westermarck 2018). This allowed the development of P2A-activating drugs (PADs) — 
small molecules disrupting the interaction between PP2A and its endogenous inhibitors 
(Vainonen et al. 2021).  
In 2016 Smith et al. showed that FLT3-ITD expression led to PP2A transcriptional 
downregulation in cell lines and patient samples (Smith et al. 2016). The use of PADs 
FTY720 and AAL(S) resulted in proliferation arrest and cell death specific for FLT3-ITD 
expression.  
The same group earlier discovered a similar relationship between PP2A and c-KIT. 
Mutant c-KIT myeloid cells were shown to downregulate PP2A, and overexpression of PP2A 
inhibited the proliferation of c-KIT mutant cells (Roberts et al. 2010). FTY720 exhibited 
preferential cytotoxicity to c-KIT mutant leukemia models and was suggested as a 
therapeutic strategy for c-KIT-positive cancers. 
Similar to the other tyrosine kinases, BCR-ABL1 was shown to rely on PP2A 
inhibition to drive leukemia. Importantly, BCR-ABL1 induced SET expression in the dose- 
and kinase activity-dependent manner upon CML progression from the chronic phase to the 
blastic phase (Neviani et al. 2005). The protein levels of CIP2A were also significantly higher 
at the time of diagnosis in CML patients who later progressed to bast crisis (Lucas et al. 
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2011). These studies suggested that that PP2A inactivation is essential for CML blastic 
transformation — one of the main therapeutic challenges in the BCR-ABL1-positive 
population. FTY720 showed great promise in impairing the proliferation of BCR-ABL1-
positive myeloid and lymphoid cell lines and progenitors (Neviani et al. 2007). Overall, 
PP2A inactivation seems to be a common tumorigenesis mechanism in cancers driven by 
oncogenic tyrosine kinases. 
PP2A was also proposed as a critical regulator of LSCs survival. The 2013 study from 
Perrotti’s group reported that while BCR-ABL1 activity in TKI-resistant CML quiescent 
LSCs was low, its expression was essential for the JAK2/β-catenin mediated inhibition of 
PP2A. In the context of CML LSCs, PP2A activation was shown to decrease survival and 
self-renewal of quiescent CML LSCs in serial transplantation assays (Neviani et al. 2013).  
One of the best characterized oncogenic targets of PP2A is MYC. High MYC 
expression in AML was associated with poor prognosis and the increased risk of relapse 
(Ohanian et al. 2019; Yun et al. 2019). MYC acts as a signaling crosspoint of the cell with 
multiple growth-regulatory pathways converging with its upregulation, including MLL-
fusion-driven oncogenesis, RAS, Hedgehog, WNT, NOTCH, and JAK/STAT pathways — all 
reported to be deregulated in AML (Kress et al. 2015). c-MYC is activated by 
phosphorylation at serine 62 (S62) that stabilizes its protein levels (Pulverer et al. 1994), and 
subsequent phosphorylation on threonine 58 (T58) is reported to target it to degradation 
(Gregory et al. 2003; Yeh et al. 2004). Leukemia and lymphoma cell lines are reported to 
stabilize MYC protein levels via mutations at or near the T58 site, impaired activity of 
glycogen synthase kinase3β (GSK3β) (responsible for T58 phosphorylation) (Malempati et 
al. 2006), mutations in the MYC ubiquitin ligase, FBW7 (O'Neil and Look 2007), and 
downregulation of PP2A.  
PADs effectively reduced MYC activity in other types of cancers (Farrell et al. 2014; 
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Farrington et al. 2020). Controversially, in human T-cell ALL cell lines, PAD iHAP1 induced 
apoptosis through dephosphorylation of the transcription factor MYBL2, but not c-MYC, 
suggesting that different PP2A substrates are kept in check by diverse mechanisms (Morita 
et al. 2020). Of note, other phosphatases have also been reported to support MYC stability 
by dephosphorylating its T58 residue, such as PHLPP2 in the context of a mouse model of 
metastatic prostate cancer (Nowak et al. 2019), Eya3 (Zhang et al. 2018), or SCP1 (Wang et al. 
2016a), and their role in MYC regulation could be of interest in leukemias. 
1.2.2.9. CD45 
CD45 is also known as a protein tyrosine phosphatase receptor type C (PTPRC). It 
comprises a glycosylated extracellular segment, a transmembrane domain, and a conserved 
intracellular fragment with two tandemly repeated domains (Thomas et al. 1985). The 
sequence similarity of the intracellular domains of CD45 to PTP1B led Tonks et al. to 
demonstrate that this membrane protein indeed exhibited a protein tyrosine phosphatase 
activity (Tonks et al. 1988a). 
Historically, CD45 has been widely used in flow-cytometry as a marker of all 
nucleated hematopoietic cells. In the absence of CD45 or its phosphatase catalytic activity, T 
lymphocytes fail to become activated through the T-cell receptors, leading to severe 
combined immunodeficiency (Pingel and Thomas 1989; Koretzky et al. 1990; Kung et al. 
2000). Thomas et al. and others showed that CD45 dephosphorylated the auto-inhibitory 
tyrosines of SFKs, resulting in their conformational change that activated downstream 
signaling (Ostergaard et al. 1989; Thomas and Brown 1999). The expression of a 
constitutively active SFK, LckY505F, in CD45-deficient mice rescued CD45-loss associated 
block in T-cell development (Seavitt et al. 1999).  
The discovery of the phosphatase activity of CD45 and its biological role in 
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promoting T lymphocyte proliferation served as an important conceptual advance in the 
field of phosphatases as a demonstration of their ability to actively regulate cell signaling 
rather than merely antagonize RTKs functions (Tonks 2013). For one, the example of CD45 
invalidates the proposed designation of phosphatases as “erasers” since its activity leads to 
an increase in phosphorylation of a number of downstream targets. 
CD45 knockdown impaired AML outgrowth upon transplantation (Saint-Paul et al. 
2016). On the other hand, CD45 was also shown to be a negative regulator of JAKs (Irie-
Sasaki et al. 2001), thus AML cells have to strike a balance between CD45 cellular functions 
that are likely context-specific. 
While looking for novel compounds with preferential toxicity towards HOXA9-
MEIS1-transformed cells, Saint-Paul et al. showed that Pyrido[4,3-b]quinoxaline (PyQ) 
exhibited anti-leukemic properties both in vitro and in vivo (Saint-Paul et al. 2016). They 
reported that CD45 in AML cells was associated with lipid rafts — cholesterol- and 
glycosphingolipid-enriched patches located in the plasma membrane, promoting Src 
signaling. PyQ treatment resulted in CD45 dissociation from the lipid rafts and inhibitory 
phosphorylation on Src kinase Lyn. 
Of note, CD45 CRISPR-mediated knockout in the standardized culture conditions 
did not cause proliferation defects in any human leukemia cell lines, according to DepMap 
(Meyers et al. 2017; Dempster et al. 2019). Since CD45 is also reported to suppress JAKs, 
more studies are needed to delineate the roles of CD45 in different contexts. 
1.2.2.10. PTP1B 
PTP1B was the first isolated protein-tyrosine phosphatase (Tonks et al. 1988b). Early 
on, its activity has been associated with type II diabetes and obesity, and it has numerous 
other functions in the cell (Tonks 2003). 
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Tonks’ group was the first to notice in 1998 that PTP1B was specifically enhanced at 
the transcriptional level in the human myeloid cells expressing BCR-ABL1 and in CML 
patient samples (LaMontagne et al. 1998). They showed that this overexpression was 
mediated through BCR-ABL1 kinase activity. Using PTP1B substrate-trapping mutant — an 
elegant phosphatase substrates discovery method also invented in Tonks’ laboratory — and 
measuring BCR-ABL1 phospho-tyrosine (pTyr) levels upon PTP1B overexpression in the 
cells, the study conclusively showed that PTP1B dephosphorylated BCR-ABL1. Later, the 
group moved on to structural studies of PTP1B that allowed to identify trodusquemine 
(MSI-1436) — a potent allosteric inhibitor of PTP1B (Krishnan et al. 2014). 
In a 2011 study, Cotter’s laboratory using PTP1B knockdown and previous 
generation PTP1B inhibitors showed that inhibition of PTP1B phosphatase activity resulted 
in BCR-ABL1 degradation in human CML cell lines through the polyubiquitination-
mediated autophagy-lysosome pathway (Alvira et al. 2011). A 2016 study by Elgehama et al. 
corroborated these findings by using a small molecule that blocked the interaction between 
BCR-ABL1 and PTP1B and exhibited preferential cytotoxicity toward human BCR-ABL1-
positive cell lines (Elgehama et al. 2016). Neviani et al. reported the importance of the 
structural role of BCR-ABL1 oncogene in leukemogenesis, particularly in maintaining LSC 
fate (Neviani et al. 2013). In this regard, PTP1B might be an attractive therapeutic target in 
BCR-ABL1-positive malignancies.  
1.2.2.11. PTPRJ 
The receptor-type protein tyrosine phosphatase PTPRJ (alias DEP-1) was first 
discovered in adherent cell cultures as associated with the high cell density (Ostman et al. 
1994) and later named one of the critical phosphatases in hematopoietic cells regulating 
SFKs, similarly to CD45 (Hermiston et al. 2009). It is often mutated in different cancers 
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suggesting its role as a tumor suppressor (Julien et al. 2011).  
PTPRJ takes off the inhibitory tyrosine phosphorylation on SFKs, enhancing their 
activity. On the other hand, PTPRJ dephosphorylates and negatively regulated downstream 
signaling by receptor tyrosine kinases, including FLT3 (Arora et al. 2011; Godfrey et al. 2012; 
Bohmer et al. 2013; Kresinsky et al. 2018). PTPRJ inactivation in AML cells was shown to 
happen via FLT3-ITD-induced reactive oxygen species (ROS) levels. In line with that, 
inhibition of ROS formation restored Ptprj activity and impaired colony formation by 
murine lymphoblasts stably expressing FLT3-ITD (Godfrey et al. 2012). Of note, Tonks’ 
group was the first to definitively show that oxidation and inactivation of PTPs by ROS was 
an important regulatory mechanism in vivo (Meng et al. 2002; Tonks 2005; Boivin et al. 2008). 
1.2.2.12. PPM1D 
TP53 is one of the most commonly mutated tumor suppressors in human cancers. It 
is a critical nod in cellular signaling networks accumulating information from multiple 
sources and processing go/no-go decisions concerning every aspect of cell viability and cell 
division. TP53 mutations in AML are considered poor prognosis (Table A) (Herold et al. 
2020). Only ~8% of de novo AML cases harbor TP53 mutations, compared to 30% of t-AML 
patients, and up to 70% of AML cases in elderly patients with complex karyotype AML 
(Molica et al. 2020).  
Zuber et al. noted the apparent absence of cooperativity between MLL-fusions and 
p53 in promoting leukemia, whereas p53-loss accelerated leukemias induced by most other 
common AML oncogenes (Zuber et al. 2009). The authors hypothesized that some leukemia 
cells develop mechanisms to evade the p53 network during leukemogenesis. For example, 
AML cells upregulate murine double minute 2 (MDM2), a negative regulator of p53 
(Khurana and Shafer 2019). Several potent and selective small-molecule MDM2 inhibitors 
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are currently explored in clinical studies with mixed reports on their benefits (Grieselhuber 
and Mims 2021). 
Protein phosphatase Mg2+/Mn2+ Dependent 1D (PPM1D) is an important negative 
regulator of p53 (Lu et al. 2008). It is also called wild-type p53-induced phosphatase 1, 
WIP1, since p53 normally induces its expression as part of a regulatory feedback loop 
negatively regulating apoptosis. PPM1D was found to be overexpressed in several cancers 
at baseline or in response to chemotherapy (Hsu et al. 2018). Hsu et al. showed that PPM1D 
mutations conferred resistance to apoptosis to cells, specifically under the selective pressure 
of cytotoxic therapies. Recently, PPM1D gain-of-function mutations were reported to be 
common in patients with t-MDS and t-AML (Lindsley et al. 2017). This makes PPM1D a 
potential therapeutic target in the combination therapies against TP53 wild-type leukemias.  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1.3. Current and emerging agents and regimens for AML 
This chapter describes currently approved therapies for AML and underlines the importance 
of identifying new targets and regimens, specifically for the patients ineligible for the intensive 
therapy and patients presented with relapsed AML or AML refractory to all other treatments (R/R). 
1.3.1. Intensive therapy 
The standard first-line therapy for AML remained largely unchanged since 1973, 
with few modifications made in the past two decades, discussed below. It consists of 
induction therapy and consolidation therapy (Carter et al. 2020). The goal of induction 
therapy is complete remission defined by the presence of less than 5% of leukemic blasts in 
the post-induction bone marrow differential. It is chemotherapy with a common “7+3” 
regimen of 7 days of cytosine-arabinoside (cytarabine, or ara-C) infusions and co-
administration of an anthracyclin (daunorubicin or idarubicin) in the first 3 days. 
Cytarabine mimics deoxycytosine and gets incorporated into human DNA in the S phase of 
mitosis, preventing DNA synthesis in rapidly dividing cells. Anthracyclines are DNA 
intercalating agents inhibiting topoisomerase II functions, which results in DNA damage 
and apoptosis induction. Besides severe bone marrow suppression and corresponding 
complications (anemia, need for blood transfusions, increased risk of infections, and sepsis), 
each drug has its own toxicity profile. For example, anthracyclines exhibit cardiotoxicity, 
limiting the most intensive induction therapy to people under 60 or otherwise in good 
health. The recent improvement in the induction therapy administration is CPX-351 — a 
liposomal formulation of cytarabine and daunorubicin with enhanced pharmacodynamics 
and pharmacokinetics, demonstrating better outcomes in high-risk patients 60–75 years old 
(Lancet et al. 2018). Following successful clinical trials, FDA approved CPX-351 for newly 
diagnosed AML with poor prognosis and t-AML (Alfayez et al. 2020), and the improved 
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overall survival was confirmed in a recent 5 years follow-up study (Lancet et al. 2020). 
Even if a patient achieves a complete remission upon the conventional induction 
therapy, they will likely relapse in the following year without consolidation therapy. Again, 
more options are available for younger patients, such as high-dose ara-C (HiDAC) and stem 
cell transplant. Older patients ineligible for these treatments have benefited the most from 
the recent approvals of novel targeted therapies for AML discussed below. 
Conventional chemotherapies cannot completely eliminate leukemic clones as they 
lack to address specific genetics and epigenetics alterations in the AML cells and distinct 
cellular states, making them more resistant to cytotoxic agents (such as LSCs). Most recently 
approved AML therapies target molecular pathways uniquely required for AML cell 
proliferation and survival (Fig. C). 
1.3.2. Gemtuzumab ozogamicin (GO) 
Gemtuzumab ozogamicin was the first monoclonal antibody (mAb) therapy 
developed against AML. It is an antibody-drug conjugate directed at the CD33 antigen 
highly expressed on the surface of AML cells. The CD33 mAb is covalently linked with a 
cytotoxic drug N-acetyl gamma calicheamicin. GO is usually considered in CD33high and 
CBF-AML patients at both induction and consolidation phases. Despite low levels of CD33 
in CBF-AML patients (Appelbaum and Bernstein 2017), the addition of GO increased their 
estimated long-term survival rate from 50% to 75%, making t(8:21) and inv(16)/t(16;16) 
CBF-characteristic translocations better risk in the absence of most other abnormalities 
(Table A) (Kantarjian et al. 2021). The proposed theories for GO efficacy in CD33low CBF-
AML patients cohort are the enhanced sensitivity of CBF-AML blasts to cytotoxic agents and 
the presence of CD33 at the surface of their LSCs (Walter et al. 2012). 
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1.3.3. FLT3 inhibitors 
The prevalence of FLT3 mutations in the AML population, their established role in 
leukemogenesis, and association with poor prognoses made this kinase a desirable target for 
drug development. Midostaurin (April 2017) and gilteritinib (November 2018) were the first 
FLT3 inhibitors approved by the FDA for therapy in adult patients with relapsed or 
refractory (R/R) AML positive for FLT3 mutations (Kim 2017; Dhillon 2019). They are now 
becoming a standard practice in FLT3mut AML considered both at induction and 
consolidation phases (Kantarjian et al. 2021). Other highly selective FLT3 inhibitors such as 
quizartinib and crenolanib are currently evaluated in clinical trials both in the upfront and 
R/R settings. 
Although FLT3 targeting showed great initial promise in the clinic, and FLT3 
inhibitors achieved impressive potency and specificity, multiple resistance mechanisms have 
already emerged. The most common include on-target mutations, upregulation of 
alternative signaling pathways (e.g., mutations in RAS pathway and kinases AXL and 
PIM1), elevated paracrine signaling of FL in the bone marrow AML niche through the wild-
type allele of FLT3, and drug clearance in the liver and bone marrow microenvironment 
(Daver et al. 2019; Eguchi et al. 2020).  
1.3.4. IDH1/2 inhibitors 
The inhibitors for isocitrate dehydrogenases IDH1 and IDH2 represent another set of 
FDA-approved drugs targeting AML-specific molecular alterations. Mutations in isocitrate 
dehydrogenases IDH1 and IDH2 are reported for up to 20% of AML patients (DiNardo et al. 
2015). IDH1/2 are metabolic enzymes that catalyze the conversion of isocitrate to α-
ketoglutarate (αKG) accompanied by NADPH production (Martelli et al. 2020). The 
mutations result in the neomorphic activity of the enzymes: they consume NADPH to 
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convert αKG into R-2-hydroxyglutarate (R-2-HG). R-2-HG is an oncometabolite that 
accumulates in IDH1/2mut AML cells at high levels and poisons the activity of enzymes, 
relying on αKG for their function. In particular, epigenetic modifiers, such as TET1/2 DNA 
demethylases and histone lysine demethylases (KDMs), are affected by the IDH1/2 
mutants, which results in DNA and histone hypermethylation. Other IDH1/2mut specific 
changes include dysregulation of glutamine and tricarboxylic acid (TCA) cycle metabolism 
and multifaceted metabolic reprogramming (Carter et al. 2020). 
IDH1R132H knock-in allele was shown to cause myeloproliferative phenotype in mice, 
accompanied by the characteristic leukemic “hypermethylation signature” (Sasaki et al. 
2012). The oncogenic role of IDH2 mutation was directly demonstrated in mouse models 
first by acute genetic inactivation (Kats et al. 2014) and later with the development of IDH2 
specific inhibitors (Kats et al. 2017). Both IDH1 and IDH2 inhibitors lowered the levels of 
R-2-HG and induced terminal differentiation of cells, retaining the mutations. The success of 
pre-clinical trials and the ease of patient stratification studies prompted the rapid 
development of IDH1/2 mutant specific inhibitors that soon passed the clinical trials for 
FDA approval (Martelli et al. 2020).  
The activating mutations in NRAS, KRAS, and PTPN11 are predictive of a decreased 
clinical response to IDH1/2 inhibitors. Secondary resistance mechanisms also included 
phospho-signaling pathways and on-target mutations. 
1.3.5. Hypomethylating agents (HMAs) 
AML is characterized by dysregulated DNA methylation. Spencer et al. in 2017 
attributed at least one such change, CpG island hypermethylation, to a byproduct of the 
rapid cellular proliferation, not inherently leukemogenic (Spencer et al. 2017). They argued 
that AML samples with the dominant-negative mutations in DNA methyltransferase 3A 
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(DNMT3A) exhibited dramatically reduced patterns of DNMT3A-driven CpG island 
hypermethylation, despite these mutations present in ~22% of de novo AML and 
significantly associated with poor prognoses (Ley et al. 2010). Nevertheless, DNA 
hypermethylation signature is characteristic for other common mutations in AML such as 
IDH1/2 and TET2. The use of DNA HMAs, such as azacitidine or decitabine, has shown 
modest clinical benefits and has been approved by FDA for the first-line treatment of AML 
in patients unfit for conventional chemotherapies. In September 2020, azacitidine was also 
approved as first-of-kind maintenance therapy in AML patients in first remission after 
standard induction and consolidation regimens (Roboz et al. 2016).  
1.3.6. Hedgehog (HH) pathway inhibitor: glasdegib 
The non-canonical Hedgehog (HH) pathway has emerged as a target in AML only in 
the past decade. It is a well-conserved pathway in the embryogenesis regulating 
maintenance, fate determination, and regeneration of adult tissues (Ingham et al. 2011). In 
2014 Zahreddine et al. showed that HH glioma zinc finger transcription factor GLI1 mRNA 
levels were elevated at relapse and conferred drug resistance to AML cells (Zahreddine et al. 
2014). The HH positive regulator Smoothened (SMO) and GLI1 were also reported to be 
upregulated in radiation-resistant AML (Li et al. 2016). Later evidence suggested HH 
signaling to be implicated in LSCs maintenance (Zhao et al. 2009). 
The SMO inhibitor glasdegib (PF-04449913) decreased leukemia initiation in serial 
transplantation assays in PDX mouse models (Fukushima et al. 2016). In clinical trials, 
glasdegib showed low toxicity and significant improvement in the overall survival of older 
patients with AML, resulting in its FDA approval in November 2018 for patients ≥75 years 
old or ineligible for intensive therapy (Hoy 2019). It is continued to be used in the clinic with 
moderate clinical benefits (Cortes et al. 2020). 
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1.3.7. Bcl-2 inhibitor: venetoclax 
AML cytogenetic and molecular abnormalities often include activation of oncogenes 
(FLT3, BCR-ABL1, etc.) and inactivation of tumor suppressor genes (TP53, etc.). In addition 
to these driver mutations, cancer cells exhibit a variety of cellular stress phenotypes 
associated with the selective pressure for unlimited proliferation. These stress phenotypes 
need to be kept in check by non-mutated genes that cancer cells become dependent on. The 
arising context-specific cancer vulnerabilities are termed non-oncogene addictions (Luo et 
al. 2009). For example, cancer cells have to maintain a precarious balance between pro-
apoptotic and anti-apoptotic machinery, paradoxically leaving them more susceptible to 
apoptosis (Sarosiek and Letai 2016). 
Since the early 1990s, researchers reported that AML cells had increased BCL-2 
expression associated with increased growth in vitro and poor prognoses. BCL-2 and MCL-1 
(mentioned above as upregulated by the FLT3 kinase) are frequently exploited by AML cells 
to prevent the mitochondrial pathway of apoptosis (Carter et al. 2020). BCL-2 specific 
inhibitor venetoclax was designed to fit its BH3-binding site, mimicking the inactivating 
action of BH3-only proteins on BCL-2 and showed impressive selectivity against its target 
(Merino et al. 2018). FDA first approved it in 2016 as a monotherapy for patients with R/R 
chronic lymphocytic leukemia (CLL) with del(17p) (TP53 deletion) (Deeks 2016). Venetoclax 
induced apoptosis in AML cell lines and primary patient samples in a BCL-2-dependent 
manner (Pan et al. 2014). While not as effective as monotherapy, venetoclax showed clinical 
benefits in combination with low-dose chemotherapy and HMAs and was approved in 
November 2018 for patients ≥75 years old or unfit for conventional chemotherapies (Apel et 
al. 2021). However, it is important to note that resistance to venetoclax regimens develops in 
less than 2 years (DiNardo et al. 2020a).  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Figure C. History of AML therapies. 
Timeline of approved clinical therapies in the United States for the treatment of AML. Figure from 
Carter et al. 2020, Fig. 1. 
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1.4. The search for non-oncogene addictions 
This chapter introduces the reader to the high-throughput approach adopted by the Vakoc 
laboratory to search for novel genetic dependencies in cancer. The latter can include oncogene or non-
oncogene addictions, and two examples of mechanisms for non-oncogene addiction are provided. 
Many of the currently approved precision medicines against AML discussed in the 
previous section are based on the concept of oncogene addiction (FLT3, IDH1/2). However, 
tumor heterogeneity and secondary resistance challenge their long-term success in the clinic. 
The emerging strategy is identifying non-oncogene addictions contributing to a more 
extensive repertoire of cancer drivers, as exemplified by venetoclax. While not immune to 
resistance, venetoclax showed broad activity against AML with different drivers.  
Some of these non-oncogene addictions arise as collateral vulnerabilities. For 
example, cancer cells may lose gene A with the deletion of a tumor suppressor gene or as a 
part of a genetic streamlining program. If gene A controlled one of the two redundant 
pathways important for cell fitness, the cells would become addicted to the genes 
supporting the remaining pathway. Other non-oncogene addictions are essential 
counterparts of cellular stress phenotypes constituting the cancer condition, such as the 
increased anti-apoptotic signaling discussed above or altered metabolic state of cancer cells 
(Luo et al. 2009).  
1.4.1. Examples of mechanisms for non-oncogene addictions 
1.4.1.1. Genetic streamlining 
The genetic streamlining hypothesis postulates that cancer cells suffer from a burden 
of non-adaptive alterations while ensuring unlimited proliferation. For example, the 
increased hypermethylation observed in AML cells was recently implicated by our group in 
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two synthetic lethal non-oncogene addictions: the dependency on SLC5A3 myo-inositol 
transporter in the AML cells with silencing of ISYNA1, the rate-limiting myo-inositol 
biosynthesis enzyme; and the dependency on Fanconi anemia proteins in the AML cells that 
epigenetically silence the expression of ALDH2 (Wei et al. 2020; Yang et al. 2021). 
Another example is the hypermethylation of the CpG island at the promoter region 
of asparagine synthetase (ASNS) in ALL cells that prevents ATF4 recruitment and its 
subsequent transcription (Jiang et al. 2019). Asparagine depletion is an important therapy 
option in ALL patients, made possible via treatment with a purified bacterial enzyme L-
asparaginase, depleting circulating asparagine (Avramis 2012). 
AML cell lines that lack the expression of argininosuccinate synthetase 1 (ASS1) 
depend on extracellular arginine concentrations and were sensitive to arginine deiminases 
(Miraki-Moud et al. 2015; Mussai et al. 2015). 
1.4.1.2. Altered metabolism 
Cancer cells are characterized by metabolic reprogramming that serves their 
increased need for protein synthesis and energy production. One example of this metabolic 
reprogramming is the Warburg effect, whereas cancer cells exhibit high aerobic glycolysis 
using up pyruvate instead of a more efficient oxidative phosphorylation (OXPHOS) coupled 
ATP synthesis in the mitochondria (Warburg 1956). This apparent inefficiency was later 
appreciated as a necessary anabolic adaptation that allows cells to produce enough nutrients 
for proliferation via glycolysis interconnected pathways such as the pentose-phosphate 
pathway supplying cells with nucleotides (Hay 2016). Similar to other cancers, high glucose 
consumption and a characteristic glucose metabolic signature were observed in AML 
patients (Chen et al. 2014; Cunningham and Kohno 2016). AML oncogene FLT3-ITD was 
specifically shown to confer dependence on glycolysis and sensitivity to its pharmacologic 
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inhibition (Ju et al. 2017). Ye et al. proposed that leukemia cells could cause systemic glucose 
metabolism changes in patients through driving insulin resistance (Ye et al. 2018). Contrary 
to the original Warburg’s hypothesis, both OXPHOS and TCA cycles are intact in cancer 
cells and also feed multiple biosynthetic pathways. 
A few recent papers focused on the differences in metabolism between LSCs and 
bulk AML cells. First, LSCs, similar to HSCs, have been shown to contain less ROS levels as 
compared to the bulk AML blasts (Lagadinou et al. 2013). Second, these “ROS-low” cells 
with functional characteristics of LSCs preferentially relied on OXPHOS for ATP production 
as opposed to the bulk AML blasts that required glucose for their proliferation. OXPHOS is 
coupled with the TCA cycle, which, in  de novo AML patients, is fueled by the constant 
supply and catabolism of amino acids, making these LSCs hypersensitive to the amino acid 
levels in contrast to bulk AML blasts or normal HSPCs (Jones et al. 2018). LSCs from R/R 
AML patients were demonstrated to develop metabolic plasticity allowing them to utilize 
other fuels and drivers for their energy metabolism, such as fatty acids and nicotinamide 
(Jones et al. 2018; Jones et al. 2020). The distinct metabolic states of different populations of 
AML cells led to context-specific dependencies, such as the novel requirement of R/R LSCs 
for nicotinamide phosphoribosyltransferase (NAMPT) — the rate-limiting enzyme in 
nicotinamide metabolism (Jones et al. 2020). Interestingly, Pereira et al. showed that different 
AML cell lines maintain distinct metabolic profiles, with some cell lines more dependent on 
OXPHOS, whereas others exhibited reliance on glycolysis. Thus, different AML cell lines 
could also potentially exhibit unique vulnerabilities that correlate with their energy 
metabolism (Pereira et al. 2018). 
In the interest of time, we will only briefly outline some other examples of metabolic 
rewiring in AML with a specific focus on the alterations in amino acid metabolism. 
Cancer cells were shown to become addicted to glutamine, which could be utilized 
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in addition to pyruvate to fuel the TCA cycle (Hensley et al. 2013). In AML cells, inhibition 
of glutaminase (GLS) catalyzing glutaminolysis, the first step of glutamine conversion into 
the critical TCA metabolite αKG, was reported to induce apoptosis and synergized with the 
BCL-2 inhibition (Jacque et al. 2015). Besides TCA, αKG is used by the cell for fatty acid 
synthesis, NADPH production, and protection from ROS via glutathione (Kreitz et al. 2019). 
Glutaminolysis was shown to act as a metabolic adaptation in response to TKIs in FLT3-ITD-
driven leukemia and a metabolic dependency in IDH1/2mut AML (Gallipoli et al. 2018; 
Matre et al. 2016).  
Glutamine also serves as one of the central nodes in anabolism (Nicklin et al. 2009). 
The other glutaminolysis product, glutamate, acts as a nitrogen source for the biosynthesis 
of amino acids and nucleotides. Apart from amino acid biosynthesis, glutamine contributes 
to the transport of other amino acids into the cells, such as leucine, a major regulator of 
mammalian target of rapamycin mTORC1 nutrient sensor. One leucine molecule is 
transported into the cell via a heterodimeric bidirectional antiporter SLC7A5/SLC3A2 in 
exchange for the export of one glutamine molecule. The knockout of the high-affinity 
glutamine transporter ASCT2 (SLC1A5) was shown to impair leukemogenesis in human 
AML cell lines and in mouse AML models in contrast with minimal to moderate defects for 
the normal hematopoiesis (Willems et al. 2013; Ni et al. 2019). These effects were coupled 
with broad metabolic changes associated with the tight balance between glutamine levels in 
the cell and other amino acids biosynthesis and transport, as well as glycolytic and pentose 
phosphate pathways. In particular, permeable leucine analog rescued the Slc1a5-knockout 
phenotype through restoring mTORC1 signaling. Importantly, αKG failed to rescue Slc1a5-
depleted leukemic cells whereas promoting survival of normal HSPCs with the Slc1a5 
knockout. This fact illustrates the AML-specific dependency on amino acid homeostasis 
independent of the other glutamine role in supporting aberrant glycolytic levels of AML. 
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Leucine and other branched-chain amino acids (BCAAs) can also be synthesized de 
novo via BCAA transaminases 1 (BCAT1) and 2 (BCAT2). Interestingly, BCAT1 was found to 
be upregulated in LSCs (Raffel et al. 2017). Raffel et al. found the increased BCAAs 
production to be associated with the decrease in αKG levels and the following 
downregulation of αKG-dependent epigenetic regulators resulting in DNA and histone 
hypermethylation similar to IDH1/2 mutations. BCAT1 overexpression and BCAAs were 
also implicated in CML progression from chronic to blast phase and de novo AML (Hattori et 
al. 2017). 
 FLT3-ITD was reported to drive de novo serine biosynthesis (increased expression of 
PHGDH and PSAT1) and uptake (increased expression of SLC1A4 and SLC1A5) through 
regulating the mTORC1-ATF4 axis (Bjelosevic et al. 2021). FLT3-ITD-driven AML cells 
exhibited sensitivity to PHGDH inhibitors, potentially through the restriction of serine 
contribution to nucleotide biosynthesis. 
1.4.2. Genetic screens for non-oncogene addictions 
The cornerstone of modern cancer target discovery is functional genomics made 
possible by the Human Genome Project and the advances in the precise gene perturbation 
techniques. Simultaneous inactivation of multiple genes in isogenic backgrounds led to the 
rapid expansion of the universe of putative cancer targets and provided insights into 
already known and newly discovered molecular mechanisms and cellular functions.  
1.4.2.1. Before CRISPR 
Before the discovery of RNA interference (RNAi), large-scale genetic perturbations in 
mammalian systems were attempted via random mutagenesis, for example, the retroviral 
insertional mutagenesis, primarily useful for the discovery of oncogenes (Uren et al. 2005). 
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Later, transposon insertional mutagenesis was introduced, first the Sleeping Beauty, then the 
PiggyBac. All these systems are limited to their integration site preferences, but to this day, 
they serve as a powerful tool for in vivo forward genetic screens (Takeda et al. 2021). 
RNAi, a conserved cellular pathway for the targeted protein expression 
downregulation, allowed high-throughput screening of hundreds of genes in mouse and 
human cancer cell lines. RNAi screens uncovered many novel therapeutic targets (Zuber et 
al. 2011b; Zuber et al. 2011c) and therapy resistance mechanisms. However, these techniques 
have limitations such as low resolution due to variable gene inactivation, dependent on the 
baseline expression level of the target, and serious off-target effects (McDonald et al. 2017). 
1.4.2.2. CRISPR-Cas9 
CRISPR-Cas9 system has proven to be a breakthrough innovation in gene editing, 
driving the explosive growth of applications and bringing its founders Emmanuelle 
Charpentier and Jennifer Doudna the Nobel Prize in Chemistry less than a decade after the 
discovery of its last component — tracrRNA — in 2011 (Deltcheva et al. 2011; Knott and 
Doudna 2018). CRISPR-Cas9 allowed high-resolution genome-wide loss-of-function screens 
in hundreds of cancer cell lines. Soon after the technology became accessible to independent 
research groups, multi-institutional consortia, such as DepMap, started a major effort in 
mapping cancer dependencies both through massively parallel technology implementation 
and providing open access to the results (Meyers et al. 2017; Dempster et al. 2019). 
Some of the important considerations in designing CRISPR-Cas9 loss-of-function 
screens include predicting sgRNAs off-target effects (Hsu et al. 2013) and ensuring that the 
sgRNAs target exons that encode the functional domains of the proteins (Shi et al. 2015). The 
latter approach, described in detail by our group, dramatically increased the signal-to-noise 
ratio of the screens and even allowed de novo identification of cancer-relevant protein 
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domains upon tiling the exons of the candidate genes with potent sgRNAs.  
Other targets, elusive for the straightforward screening approaches, are genes that 
share a common role in supporting a cell fitness pathway. These types of targets require 
double sgRNA library systems for combinatorial perturbation that have been described in 
the literature and independently designed in our laboratory (Wong et al. 2016; Han et al. 
2017; Klingbeil, unpublished).  
Most of the high-throughput screens carried out in the literature and in the public 
databases were performed in the standardized 2D cell cultures. There have been multiple 
reports in the literature on the discrepancies between these systems and more physiological 
mediums of cell culturing (albeit arguably less adaptable for the high-throughput screening 
approaches) (Boj et al. 2015; Kota et al. 2018; Chow and Chen 2018; Rossiter et al. 2020). 
However, the data from our laboratory suggest that 2D conditions largely recapitulate cell-
autonomous mechanisms of cell proliferation, at least for AML (Wei et al. 2020).  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1.5. HAD phosphatases in cancer 
Our study identified an HAD phosphatase required for AML cell proliferation. This chapter 
introduces the reader to HAD phosphatases, their catalytic mechanism, and the few known examples 
of HAD phosphatases playing a role in cancer. 
Haloacid dehalogenase (HAD) hydrolases, named after the archetypal prokaryotic 
enzyme, are present in all three domains of life. The superfamily encompasses a broad range 
of enzymes that catalyze the hydrolysis of diverse substrates, using an active site aspartate 
in nucleophilic catalysis (Burroughs et al. 2006). The majority of members of this 
superfamily serve as phosphatases (phosphate monoester hydrolases). They 
dephosphorylate a wide range of substrates: from low molecular weight metabolites to 
protein residues with exquisite specificities (Seifried et al. 2013).  
The mammalian HAD phosphatase family members can be identified by the highly 
conserved catalytic core residues embedded in signature motifs. HAD signature motif 1 has 
the consensus sequence hhhDxDx(T/V)(L/V)h, where h is a hydrophobic residue, and x — 
any aminoacid. The two aspartate residues (Asp, D) in the active site are essential for the 
characteristic two-step catalytic mechanism (Fig. D), and coordinate the Mg2+ in the active 
site. Motif 2 has the consensus sequence hhh(S/T), and the conserved serine/threonine 
(Ser/Thr, S/T) residue forms a hydrogen bond with the phosphoryl group of the substrate 
to correctly position it for the nucleophilic attack. Motif 3 contains a conserved lysine (Lys, 
K) residue that stabilizes the negative charge of the phosphoryl group and the phospho-
aspartyl intermediate together with Ser/Thr of motif 2. Motif 4 contains at least two of the 
Asp (D)/Glu (E)/Asn (N)/Ser (S) residues and hydrophobic residues. The conserved 
residues of Motif 4 together with Motif 1 coordinate Mg2+ in the active site. 
Motifs 1–4 are positioned in a Rossmann-like (Rossmannoid) fold, characterized by a 
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β-sheet sandwiched between α-helices. Other conserved structural elements of the HAD 
phosphatases, such as the squiggle, flap, and cap domains, allow the enzymes to alternate 
between closed and open states of the active site cavity, regulating solvent access during the 




Figure D. Catalytic mechanism for HAD phosphatases.  
Numbering indicates catalytic residues in Eya3, a murine HAD phosphatase. Sub — substrate.  
Motif 1 residues are red, motif 2 residues are green, motif 3 residues are cyan, and motif 4 residues are 
orange.  
The catalysis starts with binding the phosphorylated substrate mediated by Mg2+ ion and substrate 
specificity determinants outside of the active site (not shown). First, the catalytic Asp (Asp246 in 
Eya3) initiates a nucleophilic attack on the phosphoryl group of the substrate, forming a 
phosphoaspartyl intermediate stabilized by Mg2+. Asp+2 (Asp248) serves as a general acid motif to 
protonate the leaving substrate. Second, the phosphoaspartyl intermediate is hydrolyzed by a 
nucleophilic attack of a water molecule, resulting in the release of the phosphate group and 
regeneration of the catalytic Asp. Asp+2, this time serves as a general base motif by deprotonating the 
water nucleophile.  











































































































1.5.1. EYA phosphatases 
The family of Eya proteins is one of the best studied in the HAD superfamily. Eya 
was originally identified in Drosophila as an essential transcriptional co-activator of the Six 
family of homeoproteins that regulated organ development (Pignoni et al. 1997; Chen et al. 
1997). Soon followed the discovery that Eya belongs to the HAD superfamily and exhibits 
protein tyrosine phosphatase catalytic activity (Tootle et al. 2003), though it might not be 
required for its role in transcriptional activation after all (Jin et al. 2013). In mammals, Eya 
paralogs (Eya1–4) regulate the formation of many organs, and congenital mutations in Eya 
result in developmental abnormalities (Jemc and Rebay 2007). 
The phosphatase activity of Eya proteins has been associated with multiple 
pathways important for cancer progression, such as promoting cancer cell proliferation and 
metastasis (Pandey et al. 2010), angiogenesis (Wang et al. 2016b), and activation of Sonic 
hedgehog (Shh) signaling in medulloblastoma (Eisner et al. 2015).  
One of the best defined roles for Eya1–3 proteins is dephosphorylation of the C-
terminal pY142 on histone H2AX, independently confirmed in 2009 by Tonks’ and 
Rosenfeld’s groups. H2AX phosphorylation drives DNA damage signaling priming cells for 
apoptosis. Dephosphorylation by Eya promotes DNA repair, making cells more resistant to 
DNA-damaging chemo- and radiotherapies (Krishnan et al. 2009; Cook et al. 2009). A few 
cancers are known to overexpress Eya, such as ovarian carcinomas and Ewing sarcomas 
(Zhang et al. 2005; Robin et al. 2012). Another potential substrate for Eya proteins is the 
estrogen receptor β (ERβ) activating residue pY36. Active ERβ acts as a tumor suppressor in 
cell lines and mouse xenograft models (Yuan et al. 2014), and high ERβpY36 levels correlate 
with better prognoses in patients. 
Abl kinase was shown to relocalize Eya to the cytoplasm by phosphorylating its PST-
rich region (Xiong et al. 2009). Among the potential additional Eya functions in the 
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cytoplasm is the recently reported Eya3 interaction with the B55α-subunit of PP2A, which 
results in c-Myc dephosphorylation at its pT58 residue, protecting it from degradation (Li et 
al. 2017; Zhang et al. 2018). 
Given the diverse emerging roles of Eya phosphatases in human cancers, various 
research groups sought to develop inhibitors against these targets. The combination of high 
throughput screening and structural biology resulted in the discovery and design of the 
several lead compounds (Park et al. 2011; Tadjuidje et al. 2012; Pandey et al. 2013; Krueger et 
al. 2013) with some showing promise in cell line models (Wang et al. 2016b; Krueger et al. 
2014).  
1.5.2. PDXP/chronophin 
The unique HAD phosphatases feature — cap domain — allows members of this 
phosphatase family to process a wide range of substrates. C0 caps are very small and do not 
restrict access to the open HAD active site. Therefore, C0 HAD members, such as CTD-
phosphatases, are more likely to process macromolecular substrates that themselves would 
serve as a cap to exclude solvent during catalysis. Bulky C1/C2 cap modules are sufficient 
to restrict access to the catalytic cavity and allow HAD phosphatases to act on low 
molecular weight substrates trapped in the active site by cap closure (Seifried et al. 2013). 
Interestingly, for some capped phosphatases, such as PDXP (chronophin), protein 
phosphatase activity has also been reported despite the seemingly occluded active sites.  
Pyridoxal phosphatase (PDXP or chronophin) dephosphorylates pyridoxal 5ʹ-
phosphate (PLP), the active form of vitamin B6. It was initially purified from human 
erythrocytes in 1992 (Fonda 1992) and was later recognized as a C2-cap HAD phosphatase 
(Burroughs et al. 2006). PDXP regulates cellular PLP concentrations and consequently PLP-
dependent enzymes. Increased PLP catabolism was associated with an increased risk of lung 
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cancer (Fanidi et al. 2018). Conversely, clear cell renal carcinomas and AML cells were 
shown to be dependent on the elevated PLP levels suggesting that in these contexts an 
increased PDXP function would be therapeutically beneficial (Ochocki et al. 2018; Chen et al. 
2020). PDXP is often lost or hypermethylated in glioblastomas (Schulze et al. 2016), 
sometimes due to IDH1/2-mutations (Ceccarelli et al. 2016), also common in AML. It would 
be interesting to see whether similar PDXP promoter hypermethylation might be exploited 
by AML cells to sustain high PLP levels.  
1.5.3. Other 
There are few reliable reports on the roles of other HAD phosphatases in cancer. 
CTDSP2 (encoding phosphatase SCP2) is often co-amplified in sarcomas with CDK4 
(Su et al. 1997), but its role as a driver mutation in this disease has not been definitively 
shown.  
SCP3 was reported to activate the tumor suppressor retinoblastoma protein 1 (pRb1) 
in cells via dephosphorylation, thereby inhibiting cell cycle progression (Kashuba et al. 
2004). Its gene, CTDSPL, is deleted or mutated in the majority of human carcinomas, 
including small cell lung cancer and renal cell carcinomas, and exhibited tumor suppressive 
phenotype in mice. 
Gain-of-function mutations in 5’-nucleotidase, NT5C2, have been implicated in 
chemotherapy resistance in ALL since they were specifically acquired at relapse (Oshima et 
al. 2020). NT5C2mut can inactivate nucleoside-analog chemotherapy drugs in the cytosol.  
Polynucleotide 5’-kinase⁄3’-phosphatase (PNKP) is involved in DNA repair and 
confers cancer cells protection from ionizing radiation. This prompted the development of 
small-molecule inhibitors for PNKP for their potential utility in sensitizing human tumors to 
gamma-radiation (Freschauf et al. 2009).  
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L-3-Phosphoserine phosphatase (PSPH) upregulation was associated with squamous 
cell carcinoma in an insertion-mutagenesis transgenic mouse model and was shown to be a 
dependency in cell lines, albeit independent of its role in serine biosynthesis (Bachelor et al. 
2011). The serine biosynthetic pathway is itself a vulnerability in many cancers, as shown by 
RNAi and CRISPR screens (Possemato et al. 2011; Meyers et al. 2017; Dempster et al. 2019). 
For example, serine biosynthesis was recently reported to be a dependency in FLT3-ITD-
driven acute myeloid leukemia (Bjelosevic et al. 2021). A selective inhibitor of PSPH based 
on a structural analogy with L-3-Phosphoserine has been described and could be potentially 
explored in cancers dependent on the de novo serine biosynthesis (Hawkinson et al. 1996). 
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1.6. Current state of research on the topic of this dissertation 
The main focus of this dissertation — phosphatase SCP4 — is a relatively poorly studied 
protein with no prior reports of SCP4 functions in the context of human AML. Similarly, two 
interacting partners of SCP4 — paralog kinases STK35 and PDIK1L — uncovered in the course of 
our study have no clearly defined roles in cell signaling. This chapter summarizes most of the 
published literature mentioning either one of these enzymes and emphasizes the novelty of our 
discovery. 
1.6.1. SCP4 
As of May 2021, a search of the scientific literature in PubMed using SCP4 aliases 
“HSPC129” OR “CTDSPL2” OR “SCP4” returns just 10 research papers after it was first 
cloned among other cDNAs in 2000, ironically, from CD34+ HSPCs (Zhang et al. 2000). Its 
length was correctly determined to be 466 amino acids. The next unbiased study exploring 
subcellular localizations of N-terminally FLAG-tagged cDNAs of unknown cellular 
functions showed striking localization for FLAG-SCP4 at the nuclear rim of human liver 
cancer cells. The latter led Kemmer et al. to propose its association with the nuclear pore 
complex (Kemmer et al. 2006).  
The first study fully dedicated to SCP4 by Qian et al. appreciated the conservation of 
the catalytic residues between FCP1, SCP1, and SCP4 (Qian et al. 2007). All three enzymes 
belong to the HAD family of phosphatases. Although the previous chapter of this 
dissertation introduces the same conserved residues as largely invariant for the catalytic 
mechanism of most HAD phosphatases, Qian et al. proposed that SCP4 might perform a 
similar function to FCP1 and SCP1, which by that time was established as 
dephosphorylation of the C-terminal domain (CTD) tail of the largest subunit of RNA 
polymerase II (Pol II). Thus, the gene and protein names for the entry became CTD small 
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phosphatase-like 2 (CTDSPL2) or small CTD phosphatase 4 (SCP4). Qian et al. optimized 
the E. coli (BL21) purification protocol, including truncation of the first 156 N-terminal 
amino acids that interfered with its expression in bacteria and confirmed its strong 
phosphatase activity in vitro against p-nitrophenyl phosphate and both phosphoserine-5 
(pSer5) and phosphoserine-2 (pSer2) of GST-CTD of Pol II. 
The first paper implying a role for SCP4 in hematopoiesis came out in 2010. Ma et al. 
noticed that SCP4 was expressed at a higher level in erythroid cultures from umbilical cord 
blood than in the adult bone marrow blood, and its expression was upregulated upon 
hemin-induced erythroid differentiation of K562 (Ma et al. 2010). However, their SCP4 RNAi 
knockdown experiments showed that SCP4 was largely dispensable for that process. Later 
work, discussed in more detail below, reported relocalization of SCP4 from the nucleus into 
the cytoplasm in K562 cells treated with hemin for 48 hours (Wani et al. 2016). 
In 2014 Zhao et al. presented data suggesting that SCP4 could dephosphorylate 
transcription factors SMAD1/5/8 in the canonical bone morphogenetic protein (BMP) 
signaling pathway in vivo and in vitro, but not Pol II in vivo (Shen et al. 2014; Zhao et al. 
2014). Through dephosphorylation of the C-terminal SXS motif of SMADs and subsequent 
SMADs nuclear exclusion, SCP4 was reported to negatively regulate BMP signaling induced 
osteoblastic differentiation (Zhao et al. 2014). Notably, just the predicted phosphatase-
domain fragment SCP4263-466 used in that study could not dephosphorylate SMAD1 in vitro 
in contrast to the full-length SCP4 while being expressed and retaining its phosphatase 
activity. The study also reported SMAD1/SCP4 direct binding positively correlating with 
the SMAD1 phosphorylation status. 
The next relevant data on SCP4 came from a 2016 study by Wani et al., who first 
showed that besides preferential nuclear localization, also confirmed in most previous 
works, SCP4 exclusively localized to the chromatin fraction following histone acid 
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extraction protocol for fractionation (Wani et al. 2016). They reported ChIP-qPCR and 
immunofluorescence staining results suggesting the broad distribution of SCP4 over the 
chromatin with some preference towards regions with the enrichment of the H3K27me3 
heterochromatin associated histone mark. 
A 2017 study started a series in the literature on SCP4 potential involvement in 
FoxOs transcription factors regulation (Liu et al. 2017). In murine myoblasts cell line C2C12, 
Liu et al. showed evidence that SCP4 dephosphorylated FoxO1/3a transcription factors, 
promoting their retention in the nucleus. These findings were corroborated the following 
year in vivo and in vitro by Cao et al. (the same group that reported SMADs as potential 
SCP4 substrates) (Cao et al. 2018). Once again, this research group showed stable binding 
between SCP4 and its potential substrates FoxO1/3a in co-IP studies. Ectopic expression of 
SCP4 in a mouse immortalized fibroblasts cell line NIH3T3 resulted in the disruption of the 
dynamic FoxO1/3a nucleus-cytoplasm shuttling in serum starvation experiments 
dependent on SCP4 catalytic activity suggesting a physiological role for FoxO1/3a 
dephosphorylation by SCP4 in promoting nuclear FoxO1/3a retention. More importantly, 
Cao et al. generated SCP4 knockout mice using an SCP4 gene-trap construct. SCP4-/- mice 
completed embryonic development but died within 24 hours after birth due to glucose 
deficiency. Cao et al. proposed that SCP4 was upregulated by glucose deprivation to 
positively regulate FoxO1/3a transcriptional activity in promoting gluconeogenesis under 
physiological conditions. Of note, the reported phenotype for SCP4-null mice is strikingly 
different to FoxO1-null and FoxO3a-null mice. FoxO1-null mice perish just before embryonic 
day 11 due to failures in vascular development, whereas FoxO3a-null mice are viable and 
look similar to their littermate controls (Hosaka et al. 2004). 
The only study so far directly showing a potential role of SCP4 in cancer was done 
by Winans et al. in 2017. In an avian leukosis virus (ALV)-induced B-cell lymphoma model, 
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scp4 was shown earlier to be a common ALV-integration site (Justice et al. 2015). The viral 
promoter drove transcription of an almost intact scp4 with only the first 63 amino acids 
missing (of note, the identity between human and chicken proteins is >93%). Winans et al. 
also reported that scp4 ectopic expression confers some protection to chick embryo 
fibroblasts from apoptosis induced by oxidative stress. 
Overall, our understanding of the cellular roles of SCP4 in various contexts is 
currently limited. First of all, there is no definitive evidence that SCP4 is indeed associated 
with Pol II in vivo during transcription. In this regard, the functional role of SCP4 could be 
elucidated through global ChIP-Seq experiments using well-established antibodies for Pol II 
total levels and Ser2/5/7 phosphorylation upon SCP4 knockout/overexpression. Similarly, 
there is still no ChIP-Seq data for SCP4, given its remarkable association with chromatin. No 
study has yet attempted unbiased RNA-Seq or proteomics analysis for SCP4 knockout or 
catalytically dead samples. 3/10 studies on SCP4 were performed by the same group that 
proposed new substrates for SCP4 in each new context, suggesting that SCP4 functions in 
the cell are largely context-dependent.  
1.6.2. STK35/PDIK1L 
STK35 and PDIK1L belong to a distinct New Kinase Family 4 with largely unknown 
functions. Interestingly, they are a relatively new evolutionary branch reliably detected (and 
relatively well conserved) only in vertebrates (Goyal et al. 2009). According to the Human 
Protein Atlas, STK35 and PDIK1L localize to the nucleoplasm, but the functions of these 
enzymes in this cellular compartment are unclear.  
STK35 has been shown to confer a proliferative advantage in human colorectal 
cancer and osteosarcoma via suppressing apoptosis and promoting glycolysis (Wu et al. 
2018; Yang et al. 2020). High expression of STK35 was associated with unfavorable prognosis 
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in the liver and colorectal cancers. In endothelial cells, STK35 supported cell migration in the 
wound healing assays (Goyal et al. 2011). In humans, STK35 was shown to have a higher 
expression in the retina and testis, and STK35 knockout mice exhibited a range of defects in 
spermatogenesis and eye development (Miyamoto et al. 2018). Interestingly, SCP4 was also 
shown to have a relatively higher expression in the testis in the single cell studies, 
specifically in spermatids (Human Protein Atlas: Qian et al. 2007; Uhlen et al. 2015). Serum 
PDIK1L levels have been implicated in endometriosis detection (Greenbaum et al. 2021).  





2.1. Phosphatase domain-focused CRISPR screening identifies context-specific 
dependencies in human cancer cell lines 
A prior study from our laboratory described a domain-focused CRISPR-Cas9 genetic 
screening strategy that can nominate novel dependencies in cancer by targeting insertion/
deletion (indel) Cas9-mediated mutagenesis to domain-encoding exons (Shi et al. 2015). Our 
group has previously applied this method to identify well-established and novel phospho-
catalytic dependencies in AML among human kinases (Tarumoto et al. 2018). For this 
dissertation, we set out to discover AML-specific dependencies among human 
phosphatases. 
We have first selected all the genes comprised by the group “Phosphatases” 
according to the HUGO Gene Nomenclature Committee at the European Bioinformatics 
Institute. This database in 2016 included 217 genes that encoded proteins with phosphatase 
domains with protein and non-protein substrates (Fig. 1A; Appendix 1). Using the CSHL 
CRISPR sgRNA design tool (El Demerdash, unpublished), we manually curated 1,958 
sgRNAs targeting exons that encoded phosphatase domains of the 217 genes. The library 
was supplemented with positive and negative control sgRNAs and cloned in a pooled 
manner. We used this bespoke library to perform negative selection ‘dropout’ screens in 
eight leukemia and four solid tumor human cancer cell lines (Fig. 1B; Fig. 2; Appendix 2). 
All the cell lines used in the screens have been previously derived in our laboratory from the 
original cell lines to stably express human codon-optimized  Streptococcus pyogenes  Cas9 
protein. The performance of spike-in negative and positive control sgRNAs validated the 
overall quality of these screens (Fig. 3).  
The screens revealed that sgRNAs targeting 187 of the phosphatase domains showed 
no significant impairment of cell fitness in any cell lines tested, similarly to the other screens 
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previously performed in our laboratory. 11/217 (5.1%) phosphatases were essential in ten or 
more cell lines (Fig. 2; Appendix 2) and are likely required for general cell survival. For 
example, FCP1 (CTDP1) and SSU72 phosphatases act on the C-terminal domain of the 
largest Pol II subunit and regulate transcription initiation, elongation, and termination 
(Cossa et al. 2021). The remainder of the targeted phosphatases showed varying degrees of 
specificity, which included the validation of known context-specific phosphatase 
dependencies. For example, the requirement for the phosphatase SHP2 (PTPN11) correlated 
with the RAS mutation status. KRAS G12D, G13D, and NRAS Q61L/H mutations conferred 
resistance to SHP2 CRISPR knockout (Fig. 4A), which corroborates and extends previous 
similar findings (see Introduction §1.2.2.7). Only the cell lines with the wild-type TP53 
showed dependence on WIP1 (PPM1D) (Fig. 4B). WIP1 is known to negatively regulate the 
p53 signaling pathway (see Introduction §1.2.2.12). We have also confirmed the non-
oncogene addiction of the Philadelphia chromosome-positive CML cell line K562 to PTP1B 
(PTPN1) (Fig. 4C), consistent with the data suggesting that PTP1B supports the function of 
BCR-ABL1 protein (see Introduction §1.2.2.10). 
Next, we ranked all of the phosphatases based on their relative essentiality in AML 
versus non-AML contexts, which nominated SCP4 (CTDSPL2) as the top-ranking AML-
biased dependency (Fig. 2). Among the AML cell lines screened, five showed SCP4 
dependency, with MOLM-13 being the most sensitive. In contrast, AML cell lines U937 and 
Kasumi-1 and the CML line K562 did not show significant cell fitness defects upon SCP4 
targeting. None of the evolutionary close SCP subfamily members showed deleterious 
phenotype upon perturbation, except for the CTDSP2 gene that is located in the 12q13-15 
amplicon of the RMS cell line Rh30 (Fig. 4D) and thus constitutes a CRISPR-artifact due to 
an increased number of double-strand breaks. Since no prior study has implicated SCP4 in 







Figure 1. Phosphatase domain-focused CRISPR screen library design and negative selection 
‘dropout’ screen schematics.  
(A) Categorization of human phosphatases targeted by CRISPR-Cas9 genetic screens in this study.  
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Figure 2. The summary of dependencies discovered in the phosphatase domain-focused CRISPR 
screens.  
Extracted essentiality scores for phosphatases demonstrating AML-bias or pan-essentiality. Plotted is 
the log2 fold-change of sgRNA abundance during ~11 population doublings. The effects of individual 
sgRNAs targeting each domain were averaged. *, catalytic subunit; AML, acute myeloid leukemia; 
CML, chronic myeloid leukemia; SCLC, small cell lung cancer; PDAC, pancreatic ductal 
adenocarcinoma; RMS, rhabdomyosarcoma. 
Average log2 fold-change






























































































































































Figure 3. The performance of spike-in negative and positive control sgRNAs.  






























































Figure 4. Phosphatase domain-focused CRISPR screening identifies context-specific dependencies 
in human cancer cell lines.  
Extracted essentiality scores for selected phosphatases. Plotted is the log2 fold-change of sgRNA 
abundance during ~11 population doublings. The effects of individual sgRNAs targeting each 









































































































2.2. SCP4 is an acquired dependency in human AML cells 
To validate the AML-biased essentiality of SCP4, we performed competition-based 
proliferation assays comparing SCP4 sgRNAs to positive (ROSA) and negative (PCNA) 
control sgRNAs in a total of 23 human cancer cell lines: 14 leukemia, 4 pancreatic cancer, 3 
rhabdomyosarcoma, and 2 lung cancer lines. All sgRNA experiments were carried out in 
Cas9-expressing cell lines. The indicated sgRNAs were linked to GFP, and the GFP+ 
population depletion indicated the loss of cell fitness caused by Cas9/sgRNA-mediated 
indel mutations in the endogenous gene sequence (Fig. 5A). 
In these assays, ten leukemia cell lines demonstrated a clear dependency on SCP4, 
whereas four of the leukemia cell lines and all of the solid tumor cell lines were insensitive 
to SCP4 sgRNAs at the same timeframe (Fig. 5B). The sensitive cell lines included 
engineered human MLL-AF9/NrasG12D and MLL-AF9/FLT3ITD AML cell lines (Wei et al. 
2008). In contrast, an sgRNA targeting the DNA replication protein PCNA suppressed the 
growth of all cell lines tested. We confirmed that the differential SCP4 requirement was not 
due to any differences in genome editing efficiency through Western blots (Fig. 6). We have 
also performed rescue experiments using a cDNA encoding N-terminally FLAG-tagged 
sgRNA-resistant SCP4 sequence to ensure that the growth arrest caused by SCP4 sgRNAs 
occurred via an on-target mechanism (Fig. 7).  
In order to better characterize the AML cell phenotype following SCP4 knockout, we 
assessed cell cycle progression and apoptosis. Using flow cytometry-based BrdU 
incorporation measurements, we found that SCP4 inactivation in MOLM-13 cells by day 5 
post-infection with sgSCP4 led to a G1/G0-arrest judged by the accumulation of the cells in 
the G1 phase of cell cycle and the depletion of cells progressing into the S phase (Fig. 8A,B). 
Concurrently, Annexin V staining revealed increases in the early and late apoptosis in the 
same population (Fig. 8C,D).  
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To extend our findings into a more physiological context, we validated that targeting 
SCP4 attenuated the growth of MOLM-13 cells when injected via tail vein and expanded in 
immune-deficient mice (Fig. 9). Therefore, the dependency on SCP4 is not altered by the in 
vitro versus in vivo growth conditions (the possibility discussed in Introduction §1.4.2.2).  
We verified that Scp4 was essential in an engineered murine AML cell line MLL-
AF9/NrasG12D (RN2) (Zuber et al. 2011a), an effect that was rescued by the expression of the 
human SCP4 cDNA (Fig. 10A). However, immortalized NIH3T3 murine fibroblasts were 
unaffected by SCP4 sgRNAs (Fig. 10B), suggesting that the AML-biased dependency on 







Figure 5. SCP4 is an AML-biased dependency.  
(A) Scheme of a competition-based proliferation assay for a negative control (ROSA) and a positive 
control (PCNA). (B) Competition-based proliferation assays in 23 human cancer cell lines infected 
with the indicated sgRNAs. PDAC, Pancreatic Ductal Adenocarcinoma; RMS, rhabdomyosarcoma. 
n=3. 
All bar graphs represent the mean ± SEM. All sgRNA experiments were performed in Cas9-
expressing cell lines. ‘e’ refers to the exon number targeted by each sgRNA. The indicated sgRNAs 
were linked to GFP. GFP+ population depletion indicates loss of cell fitness caused by Cas9/sgRNA-
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Figure 6. The differential requirement for SCP4 in leukemia cells.  
(A) Western blot of whole-cell lysates from MOLM-13 cells on day 5 post-infection with the indicated 
sgRNAs. (B) Competition-based proliferation assay in MOLM-13 cells infected with the indicated 
sgRNAs. n=3. (C) Western blot of whole-cell lysates from K562 cells on day 5 post-infection with the 
indicated sgRNAs. (D) Competition-based proliferation assay in K562 cells infected with the 
indicated sgRNAs. n=3.  
All bar graphs represent the mean ± SEM. All sgRNA experiments were performed in Cas9-
expressing cell lines. ‘e’ refers to the exon number targeted by each sgRNA. The indicated sgRNAs 
were linked to GFP. GFP+ population depletion indicates loss of cell fitness caused by Cas9/sgRNA-








































































Figure 7. Validation of the on-target effect of SCP4 knockout.  
(A) Design of CRISPR-resistant mutant of SCP4. (B) Western blot of whole-cell lysates from 
MOLM-13 cells stably expressing empty vector (EV), wild-type (WT), or CRISPR-resistant (CR) 
FLAG-SCP4. (C) Competition-based proliferation assay in MOLM-13 cells stably expressing empty 
vector, wild-type, or CRISPR-resistant FLAG-SCP4 infected with the indicated sgRNAs. n = 3.  
All bar graphs represent the mean ± SEM. All sgRNA experiments were performed in Cas9-
expressing cell lines. ‘e’ refers to the exon number targeted by each sgRNA. The indicated sgRNAs 
were linked to GFP. GFP+ population depletion indicates loss of cell fitness caused by Cas9/sgRNA-
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Figure 8. SCP4 inactivation in MOLM-13 cells leads to a G1/G0-arrest and the induction of 
apoptosis.  
(A) Representative flow cytometry analysis of BrdU incorporation and DNA content to infer cell cycle 
stage in MOLM-13 cells on day 5 post-infection with the indicated sgRNAs. (B) Quantification of the 
different cell cycle stages in MOLM-13 cells on day 5 post-infection with the indicated sgRNAs. n = 3. 
(C) Representative flow cytometry analysis of DAPI (indicating permeable dead cells) and annexin-V 
staining (a pre-apoptotic cell marker) in MOLM-13 cells on day 5 post-infection with the indicated 
sgRNAs. (D) Quantification of live and apoptotic cells.  
All bar graphs represent the mean ± SEM. All sgRNA experiments were performed in Cas9-
expressing cell lines. ROSA, negative control. 
Data collected by Zhaolin Yang. 
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Figure 9. Targeting SCP4 attenuates the growth of MOLM-13 cells in xenograft mouse model of 
AML. 
(A) Bioluminescence imaging of NSG mice transplanted with luciferase+/Cas9+ MOLM-13 cells 
infected with either sgROSA or sgSCP4. (B) Quantification of bioluminescence intensity. n=3. p-value 
was calculated by unpaired Student’s t-test. *p < 0.05.  
All bar graphs represent the mean ± SEM. ROSA, negative control. 













































Figure 10. AML-biased dependency on SCP4 is conserved across species. 
Competition-based proliferation assays in murine RN2 MLL-AF9/NrasG12D AML cells (A) and NIH 
3T3 immortalized fibroblasts (B) infected with the indicated sgRNAs. Rescue in the RN2 cells stably 
expressing human SCP4 is shown. n=3.  
All bar graphs represent the mean ± SEM. All sgRNA experiments were performed in Cas9-
expressing cell lines. ‘e’ refers to the exon number targeted by each sgRNA. The indicated sgRNAs 
were linked to GFP. GFP+ population depletion indicates loss of cell fitness caused by Cas9/sgRNA-



























































2.3. SCP4 is dispensable in normal hematopoietic progenitor cells 
Blood is one of the few human organs that requires constant replenishing. Signaling 
alterations in AML can include genes and pathways essential for normal haematopoetic 
stem cell differentiation and proliferation of the early haematopoetic progenitors, thus 
posing significant challenges for the targeted therapies development. To evaluate the SCP4 
requirement in non-transformed hematopoietic cells, we set up the collaboration with the 
group of Dr. Mitchell Weiss, the Chair of Hematology Department at St. Jude Children's 
Research Hospital (Memphis, Tennessee). Together with Weiss’ group we performed 
electroporation of Cas9:sgRNA ribonucleoprotein (RNP) complexes into human CD34+ 
HSPCs (Metais et al. 2019). Since sgRNA presence in the cells in this experiment was not 
coupled with the GFP reporter expression, we have optimized an RT-qPCR assay to measure 
the presence of indels at the genomic loci targeted by each sgRNA. To this end, we designed 
pairs of RT-qPCR primers with one primer spanning the Cas9 endonuclease cleavage site 
and the second 100–150 bp away. We benchmarked RT-qPCR-based indel measurements 
against Western blot of MOLM-13/Cas9+ cells infected with our standard lentiviral vector 
encoding sgRNA linked to GFP at two different infection rates (Fig. 11A–C). RT-qPCR 
measurements of editing efficacy corresponded to the Western blot results of SCP4 depletion 
in the same populations, as well as their infection rates.  
The Cas9:sgRNA RNP complexes electroporation into human CD34+ HSPCs resulted 
in a mixed population of cells with an average of 60% cells harboring on-target indel 
mutations on day 5 post-electroporation as estimated by RT-qPCR assay for each replicate. 
As a control, a Mock population (not electroporated) and the population electroplated with 
Cas9:sgRNA RNP harboring a non-targeting (NT) gRNA were used. Immediately after 
electroporation, the cells were divided into myeloid, erythroid, and megakaryocyte lineages 
or mixed with methylcellulose for the colony-forming cell (CFC) assay (Fig. 11D).  
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Each lineage was supplemented with the cytokines promoting its respective 
differentiation and propagated in culture for 16 days. Throughout differentiation into each 
lineage, the genomic DNA was collected from the cells for indel measurements, and Western 
blot samples were made on days 5 and 8 of differentiation. Unlike the effects of targeting the 
essential transcription factor MYC, we observed no evidence that SCP4-deficient cells 
experienced any fitness disadvantage during 16 days of culturing under conditions that 
promoted myeloid, erythroid, or megakaryocytic differentiation (Fig. 11E–G). For myeloid 
lineage, we additionally showed the presence of indels throughout the course of 
differentiation with an orthogonal method using Surveyor nuclease assay (Fig. 11K). More 
importantly, Western blots clearly showed decreased SCP4 protein levels on day 8 — the 
day by which the cell populations got committed to their respective lineages (Fig. 11H–J; 
Fig. 12). 
Lineage-specific in vitro differentiation of HSPCs was measured by flow cytometry 
on days 5 and 8 with the cell surface markers corresponding to each respective lineage. Flow 
cytometry results demonstrated that SCP4-depleted HSPCs showed no defect in 
differentiation into these three lineages (Fig. 12). The CFC assay revealed that the absolute 
cell viability declined for each condition after RNP electroporation, including NT sgRNA, as 
compared to the Mock population (Fig. 13A). However, the HSPC population comprising 
SCP4 knockout clones gave rise to similar relative ratios of colonies as both control HSPCs 
populations (Fig. 13B). 
These findings are consistent with the survival of SCP4-/- mice to the neonatal stage 
of development (Cao et al. 2018) since a severe defect in hematopoiesis would have led to 
the embryonic lethality of these animals. Collectively, these data suggest that SCP4 is 
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Figure 11. SCP4-depleted HSPCs did not experience any fitness disadvantage during 16 days of 
culturing under conditions that promote myeloid, erythroid, or megakaryocytic differentiation. 
(A) Scheme of RT-qPCR assay design. Ribonuclease complex of CRISPR-Cas9 system showing sgRNA 
bound to Cas9 protein and PAM sequence downstream from cleavage site. Primers for RT-qPCR 
sequence are shown. Adapted from Marius Walter, CC BY-SA 4.0, via Wikimedia Commons. (B) RT-
qPCR analysis of indels presence in MOLM-13 cells infected with sgSCP4 linked to GFP with %GFP 
measured by GUAVA as 50% (blue) or >90% (orange). (C) Western blot of whole-cell lysates from 
MOLM-13 cells on day 5 post-infection with the indicated sgRNAs. (D) Scheme of the editing and 
differentiation experiments performed in human peripheral blood CD34+ cells. The cell surface 
markers, corresponding to each differentiated lineage, used in the flow cytometry panels in CD34+ 
experiments, are shown. (E–G) RT-qPCR analysis of indels presence in CD34+ cells electroporated 
with Cas9 loaded with the indicated sgRNAs over the course of culturing in myeloid (E), erythroid 
(F), and megakaryocyte (G) conditions. The effects of individual sgRNAs for SCP4 were averaged. n = 
4. (H–J) Western blot of whole-cell lysates from CD34+ cells electroporated with Cas9 loaded with the 
indicated sgRNAs, day 8 post-electroporation, culturing in myeloid (H), erythroid (I), and 
megakaryocyte (J) conditions. (K) Surveyor Assay analysis of indels presence during in CD34+ cells 
electroporated with Cas9 loaded with the indicated sgRNAs over the course of culturing in myeloid 
conditions. 
All bar graphs represent the mean ± SEM. ‘e’ refers to the exon number targeted by each sgRNA. ND, 
not detected.  




Figure 12. SCP4-depleted HSPCs showed no defect in differentiation into myeloid, erythroid, or 
megakaryocytic lineages. 
(A, C, E) Representative flow cytometry analysis of CD34+ differentiation into myeloid (A), erythroid 
(B), and megakaryocyte (C) lineages. (B, D, F) Quantification of the flow cytometry analysis of 
myeloid (B), erythroid (D), and megakaryocyte (F) differentiation of CD34+ cells electroporated with 
Cas9 loaded with the indicated sgRNAs. The effects of individual negative controls and sgRNAs for 
SCP4 were averaged. n = 4. 
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Figure 13. SCP4-depleted HSPCs showed no differences in relative representation of the colony-
forming units. 
The Human Colony Forming Cell (CFC) assay using methylcellulose. (A) Absolute numbers of 
colonies. (B) Relative numbers of colonies. GEMM, colony forming unit-granulocyte, erythrocyte, 
macrophage, megakaryocyte; GM, colony forming unit-granulocyte, macrophage; CFU-E, colony 
forming unit-erythroid; BFU-E, burst forming unit-erythroid. 
Experiment set up together with Ruopeng Feng and Yu Yao. 
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2.4. The catalytic phosphatase activity of SCP4 is essential in AML 
SCP4 (466 amino acids in Homo sapiens) is found in the majority of eukaryotes except 
for most fungi and Drosophilids. Its C-terminus (amino acids 236–466) containing the 
phosphatase domain is highly conserved among the vertebrates, whereas amino acids 1–236 
are less conserved and are predicted to be intrinsically disordered (Fig. 14A,B) (Chang et al. 
2018; Meszaros et al. 2018). 
Our laboratory has previously used CRISPR exon scanning to map the regions of 
proteins functionally important for supporting cancer cell survival and proliferation (Shi et 
al. 2015; Shen et al. 2015). To determine the minimal fragment of SCP4 required in AML, we 
performed a negative selection CRISPR-Cas9 screening in MOLM-13 cells with a pooled 
library of 85 sgRNAs tiling along each of the SCP4 exons. 
By quantifying sgRNA depletion along the length of the gene, we observed a pattern 
in which most sgRNAs (32/43, 74.4%) targeting exons encoding amino acids 1–235 did not 
result in any growth arrest phenotype, whereas most sgRNAs (32/42, 76.2%) targeting the 
236–466 segment experienced negative selection (Fig. 14C,D; Appendix 3). These results 
suggest that indel mutations produce a higher proportion of null alleles when targeting the 
C-terminal segment of SCP4, which indicates that the phosphatase domain is critical for 
AML growth (Shi et al. 2015). Notably, SCP4/CTDSPL2 sgRNAs used in Project Achilles/
DepMap genome-wide screens (Meyers et al. 2017; Dempster et al. 2019) exclusively target 
the 1–235 segment of the protein (Fig. 14D), which explains why an AML dependency was 
not observed in these data.  
To corroborate the CRISPR exon scanning results, we performed cDNA rescue 
experiments evaluating the ability of different SCP4 truncations and mutations to 
complement the inactivation of the endogenous SCP4. Similar to the results obtained with 
the wild-type protein, the SCP4236-466 truncation was sufficient to rescue the knockout of the 
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endogenous SCP4, which verified that the N-terminal half of SCP4 was dispensable in AML 
(Fig. 15). 
SCP4 belongs to the HAD superfamily of phosphatases characterized by the 
conserved active site sequence DxDx(T/V) (see Introduction §1.5) (Fig. 16A,B). Both 
aspartates (D293 and D295 in SCP4) are required for the substrate dephosphorylation. To 
determine whether SCP4 catalytic function was required in AML, we cloned three different 
catalytic mutants of SCP4: SCP4D293A, SCP4D295A, and SCP4D293A/D295A. Despite similar 
expression levels to the wild-type protein, all three mutants were unable to support 
MOLM-13 growth (Fig. 16C,D). Collectively, these genetic experiments suggest that the 




Figure 14. Defining functionally important regions of SCP4. 
(A) Relative evolutionary conservation score for each residue, from 0 — least conserved to 1 — most 
conserved. Based on data from Chang et al. 2018. (B) Protein disorder prediction score for each 
residue, from 0 — least disordered to 1 — most disordered. IUPred2 (orange) predictions of the global 
structural disorder that encompasses at least 30 consecutive residues of SCP4. ANCHOR2 (blue) 
probabilities of each residue being part of a binding region. Based on data from Meszaros et al. 2018. 
(C) Running average of log2 fold changes of the CRISPR-scan of SCP4 with all the possible sgRNAs. 
SCP4 protein amino acid numbers are indicated along the x axis. (D) The CRISPR-scan of SCP4 with 
all the possible sgRNAs. Deep sequencing-based measurement of the impact of 85 SCP4 sgRNAs on 
the proliferation of MOLM-13 cells.  
Data in (C) and (D) collected by Bin Lu. 
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Figure 15. SCP4236-466 is sufficient to support AML cell proliferation. 
(A) Domain architectures of human SCP4 wild-type and the truncated version SCP4236-466 used in this 
study. (B) Western blot of whole-cell lysates from MOLM-13 cells stably expressing empty vector or 
CRISPR-resistant SCP4236-466. (C) Competition-based proliferation assay in MOLM-13 cells stably 
expressing empty vector or CRISPR-resistant SCP4236-466 infected with the indicated sgRNAs. n = 3. 
All bar graphs represent the mean ± SEM. All sgRNA experiments were performed in Cas9-
expressing cell lines. ‘e’ refers to the exon number targeted by each sgRNA. The indicated sgRNAs 
were linked to GFP. GFP+ population depletion indicates loss of cell fitness caused by Cas9/sgRNA-






























































Figure 16. SCP4 catalytic function is necessary to support AML cell proliferation.  
(A) Alignment of HAD catalytic core residues. Residues are numbered according to SCP4. Residues 
that are conserved among the phosphatase sequences are highlighted in light gray. Dark gray boxes 
indicate the conserved catalytic aspartates. Consensus sequence given; uppercase = conserved; 
lowercase = nearly invariant; h, hydrophobic residue. The HAD signature motifs are indicated under 
the consensus sequence. (B) Prediction of the steric orientation of the catalytic core residues of SCP4, 
based on an overlay with the solved structure of SCP1 (adapted PDB: 1TA0, modified). Nitrogen 
atoms are dark blue; oxygen atoms are red; magnesium atom is green; SCP4 carbon atoms are gray; 
SCP1 carbon atoms are light blue. Note, SCP1 D96 residue is tilted relative to the predicted 
orientation of its corresponding SCP4 D293 residue to account for the coordination of Mg2+ ion and 
PO42-. SCP4 structure was predicted by Phyre2 (Kelley et al. 2015) and visualized with UCSF Chimera 
(Pettersen et al. 2004). (C) Western blot of whole-cell lysates from MOLM-13 cells stably expressing 
empty vector (EV, underloaded) or CRISPR-resistant wild-type (WT) and catalytic mutants of SCP4. 
Vertical black dashed lines indicate omitted lanes from the same gel, same exposure. (D) 
Competition-based proliferation assay in MOLM-13 cells stably expressing empty vector or CRISPR-
resistant wild-type (wt) and catalytic mutants of SCP4 infected with the indicated sgRNAs. n = 3. 
All bar graphs represent the mean ± SEM. All sgRNA experiments were performed in Cas9-
expressing cell lines. ‘e’ refers to the exon number targeted by each sgRNA. The indicated sgRNAs 
were linked to GFP. GFP+ population depletion indicates loss of cell fitness caused by Cas9/sgRNA-































































Motif 1 Motif 2 Motif 3 Motif 4
SCP1 FECVLFTAS NYVKDL ILDNSPVVIDLDETLV
SCP3 FECVLFTAS NYVKDL IVDNSPVVIDLDETLV
SCP2 FECVLFTAS CYVKDL ILDNSPVVIDLDETLV
FCP1 YELHVFTFG PFSKTG IIDDRELMVDLDQTLI
D Dhhh x xTLh D D.e.hhhT.. D D...K.. D D..Dn..

















2.5. N-terminus of SCP4 promotes nuclear localization of the full-length protein 
To narrow down the potential mechanisms by which SCP4 supports AML cell 
proliferation, we have first decided to confirm its intracellular localization. Consistent with 
the previous findings (discussed in Introduction §1.6.1), both endogenous and FLAG-tagged 
SCP4 were only detected in the nuclear fraction (Fig. 17A,B) with the endogenous protein 
exclusively localized to the chromatin fraction showed by micrococcal nuclease digestion. 
However, our efforts at performing SCP4 ChIP-Seq in MOLM-13 cells failed to identify 
evidence of sequence-specific DNA occupancy both with the highly specific monoclonal 
SCP4 antibody and FLAG antibody against the ectopically expressed N-terminally tagged 
protein (data not shown).  
Therefore, we turned to biochemical approaches to further understand the 
mechanism of SCP4 dependency. We decided to focus on the protein-protein interactions of 
SCP4 in its native cellular context in the nucleus with the hope that this approach could 
provide us with some insights into its biological functions. While trouble-shooting the scale-
up fractionation protocol, we noticed that SCP4 was degraded upon the use of any 
detergents during fractionation, despite supplementing all the buffers with the Protease 
Inhibitor Cocktail. This degradation was specific to AML cell line MOLM-13 fractions and, 
in contrast, was not observed in a pancreas cancer cell line SUIT-2 fractions under identical 
conditions (Fig. 18A). This reminded us of another publication that reported a similar 
degradation pattern for HOXA9 in MOLM-13 cells and attributed it to the action of myeloid 
cells specific proteases neutrophil elastase (ELANE), proteinase 3 (PRTN3), and cathepsin G 
(CTSG) (Zhong et al. 2018). Our collaborators from University of Texas performed GST 
pulldown assay from MOLM-13 cytoplasmic fraction using a GST-tagged SCP4156-466 as bait 
and indeed detected all three myeloid proteases as its partners (Fig. 18B). On the other hand, 
FLAG-SCP4236-466 was present in the cytoplasm, suggesting that the protease recognition 
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sites could be located somewhere at the N-terminus (Fig. 17C). Therefore, the nuclear 
localization of the full-length SCP4 in myeloid cells may be partially supported by its 
compartmentalized degradation. Thus, we optimized a fractionation protocol without the 
use of detergents and with stringent nuclei washes from cytoplasmic contamination that 
efficiently preserved full-length SCP4 (Fig. 18C). 
Our FLAG immunoprecipitation (FLAG-IP) procedure efficiently recovered FLAG-
SCP4 complexes and removed endogenous SCP4 (Fig. 19A). For the immunoprecipitation 
coupled with mass spectrometry (IP-MS) experiments, we compared wild-type SCP4 to the 
catalytic mutant SCP4D293A, with the intent that any protein-protein interaction abrogated by 
this loss-of-function mutation would have a higher likelihood of functional significance.  
A comparison of two independent IP-MS biological replicates revealed 59 protein 
candidates (Fig. 19B) shared between FLAG-SCP4 samples and absent in negative controls. 
Among the most abundant SCP4-associated proteins, based on total spectral counts, were 
several members of the importin protein family, which function to shuttle protein cargo into 
the nucleus (Cagatay and Chook 2018) (Fig. 19C). To discriminate between the functional 
role of importins in SCP4 nuclear localization and other hypotheses, we repeated FLAG-IP 
for all the FLAG-SCP4 constructs with the addition of FLAG-SCP4236-466. The latter protein is 
smaller than 40 kDa and thus would be expected to bypass the requirement for importins in 
its nuclear import (Weis 2003), but can complement the knockout of endogenous SCP4 in 
supporting AML cell proliferation (Fig. 15; Fig. 17C). We have shown that all the full-length 
SCP4 constructs interact with importin α, KPNA2, unlike FLAG-SCP4236-466 (Fig. 20A). This 
is coherent with the nuclear localization signal (NLS) predictions that show multiple 
potential NLSs for SCP4 among its first 100 amino acids (Fig. 20B).  
Our results suggest that at least one function of the SCP4 N-terminal segment is to 




Figure 17. SCP4 is localized to the nucleus.  
Western blots of the indicated fractions from (A) MOLM-13 cells and MOLM-13 cells stably 


























































































































Figure 18. Optimization of SCP4 recovery from nuclear fractions.  
(A) SCP4 is unstable in AML cells but not in pancreatic cancer cells. Western blots of the whole-cell 
lysates (RIPA) and cytoplasm/nucleus fractions from the indicated cell lines separated in parallel 
using the same buffers containing detergents (Det) or not (ND). Vertical black dashed lines indicate 
omitted lanes from the same gel, same exposure. (B) Myeloid proteases detected by MS analysis in 
GST-SCP4 pulldown from MOLM-13 cytoplasmic fraction. # PSMs, the total number of identified 
peptide spectrum matches for the protein. (C) Representative nucleus fractions from MOLM-13 cells 
stably expressing empty vector (EV) or FLAG-SCP4 separated using buffers not containing any 
detergents with increased nuclei washes (white pellet in the schematic) from cytoplasmic 
contamination (shown in yellow in the schematic).  
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Uniprot Gene Description # PSMs
P08246 ELANE Neutrophil elastase 25
P24158 PRTN3 Myeloblastin 20
P08311 CTSG Cathepsin G 2
MS results of GST-pulldown experiment with GST-SCP4







Figure 19. IP-MS identification of FLAG-SCP4 associated proteins.  
(A) Representative FLAG-SCP4 immunoprecipitation Western blot analysis for the subsequent mass 
spectrometry (MS) analysis. Cytoplasm and nucleus fractions from MOLM-13 cells stably expressing 
empty vector, FLAG-SCP4 wild-type (wt), or catalytic mutant (D293A). Nuclear fraction was mixed 
with anti-FLAG M2 agarose overnight. The flow-through was analyzed to ensure efficient binding of 
the FLAG-tagged constructs (loaded as “unbound”). Following the extensive washing, the agarose 
amount equivalent to the cytoplasm and nucleus fractions loading was boiled in Laemmli buffer and 
loaded as “FLAG-IP." The rest was sent for the MS analysis. (B) Venn diagram depicting the overlap 
between proteins detected by MS and absent in empty vector controls in the two independent 
biological replicates. (C) Total unique peptide counts for the top hits detected by MS in two 
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Figure 20. SCP4 N-terminus promotes nuclear localization of the full-length protein.  
(A) Immunoprecipitation followed by Western blot performed with the indicated antibodies. The 
nuclear lysates were prepared from the human MOLM-13 cells stably expressing empty vector 
(empty), FLAG-SCP4wt (wt), FLAG-SCP4236-466 (236-466), catalytic mutant FLAG-SCP4D293A (D293A). 
The flow-through was analyzed to ensure efficient binding of the FLAG-tagged constructs (loaded as 
“unbound”). (B) Nuclear localization signals (NLS) predictions for SCP4 amino acid sequence 
performed by two different methods (Nguyen Ba et al. 2009; Kosugi et al. 2009). (C) Model of full 
















































































2.6. STK35 and PDIK1L bind selectively to the catalytically active form of SCP4 
Among the SCP4-associated proteins identified in our FLAG-IP-MS analysis, the 
paralog kinases STK35 and PDIK1L were remarkable as they were only detected in 
association with the wild-type SCP4 but not with the catalytically dead SCP4D293A (Fig. 19C). 
Notably, PDIK1L and STK35 are paralogs sharing 68.9% identity and 83.3% similarity (Fig. 
21A). They constitute a distinct new kinase family 4 (NKF4) and are relatively poorly 
studied (see Introduction §1.6.2).  
As no commercially available antibodies were able to detect these two kinases (data 
not shown), we cloned HA-tagged proteins for their further biochemical characterization.  
To confirm the association between SCP4 and PDIK1L, we first transiently expressed 
HA-tagged PDIK1L and FLAG-SCP4 constructs in HEK293T cells, followed by FLAG- or 
HA-IP. In accordance with the MS results, both SCP4wt and SCP4236-466 proteins showed 
similar interaction with HA-PDIK1L (Fig. 21B,C). The interaction was mitigated by the 
single amino acid substitution yielding catalytically inactive protein SCP4D293A.  
We then established MOLM-13 cells constitutively expressing HA-PDIK1L or HA-
STK35 together with empty vector or either one of the FLAG-SCP4 constructs (Fig. 21D–G). 
Similarly, we found that SCP4wt and SCP4236-466 each efficiently associated with HA-STK35 
and HA-PDIK1L, whereas this interaction was diminished with the SCP4D293A protein. 
The interaction between the endogenous SCP4 and HA-PDIK1L or HA-STK35 was 
detected in IP-MS experiments after stringent washes with salt concentrations ranging from 
150 mM up to 500 mM NaCl (Fig. 22A,B). Moreover, an MS analysis of HA-PDIK1L 
complexes from MOLM-13 cells following high salt washes identified endogenous SCP4 as 
the most enriched protein with comparable spectral counts to the PDIK1L bait (Fig. 22C). 
These biochemical experiments suggest that the kinases STK35 and PDIK1L exist in a 





































































































































































































Figure 21. STK35 and PDIK1L bind selectively to the catalytically active form of SCP4.  
(A) Domain architectures and homology heat-map of human STK35 and PDIK1L. ATP-BS, ATP-
binding site. (B,C) Immunoprecipitation followed by Western blot performed with the indicated 
antibodies. The whole-cell lysate was prepared from HEK293T 24 hours post-transfection with the 
indicated constructs. (D–G) Immunoprecipitation followed by Western blot performed with the 
indicated antibodies. The nuclear lysates were prepared from the human MOLM-13 cells stably 
expressing the indicated constructs.  
‘-’, empty vector; wt, wild-type FLAG-SCP4; 236-466, FLAG-SCP4236-466; D293A, catalytic mutant 
FLAG-SCP4D293A; IP, immunoprecipitation. Note: degradation bands appear in the wt and D293A 




Figure 22. STK35 and PDIK1L exist in a stable complex with the endogenous SCP4.  
(A,B) Total spectrum counts (TSC) for HA-PDIK1L (A), HA-STK35 (B), and endogenous SCP4 relative 
to the sum of total spectrum counts of all proteins detected by mass spectrometry on Pierce Anti-HA 
Magnetic Beads after stringent washes with washing buffers with the indicated NaCl salt 
concentrations. (C) Total spectrum counts (TSC) for HA-PDIK1L and endogenous SCP4 detected by 
mass spectrometry on Pierce Anti-HA Magnetic Beads after stringent washes with washing buffers 










































































2.7. STK35 and PDIK1L function redundantly in the same genetic pathway as SCP4 
The kinase domain-focused CRISPR screening in human cancer cell lines previously 
performed in our laboratory did not reveal a robust dependency on STK35 or PDIK1L in 
AML cell lines (Tarumoto et al. 2018). Since both kinases are expressed in AML (Fig. 23A), 
we hypothesized that their functional redundancy might conceal their essentiality in this 
context. To check this hypothesis, we first transduced AML cell lines MOLM-13 and THP1, 
and a CML cell line K562 with STK35 and PDIK1L sgRNAs linked to mCherry and GFP 
respectively in combination with each other or with an opposite color fluorophore linked to 
negative control and performed dual targeting competition-based proliferation assays (Fig. 
23B). These experiments revealed that MOLM-13 cells experienced a synergistic 
proliferation defect after the dual targeting of STK35 and PDIK1L, but the cells were less 
sensitive to targeting either gene individually (Fig. 23C). In contrast, THP1 and K562 cells 
did not show any phenotype following co-transduction with STK35 and PDIK1L sgRNAs 
(Fig. 23C). 
We then switched to using a bi-cistronic vector developed in our laboratory to 
express two sgRNAs simultaneously upon lentiviral infection (Klingbeil, unpublished). 
Using this system, we confirmed that the deleterious phenotype of STK35/PDIK1L double 
knockout in MOLM-13 cells could be fully rescued by expressing a single CRISPR-resistant 
STK35 or PDIK1L cDNA (Fig. 24A–C). Western blot experiments verified that the ectopically 
expressed HA-tagged wild-type STK35 and PDIK1L were effectively depleted upon their 
respective sgRNA and bi-cistronic vector introduction, whereas CRISPR-resistant versions 
were unaffected (Fig. 24D,E). Cell cycle analysis with the bi-cistronic vector showed that 
STK35/PDIK1L double knockout in MOLM-13 cells led to a G1/G0-arrest on day 5 post-
infection, similar to SCP4 knockout (Fig. 25; Fig. 8). 
We have then assayed the requirement for SCP4 and the pair of kinases in a series of 
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competition-based proliferation assays and confirmed that in this limited panel of cell lines, 
the dependency for SCP4 correlated with the growth arrest phenotype upon dual targeting 
of STK35 and PDIK1L (Fig. 26). For example, SCP4 and STK35/PDIK1L were not required in 
THP1, U937, and K562 cells compared to the four AML cell lines sensitive to both 
perturbations. These experiments demonstrate that STK35 and PDIK1L have redundant 
functions in AML and suggest that the requirement for these kinases is linked to the SCP4 
dependency in this context.  
We next investigated whether the catalytic kinase function of STK35 and PDIK1L 
was essential for AML cell proliferation. We have first performed multiple sequence 
alignment of STK35 and PDIK1L with other well-described human kinases and identified 
the conserved ATP-binding lysine residue present in other catalytically active kinases (Fig. 
27A) (Cherry and Williams 2004; Lucet et al. 2006; Madeira et al. 2019). Guided by prior 
studies (Kamps and Sefton 1986), we replaced this residue with histidine in the CRISPR-
resistant STK35 and PDIK1L cDNA constructs and performed competition-based 
proliferation assays evaluating whether these mutant cDNAs could rescue the lethal 
phenotype arising from the dual targeting of STK35/PDIK1L. Despite being expressed, 
albeit slightly below the level of wild-type proteins, the STK35K231H and PDIK1LK37H 
behaved as null alleles in these assays, suggesting that the presence of at least one 
catalytically active kinase in AML cells is necessary for leukemia cell proliferation (Fig. 
27B,C). 
To further investigate whether the SCP4 and STK35/PDIK1L co-dependency in AML 
reflected that these proteins functioned in a common genetic pathway, we performed an 
early time point RNA-Seq following acute genetic knockouts of SCP4 or STK35/PDIK1L. 
Polyadenylated RNA for the deep sequencing analysis was collected on day 5 following 
lentiviral infection of MOLM-13 cells with SCP4 or dual STK35/PDIK1L sgRNAs (dgSTK35-
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PDIK1L). We compared the global transcriptional changes upon these perturbations across 
15,095 genes to the datasets previously collected in our laboratory in the MOLM-13 cell line 
for the studies elucidating functional links between other proteins acting together to support 
leukemia cells proliferation, such as MYB and its coactivator TAF12 (Xu et al. 2018) or SIK3 
and MEF2C (Tarumoto et al. 2018; see Introduction §1.2.2.6) (Fig. 28). Global correlation 
analysis of these datasets in all pairwise combinations recapitulated the TAF12–MYB 
(Pearson R2 = 0.56) and SIK3–MEF2C (Pearson R2 = 0.35) connectivity described previously. 
Notably, the transcriptional changes observed in SCP4- and STK35/PDIK1L-deficient 
MOLM-13 cells were closely correlated with one another compared to these other knockouts 
(Pearson R2 = 0.63). Moreover, our data illustrate that the transcriptional changes following 
SCP4 knockout and STK35/PDIK1L double knockout were not non-specific effects of 
targeting essential genes but rather an indication that SCP4 and STK35/PDIK1L operated in 
the same genetic pathway.  
As an orthogonal approach, we defined SCP4 signatures as the top 200 genes 
downregulated (sgSCP4_dn_MOLM13) and upregulated (sgSCP4_up_MOLM13) in 
MOLM-13 cells following SCP4 knockout (Appendix 4 & 5). The effect of STK35/PDIK1L 
double knockout on SCP4 target genes was more substantial than on any of the other 20,329 
signatures from our laboratory and the Molecular Signatures Database (MSigDB v7.4) when 
interrogated via gene set enrichment analysis (GSEA) (Subramanian et al. 2005) (Fig. 29). 
The correlated transcriptional changes and the co-dependency on SCP4 and STK35/
PDIK1L across AML cell lines suggest that the physical interaction between SCP4 and 





Figure 23. STK35 and PDIK1L function redundantly to support MOLM-13 proliferation.  
(A) SCP4, STK35, and PDIK1L mRNA expression data relative to beta-actin expression (Meyers et al. 
2017; Dempster et al. 2019). (B) Scheme of a dual targeting competition-based proliferation assay and 
interpretations of its possible outcomes. (C) Competition-based proliferation assays in MOLM-13, 
THP1, and K562 cells co-infected with GFP-linked sgRNA and mCherry-linked sgRNA. Double 
mCherry+/GFP+ population depletion indicates loss of cell fitness due to genetic redundancy. n = 3. 
All bar graphs represent the mean ± SEM. All sgRNA experiments were performed in Cas9-



































































































Figure 24. Either STK35 or PDIK1L is sufficient to fully rescue the endogenous STK35/PDIK1L 
double knockout phenotype in MOLM-13 cells.  
(A,B) Design of CRISPR-resistant mutant of (A) PDIK1L (A) and (B) STK35. (C) Competition-based 
proliferation assay in MOLM-13 cells stably expressing empty vector (EV), wild-type (WT), or 
CRISPR-resistant (CR) HA-PDIK1L and HA-STK35 infected with the indicated sgRNAs. The 
indicated sgRNAs were linked to GFP. n = 3. (D,E) Western blot of whole-cell lysates from MOLM-13 
cells stably expressing empty vector (EV) or CRISPR-resistant wild-type (WT) and catalytic mutants 
of (D) PDIK1L and (E) STK35.  
All bar graphs represent the mean ± SEM. All sgRNA experiments were performed in Cas9-
expressing cell lines. ‘e’ refers to the exon number targeted by each sgRNA. Starting from Figure 5C 
and for the rest of the study bi-cistronic vector for simultaneous targeting of STK35 and PDIK1L was 
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Figure 25. STK35/PDIK1L double knockout in MOLM-13 cells leads to a G1/G0-arrest.  
(A) Representative flow cytometry analysis of BrdU incorporation and DNA content to infer cell cycle 
stage in MOLM-13 cells on day 5 post-infection with the indicated sgRNAs. (B) Quantification of the 
different cell cycle stages in MOLM-13 cells on day 5 post-infection with the indicated sgRNAs. n = 3. 
All bar graphs represent the mean ± SEM. All sgRNA experiments were performed in Cas9-
expressing cell lines. ROSA, negative control. 












































Figure 26. STK35/PDIK1L requirement is correlated with the SCP4 dependency in the context of 
AML.  
Summary of competition-based proliferation assays in the indicated cell lines. Plotted is the fold 
change (log2) of sgRNA+/GFP+ cells after 18 days in culture (average of triplicates).  
All bar graphs represent the mean ± SEM. All sgRNA experiments were performed in Cas9-
expressing cell lines. The indicated sgRNAs were linked to GFP. GFP+ population depletion indicates 
loss of cell fitness caused by Cas9/sgRNA-mediated genetic mutations. ‘dg’ refers to the bi-cistronic 
























































































Figure 27. The kinase catalytic function of STK35/PDIK1L is essential in AML.  
(A) Alignment of residues defining ATP binding site for human protein kinases. Residues that are 
conserved among the kinases sequences are highlighted in light gray. Dark gray indicates the 
conserved lysine at the ATP binding site. Consensus sequence given; uppercase = conserved, 
lowercase = nearly invariant. The predicted structural elements of protein kinases are indicated below 
the consensus sequence. (B) Competition-based proliferation assay in MOLM-13 cells stably 
expressing empty vector (EV) or CRISPR-resistant wild-type (WT) and catalytic mutant versions of 
HA-STK35 and HA-PDIK1L infected with the indicated sgRNAs. The indicated sgRNAs were linked 
to GFP. n = 3. (C) Western blot of whole-cell lysates from MOLM-13 cells stably expressing empty 









































































































Figure 28. STK35 and PDIK1L function redundantly in the same genetic pathway as SCP4.  
Correlation matrix for the global log2 fold-changes of gene expression relative to negative controls in 
each independent experiment across 15,095 genes. 
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Figure 29. STK35/PDIK1L dual perturbation significantly affects SCP4 signatures.  
(A) Definition of SCP4 signatures. Gene set enrichment analysis (GSEA) for SCP4 knockout (shown as 
a proof of principle) using all the signatures from our laboratory and all the signatures in the 
Molecular Signatures Database (MSigDB v7.4) together with the SCP4 signatures. Normalized 
enrichment score (NES) and family wise error rate (FWER) p-values are plotted for 20,689 gene sets, 
each represented as a single dot. (B,C) GSEA plots of the SCP4_down (B) and SCP4_up (C) signatures 
upon SCP4 knockout. NES and FWER p-values are shown. (D) Unbiased GSEA for dual STK35/
PDIK1L knockout using all the signatures from our laboratory and all the signatures in the Molecular 
Signatures Database (MSigDB v7.4) together with the SCP4 signatures. NES and FWER p-values are 
plotted for 20,301 gene sets, each represented as a single dot. (E,F) GSEA plots of the SCP4_down (E) 
and SCP4_up (F) signatures upon SCP4 knockout. NES and FWER p-values are shown. 
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2.8. Biochemical evidence that SCP4 functions upstream of STK35/PDIK1L 
In order to gain mechanistic insights into the mechanism that links SCP4 to STK35/
PDIK1L, we have first decided to measure the protein levels of PDIK1L and STK35 upon 
SCP4 knockout. The caveat of this experiment was that we had to use HA-tagged ectopically 
expressed proteins. However, this approach proved to be informative since upon the 
endogenous SCP4 knockout we have observed a marked reduction in the levels of both HA-
PDIK1L (Fig. 30B) and HA-STK35 (Fig. 30D) in the nuclear fractions, which effectively 
excluded the possibility that SCP4 affected transcriptional regulation of PDIK1L and STK35. 
Besides, RNA-Seq data also did not reveal significant changes in the endogenous PDIK1L 
and STK35 levels upon SCP4 knockout (Fig. 30A,C). Neither gene or protein levels of SCP4 
were affected by the double knockout of PDIK1L and STK35 (Fig. 30E,F). The directionality 
of this result suggests that SCP4 functions upstream of STK35/PDIK1L to maintain the 
protein level of these kinases. 
We next hypothesized that the physical interaction between SCP4 and STK35/
PDIK1L might allow the phosphatase to remove inhibitory phosphorylation from the 
kinases as a mechanism of signaling cooperativity. To investigate this, we mined publicly 
available phosphoproteomic datasets for the reported STK35/PDIK1L phosphorylation sites 
(Hornbeck et al. 2015; Ochoa et al. 2020). Among the 18 phosphorylation sites on STK35/
PDIK1L identified in prior studies, we noticed several located within the regulatory 
activation segment of both kinases (Fig. 31). Most eukaryotic protein kinases are activated 
by phosphorylation of specific residues in the activation loop of the activation segment 
(sometimes also called the T-loop) that often results in profound conformational changes 
(Nolen et al. 2004). However, little is known about potentially inhibitory phosphorylation 
sites in the activation segment. The kinase activation segment is also a protein-protein 
interaction region that determines the localization and regulation of a kinase and its binding 
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partners (Wolf et al. 2001). These considerations prompted us to investigate whether SCP4 
might remove phosphorylation from this segment. 
To investigate the potential role for every phosphorylated serine/threonine residue 
in the activation segment of STK35 and PDIK1L in their phospho-regulation, we generated 
MOLM-13 cells stably expressing either CRISPR-resistant phosphomutant for each of these 
residues (substitution to alanine, a non-phosphorylatable residue) or phosphomimetic 
residue (substitution to aspartate or glutamate) and performed gene complementation 
experiments with the endogenous STK35/PDIK1L double knockout. While all of the mutant 
alleles tested were expressed at comparable levels to the wild-type STK35/PDIK1L, the 
PDIK1LS194D and STK35S385D proteins were completely defective in supporting AML 
proliferation (Fig. 32A). In contrast, alanine substitutions of the same residues were fully 
functional, suggesting that mutations that mimic phosphorylation inhibit the function of 
these kinases. This supports the role of these residues as inhibitory for their respective 
kinases. Notably, the PDIK1LS194 and STK35S385 residues are located at the DFG+2 position of 
the activation loop for each kinase, which is reported on other kinases to form hydrogen 
bonds with the DFG phenylalanine to stabilize an active kinase conformation (Kornev et al. 
2006; Xie et al. 2013).  
The rest of the mutants showed no differential phenotypes between their 
phosphomutant and phosphomimetic versions. Interestingly, by aligning PDIK1L and 
STK35 to the other kinases with well-described phospho-regulation, we have nominated 
PDIK1LT217-P and STK35S414-P residues as the sites for activation loop activating 
phosphorylation (Fig. 31). However, the substitution of either residue to alanine or 
glutamate yielded fully functional proteins capable of supporting AML cell proliferation. Of 
note, simultaneous mutations of both STK35 serine 413 and serine 414 residues to alanines 
resulted in its complete loss of function (Fig. 32C).  
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To assess the possibility that SCP4 might act on either one of these phosphorylated 
residues, we have established collaboration with the group of Prof. Yan Jessie Zhang 
(College of Natural Sciences, University of Texas, Austin, Texas). Our collaborators purified 
the recombinant SCP4 phosphatase domain (156-466 amino acids), which was well-folded 
and exhibited phosphatase activity in para-nitrophenyl assays (Fig. 33A; Zhang, personal 
communication). We then ordered the commercial synthesis of the four phosphoserine- or 
phosphothreonine-containing peptides representing the activation segment phosphorylated 
residues (Fig. 33B). Three out of the four peptides shared an identical sequence and differed 
only with regard to the phosphorylation site. Zhang’s group used the peptides to quantify 
the phosphatase activity of SCP4 with each phosphopeptide using the malachite green assay 
to monitor phosphate release. Notably, SCP4 showed great specificity, dephosphorylating 
only one out of the three peptides with the identical sequence. The peptides corresponding 
to phosphoserines pS194 and pS216 of PDIK1L (pS385 and pS413 of STK35) were efficiently 
dephosphorylated by SCP4, whereas no activity was detected for the other two 
phosphopeptides (Fig. 33B). Our collaborators fitted the kinetic parameters of these 
substrates into steady-state kinetics and calculated kcat/KM as 12.63 ± 0.79 and 45.96 ± 3.06 
mM-1 min-1 for phosphopeptides containing pS194 and pS216, respectively (Fig. 33C,D). 
kcat/KM  is a way to characterize the catalytic efficiency of a given enzyme for a 
particular substrate. kcat/KM values around 105 mM-1 min-1 indicate that the conversion of free 
substrate to product is diffusion controlled, in other words, the reaction happens at collision 
of enzyme and substrate. The lower the ratio, the slower the catalysis is. However, it is 
worth noting that the intrinsic phosphatase activity can vary greatly for different enzymes, 
even between close homologs. Since a phosphatase can also be targeted to its substrate via 
regulatory subunits (as in the case of PP1) or an allosteric site binding, specificity for a given 
substrate over another one is a very important parameter.  
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SCP4 has low intrinsic catalytic efficiency with both peptides in vitro compared with 
some other HAD phosphatases and PTPs (Table 1). Still, it is comparable to an HAD 
phosphatase Dullard and only slightly weaker than FCP1 (Zhang, personal communication). 
Nevertheless, SCP4 showed excellent specificity by preferentially dephosphorylating one of 
the three peptides with the same sequence (Fig. 33B) and overall only exhibiting activity 
with 2/7 peptides tested (data not shown). Given the strong physical interaction between 
SCP4 and STK35/PDIK1L (Fig. 22), it is possible that using full-length proteins could give 
us much higher kcat/KM values. 
Overall, this data supports a model in which SCP4 as part of the phosphatase/kinase 
complex removes inhibitory phosphorylation from the activation loop of STK35/PDIK1L, 
which may allow for kinases activation. 
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Table 1.  Kinetic constants of different phosphatases towards their substrates 
Gene Enzyme Substrate kcat/KM Reference
CTDSPL2 SCP4 KVADFGLpSKVCSAS 0.2105 This study
CTDSPL2 SCP4 KCFLpSTACGTDFYM 0.766 This study
PPP1CA PP1wt KRpTIRR 0.623 Wang et al. 2011
CTDSP1 SCP1 pNPP 0.724 Zhang et al. 2006
CTDSP1 SCP1 YSPTSPSYpSPTSPS 0.166 Zhang et al. 2006
CTDSP1 SCP1 YSPTSPSYSPTpSPS 11.4 Zhang et al. 2006
CTDSP1 SCP1 EDLpSPPSPPLPK 140 Burkholder et al. 2018
PTPN1 PTP1B YDEDFpYDYEF 55,000 Selner et al. 2014
PTPN7 HePTP YDEDFpYDYEF 25 Selner et al. 2014
PTPN11 SHP-2 WDEDFpYDWEF 6,800 Ren et al. 2011
PTPN21 PTPD1 YDEDFpYDYEF 1.2 Selner et al. 2014




Figure 30. Biochemical evidence that SCP4 functions upstream of STK35/PDIK1L.  
(A,C,E) RNA-Seq transcripts per million (tpm) data for PDIK1L, STK35, and SCP4 from MOLM-13 
cells on day 5 post-infection with the indicated sgRNAs. Plotted are data from each individual RNA-
Seq replicate, the mean ± SEM. (B,D,F) Western blots of cytoplasm (Cyto) and nucleus (Nucl) 










































































Figure 31. Schematics of STK35/PDIK1L phosphorylation sites. 
Schematics of STK35/PDIK1L phosphorylation sites reported in the publicly available phospho-
proteomics datasets on STK35 and PDIK1L relative to their domain architectures. 
Based on data from Hornbeck et al. 2015 and Ochoa et al. 2020.  
aa #, amino acid number; P, phosphorylation; ATP-BS, ATP-binding site; predicted activating 
phosphorylation shown in green.  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Figure 32. S194 on PDIK1L and S385 on STK35 could serve as inhibitory phosphorylation residues. 
(A) Competition-based proliferation assay in MOLM-13 cells stably expressing empty vector (EV) or 
the CRISPR-resistant HA-PDIK1L or HA-STK35 constructs harboring the indicated amino acid 
substitutions infected with the indicated sgRNAs. n = 3. (B) Western blot of whole-cell lysates from 
MOLM-13 cells stably expressing empty vector (EV) or CRISPR-resistant HA-PDIK1L or HA-STK35 
constructs harboring the indicated amino acid substitutions. (C) Summary of competition-based 
proliferation assays in MOLM-13 cells stably expressing CRISPR-resistant HA-PDIK1L or HA-STK35 
constructs harboring the indicated amino acid substitutions infected with the indicated sgRNAs. 
Plotted is the fold change (log2) of sgRNA+/GFP+ cells after 18 days in culture (average of triplicates). 
Below are shown Western blots of whole-cell lysates of the cells stably expressing the indicated 
constructs. Black frame indicates data corresponding to panel A. 
All bar graphs represent the mean ± SEM. All sgRNA experiments were performed in Cas9-
expressing cell lines. ‘e’ refers to the exon number targeted by each sgRNA. ‘dg’ refers to the bi-
cistronic vector for simultaneous targeting of STK35 and PDIK1L. The indicated sgRNAs were linked 
to GFP. GFP+ population depletion indicates loss of cell fitness caused by Cas9/sgRNA-mediated 





























































































































































Figure 33. SCP4 exhibits exquisite substrate specificity in vitro. 
(A) Recombinant SCP4 protein purity as assessed by SDS-PAGE and Coomassie blue staining. His-
SUMO-(TEV)-SCP4 was expressed in BL21 (DE3) cells and purified by affinity, anion exchange, and 
gel filtration chromatography. Molecular weight markers are shown for reference. (B) Phosphorylated 
peptides assayed for SCP4 phosphatase activity in vitro. (C,D) Phosphatase activity of SCP4 with the 
indicated peptides plotted for kinetic fitting. Each measurement was conducted in triplicate with 
standard deviations shown as error bars.  


















































































2.9. SCP4-STK35/PDIK1L sustains the aberrant metabolic state of AML  
We next sought to understand the downstream output of this phosphatase/kinase 
complex that could account for its essential function in AML. From the aforementioned 
RNA-Seq experiments, we identified 678 genes that were significantly downregulated 
following both SCP4 knockout and STK35/PDIK1L double knockout in MOLM-13 cells and 
892 — significantly upregulated (Fig. 34A). The overlap between downregulated genes 
upon both perturbations was significant, χ2 (1, N = 3536) = 490.5493, p < .00001. Similarly, 
the overlap between genes upregulated upon SCP4 knockout and STK35/PDIK1L double 
knockout was significant, χ2 (1, N = 3841) = 385.4878, p < .00001. Overall, significant gene 
expression changes upon SCP4 depletion were more likely to overlap with significant gene 
expression changes upon dual STK35/PDIK1L targeting than not. This serves as yet another 
piece of evidence for the remarkable correlation among the global gene expression changes 
we observed (Fig. 28).  
Ontology analysis of the downregulated genes revealed enrichment for biological 
pathways concerning amino acid metabolism and transport functions (Fig. 34B). For 
example, all the major transaminases that catalyze reversible interconversion of glutamate 
into other amino acids were downregulated as well as many of the solute carriers that 
import amino acids into the cell (Fig. 34C).  
Given the profound ways amino acid biosynthesis and transport are known to be 
deregulated to support the proliferation of AML cells (see Introduction §1.4.1.2), we decided 
to measure total amino acid levels in AML cells upon SCP4 knockout and STK35/PDIK1L 
double knockout via untargeted liquid chromatography-mass spectrometry (LC-MS) 
analysis based on an in-house library of 236 hydrophilic metabolites.  
Both SCP4 knockout and PDIK1L-STK35 double knockout resulted in global effects 
on leukemia cell metabolism that were consistent between the two conditions in the three 
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independent biological replicates (Fig. 35A). The levels of several metabolites remained 
unchanged in these knockout cells, but many amino acids were present at reduced levels in 
cells deficient for either SCP4 or STK35/PDIK1L (Fig. 35B).  
For example, one of the most deficient amino acids consistent between replicates was 
proline (Fig. 35C), which could be related to the decrease in pyrroline-5-carboxylate 
reductase 1 (PYCR1) expression, encoding the rate-limiting enzyme for proline biosynthesis 
(Xiao et al. 2020) (Fig. 35D). The decreased expression of PYCR1 was shown to be implicated 
in the rewiring of proline metabolism from the TCA cycle to the urea cycle (Sharif et al. 
2019). In line with this hypothesis, we have observed consistent downregulation of several 
TCA cycle metabolites, whereas many urea cycle metabolites were among the least affected 
in all three biological replicates (Fig. 36A). The urea cycle is closely linked to the TCA cycle 
through the reversible reaction providing fumarate for the TCA cycle and de novo arginine 
biosynthesis (Fig. 36B). The rate-limiting step for this connection, argininosuccinate 
biosynthesis, also was affected by SCP4 knockout and STK35/PDIK1L double knockout 
both at the enzyme argininosuccinate synthetase 1 (ASS1) expression level (Fig. 36C) and 
argininosuccinate levels. 
Since other amino acids are also known to fuel the TCA cycle (Fig. 36B), as well as 
serving biosynthetic blocks for the rapidly growing AML cells, we propose that SCP4 
knockout and STK35/PDIK1L double knockout may result in multifaceted deregulation of 





Figure 34. Nominating the downstream output of the SCP4-STK35/PDIK1L complex. 
(A) Venn diagram depicting the overlap between statistically significant up- and downregulated 
genes in MOLM-13 cells upon SCP4 knockout and STK35/PDIK1L double knockout. DeSeq2 (n = 4). 
(B) Ontology analysis of overlapping statistically significant up- and downregulated genes in 
MOLM-13 cells upon both SCP4 knockout and STK35/PDIK1L double knockout. (C) Selected 
statistically significant downregulated genes in MOLM-13 cells upon both SCP4 knockout and 













GO:0002274 myeloid leukocyte activation
GO:0006914 autophagy
GO:0006954 inflammatory response






Top enriched pathways among significantly upregulated genes
Term Description
GO:0008652 Cellular amino acid biosynthetic process
GO:0120039 Plasma membrane bounded cell projection  
   morphogenesis
R-HSA-352230 Amino acid transport across the plasma   
   membrane






Top enriched pathways among significantly downregulated genes
Term Description
PYCR1 pyrroline-5-carboxylate reductase 1 Pro
PHGDH phosphoglycerate dehydrogenase Ser
PSAT1 phosphoserine aminotransferase 1 Ser/Glu
PSPH phosphoserine phosphatase Ser
Gene Protein
GOT1 glutamic-oxaloacetic transaminase 1
CTH cystathionine gamma-lyase
ASNS asparagine synthetase
SLC1A5 solute carrier family 1 member 5
SLC38A2 solute carrier family 38 member 2
solute carrier family 3 member 2SLC3A2









GPT2 glutamic-pyruvic transaminase 2 Ala/Glu
BCAT1 branched chain amino acid transaminase 1 BCAAs/Glu






Figure 35. SCP4 knockout and PDIK1L-STK35 double knockout result in consistent changes in the 
leukemia cell metabolism. 
(A) Correlation matrix for the global log2 fold-changes of metabolites levels upon SCP4 knockout and 
STK35/PDIK1L double knockout relative to negative control as measured in each independent 
biological replicate across 80 metabolites. (B) The correlation between log2 fold changes in the levels 
of selected metabolites upon SCP4 knockout and STK35/PDIK1L double knockout relative to 
negative control as measured by the MS analysis. Every dot represents the mean ± SEM (ntech = 6). 
Amino acids are in red, few unchanged metabolites in black for reference. Shown is a representative 
experiment of three independent biological replicates. (C) log2 fold-changes of amino acids ranked 
from lowest to highest. nbio = 3. (D) RNA-Seq transcripts per million (tpm) data for PYCR1 from 
MOLM-13 cells on day 5 post-infection with the indicated sgRNAs. Plotted are data from each 
individual RNA-Seq replicate, the mean ± SEM.  
dgPDIK1L-STK35 repl.2 1.00
sgSCP4 repl.2 0.84 1.00
dgPDIK1L-STK35 repl.3 0.73 0.88 1.00
sgSCP4 repl.3 0.67 0.93 0.88 1.00
sgSCP4 repl.1 0.70 0.74 0.65 0.68 1.00

















































































































































































































































































































































Figure 36. SCP4-STK35/PDIK1L signaling supports the aberrant metabolic state in AML.  
(A) The correlation between log2 fold changes in the levels of selected metabolites upon SCP4 
knockout and STK35/PDIK1L double knockout relative to negative control as measured by the MS 
analysis. Every dot represents the mean ± SEM (nbio = 3). (B) Selected amino acids and their functional 
links to TCA, glucose metabolism, and urea cycles. Selected downregulated enzymes are shown. 
Adapted from Albaugh et al. 2017. (C) RNA-Seq transcripts per million (tpm) data for ASS1 from 
MOLM-13 cells on day 5 post-infection with the indicated sgRNAs. Plotted are data from each 
individual RNA-Seq replicate, the mean ± SEM. 
Amino acids are in red; metabolites of urea cycle are in yellow; TCA cycle — in blue; metabolites not 
detected by LC-MS — in gray.  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2.10. Results summary 
In this study, we have employed phosphatase domain-focused CRISPR screens to 
comprehensively assay the requirements for human phosphatases in different cancer cell 
lines with a specific focus on AML. We have discovered that a poorly studied nuclear 
phosphatase SCP4 is an acquired dependency largely specific to AML cell lines. We showed 
that SCP4 role in AML is conserved between species. SCP4 knockout slowed down the AML 
progression in a mouse xenograft model. We have provided preliminary evidence 
suggesting that SCP4 is not required for proliferation and differentiation of human HSPCs, 
nominating it for further exploration as a potential therapeutic target in AML.  
Using biochemical and genetic approaches, we showed that the functional catalytic 
domain of SCP4 in the context of its C-terminal fragment SCP4236-466 is necessary and 
sufficient for supporting leukemia cell proliferation. Unbiased SCP4 interactome analysis 
revealed that SCP4 tightly associates with the kinase paralogs STK35 and PDIK1L. We 
showed that STK35 and PDIK1L play redundant roles in supporting AML cell proliferation, 
and their kinase catalytic activity is required. 
Our global transcriptome studies implicated SCP4 and STK35/PDIK1L as 
functioning in the same AML maintenance pathway. We provided evidence that SCP4/
kinases complex might serve signaling cooperativity between these two enzymes by (1) 
regulating protein levels and (2) activating the kinases. Moreover, we have discovered a 
novel site for potentially inhibitory phosphorylation at the eukaryotic kinase activation loop 
that has not been previously explored to our knowledge and might serve as a conserved 
kinases regulation mechanism. 
We reveal that one downstream output of this signaling complex is to maintain the 
expression of amino acid biosynthetic enzymes and transporters. These findings lead us to 
speculate that the SCP4-STK35/PDIK1L complex is required in AML to support the 
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pathological metabolic requirements in this disease. Given the novelty of our research in the 
context of the current data available for these relatively poorly studied enzymes, we have 
outlined the important mechanistic details for SCP4 and STK35/PDIK1L biochemistry that 
draw upon and expand the general principles of inferring biological pathways and 
mechanisms of protein regulation. 
Overall, we propose a model in which SCP4 interaction with STK35/PDIK1L in the 
nucleus results in stabilization and activation of the kinases. Together, SCP4-STK35/PDIK1L 




Figure 37. Model for SCP4-STK35/PDIK1L cooperativity in supporting the aberrant metabolic 
state in AML.  
STK35/PDIK1L in the cell are inactive when phosphorylated on the DFG+2 serine residue at the start 
of the activation loop of the activation segment. Docking of SCP4 on STK35/PDIK1L leads to STK35/
PDIK1L stabilization and activation through dephosphorylation of the inhibitory serine residue. The 
complex downstream genetic program is at least in part concerned with supporting the aberrant 
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3. DISCUSSION AND PERSPECTIVES 
3.1. The novelty 
The Human Genome Project was completed in April 2003 with 99% of the human 
genome sequenced and mapped to an accuracy rate of less than one error every 10,000 base 
pairs. The decade of genome sequencing stimulated an explosion in cloning and 
characterization of full-length cDNAs, aiding identification of transcriptional units and 
initial description of unknown proteins (Zhang et al. 2000; Kemmer et al. 2006; Wood et al. 
2019). However, the precise biochemical and cellular functions of 20–30% of human genes, 
by different estimates, remain an enigma to this day (Ellens et al. 2017; Wood et al. 2019). 
Among the difficulties in characterizing the unknowns of the human proteome are: (1) lack 
of a clear link to a phenotype; (2) absence of orthologs in tractable model systems; (3) lack of 
sequence homology to other characterized genes; (4) lack of predicted domain organization. 
There are also epistemological considerations, such as research bias in providing more 
details for the previously described proteins. For example, Edwards et al. in a 2011 essay 
“Too many roads not taken” observed that around 70% of human protein research was still 
focused on the 10% of proteins known even before the human genome was sequenced 
(Edwards et al. 2011). 
Cancer cells streamline all the cellular processes for the ultimate goal of unlimited 
survival and proliferation and, as a result, sometimes expose roles for proteins otherwise 
hidden by redundancy and cooperativity between biological pathways in the healthy cells. 
In this regard, systematic knockout screens in a diverse set of cancer cell lines can be 
instrumental in revealing novel functions of both poorly and well-studied proteins. 
Standardized data portals, such as DepMap, provide an invaluable tool for researchers for 
simultaneous assessment of dependencies on a given gene across hundreds of human cancer 
cell lines and data integration with analogous characteristics for other genes, including co-
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dependencies, expression, and mutations profiles. However, these comprehensive databases 
have their blind spots that can additionally impede research progress in the case of poorly 
studied genes.  
For example, the topic of this dissertation, SCP4, could not be adequately assessed as 
a dependency in DepMap since all the sgRNAs used in Project Achilles/DepMap genome-
wide screens exclusively targeted its N-terminus. We have conclusively shown that the 1–
235 amino acid segment of SCP4 was dispensable for the protein function and “invisible” for 
the dropout screening efforts, at least in the context of human leukemia (Fig. 14; Fig. 15).  
An additional technological limitation well-recognized in the field is the functional 
redundancy of paralogous genes, which also occluded the utility of DepMap data for 
STK35/PDIK1L. In this dissertation, we showed that catalytically active STK35 and PDIK1L 
could substitute for one another in the context of AML, and the requirement for their 
function correlated with that of SCP4 (Fig. 23–27). Curiously, even with the confounding 
factors mentioned above, the latest release of DepMap co-dependencies data (DepMap 21Q2 
Public + Score, CERES) has identified SCP4/CTDSPL2 as the top positively correlated co-
dependency of STK35 and vice versa.  
While this dissertation illustrates the capability of thoughtfully designed CRISPR-
Cas9 genetic screens to reveal novel signaling pathways in cancer, linking the dependencies 
on SCP4 and STK35/PDIK1L to any other features of the examined cell lines proved 
challenging. Based on our screens and the publicly available data of the driver mutations in 
the assayed cancer cell lines, we can generate hypotheses for the synthetic lethal hits in the 
context of the most common and well-described oncogenes and tumor suppressors such as 
RAS or TP53 (Fig. 4). In contrast, the precise molecular underpinnings of the dependency on 
the SCP4-STK35/PDIK1L signaling complex require further studies. Nevertheless, this work 
provides for the first time the phenotype link and the relevant mechanistic details for SCP4 
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and STK35/PDIK1L that will hopefully reveal the roles that these enzymes play in health 
and disease, specifically in the context of AML.  
3.2. Dissecting the roles for the N-terminus in SCP4 regulation 
Our mechanistic studies of SCP4 started by contrasting the CRISPR exon scanning 
approach with amino acid evolutionary conservation and sequence-based prediction of 
intrinsically unstructured regions (Chang et al. 2018; Meszaros et al. 2018). We observed a 
remarkable positive correlation of the likelihood for CRISPR-induced indel mutagenesis to 
disrupt SCP4 functionality with the degree of amino acid conservation and a negative 
correlation with the prediction for region disorder (Fig. 14). All three approaches gave very 
similar estimates for the SCP4 segment starting from amino acid 236 being highly 
conserved, structured, and essential for AML cell proliferation. These observations serve as 
another testament to the utility of the domain-focused CRISPR-screening approach 
developed in our laboratory (Shi et al. 2015). 
However, the N-terminal domain of SCP4 is present across many species, and it is 
reasonable to hypothesize that it serves specific functions in SCP4 regulation and 
maintenance. Our work provides evidence that the N-terminus is recognized by importins α 
and β to aid its nuclear localization (Fig. 19C; Fig. 20). There are a few definitive experiments 
we would propose for future studies in this regard. For example, we could mutate the 
predicted nuclear localization signals to sequences lacking characteristic arginines and 
lysines and enriched for hydrophobic residues and look for a deficiency in nuclear 
localization upon fractionation and the absence of complementation for the knockout of the 
endogenous gene by the misplaced SCP4. The caveat of this approach is the peculiar 
degradation we observed for the full-length SCP4 upon cytoplasmic exposure in AML cells 
(Fig. 18). An alternative approach would be to fuse the functional SCP4236-466 segment to an 
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N-terminal GFP with a nuclear export signal that would result in its size-restricted inability 
to freely pass through the nuclear pore and additional active sequestration in the cytoplasm.  
Another potential role for the N-terminus emerged from our data suggesting that the 
full-length protein could be a target of myeloid proteases (Fig. 18). In fact, Zhong et al., who 
reported myeloid cells specific degradation of HOXA9, had to perform triple knockout of 
Elane/Prtn3/Ctsg myeloid proteases in mice to be able to precipitate enough HoxA9 protein 
for ChIP-Seq experiments since no effective inhibitors exist for these proteases (Zhong et al. 
2018). Whether our efforts at performing SCP4 ChIP-Seq remained unsuccessful due to the 
same issue remains to be seen. However, SCP4236-466 protein was present in the cytoplasm 
(Fig. 17C), which leads us to speculate that the N-terminus of SCP4 might also serve as the 
landing site for the myeloid proteases. Myeloid proteases have been mostly investigated 
with regard to their extracellular roles in the context of infection or inflammation (Benarafa 
and Simon 2017). However, the competition between the importins binding the N-terminus 
to aid SCP4 nuclear localization and the myeloid proteases-mediated cytoplasmic 
degradation of SCP4 could serve its regulation in the cell. One piece of evidence in favor of 
this hypothesis would be if we detected SCP4 in the cytoplasm upon triple proteases 
knockout. Another experiment would involve blocking nuclear import through targeting the 
importins identified in SCP4 IP-MS via gene editing or pharmacologically and measuring 
total SCP4 levels. Of note, CTSG is one of the significantly down-regulated genes upon both 
SCP4 knockout and STK35/PDIK1L double knockout that could indicate a potential 
negative feedback loop if our hypothesis about the role of myeloid proteases in SCP4 
regulation was true (Supplemental Fig. S1). 
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3.3. Phosphatase/kinase complexes 
The interactions between SCP4 and PDIK1L or STK35 were detected in IP-MS 
experiments after stringent washes with salt concentrations ranging from 150 mM up to 500 
mM NaCl (Fig. 22A,B). Moreover, our data suggested a potentially 1:1 complex between 
ectopically expressed HA-PDIK1L and endogenous SCP4 (Fig. 22C), possibly due to PDIK1L 
being less stable in the absence of SCP4 (Fig. 30B). Nevertheless, this interaction was 
weakened by a single point mutation of the SCP4 active site (Fig. 21). Since the interactions 
of enzymes with their substrates are often transient (Fahs et al. 2016), it is unlikely that the 
strong binding we detect between SCP4 and STK35/PDIK1L is entirely due to an active site 
interaction with phosphorylated residues. While our experiments indicate that the 
activation loop of STK35/PDIK1L could be a substrate of SCP4, we speculate that the 
binding mechanism between SCP4 and STK35/PDIK1L represents docking involving non-
catalytic surfaces of these two proteins (Remenyi et al. 2006).  
Phosphatase/kinase complexes, while not extremely common, have been reported in 
cell biology, for example, for the kinases involved in the cell cycle progression (Helps et al. 
2000), MAPK/ERK pathway (see below). Other examples include phosphoinositide (PI) 
regulatory network (Lecompte et al. 2008) and cAMP-dependent protein kinase (PKA) 
complexes (Colledge and Scott 1999) that employ scaffold proteins for forming stable 
signaling complexes. Among the potential advantages of a stable phosphatase/kinase 
complex formation are simultaneous localization of both enzymes to a specific substrate and 
the precise temporal regulation of the phospho-signaling output of the complex due to the 
fixed phosphatase/kinase balance (Botelho 2009; Szomolay and Shahrezaei 2012).  
The A-Kinase Interacting Proteins, or AKAPs, were among the first families of 
scaffold proteins recognized for their role in cell signaling specificity (Colledge and Scott 
1999). AKAPs bind to the regulatory subunit of PKA and other enzymes in the cAMP 
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pathway and target the resulting signaling complexes to their subcellular compartments. 
One such AKAP, AKAP79/150, binds PKA, protein kinase C, and calcineurin (PPP3CB), a 
calcium-dependent protein phosphatase, and directs them to calcium entry sites, such as 
neuronal L-type calcium channels (Oliveria et al. 2007). Another AKAP, AKAP9 
(AKAP350/450, or Yotiao), provides a scaffold for the signaling complex between PKA, 
protein phosphatase 1, and PDE4D3 and targets it to NMDA receptors (Westphal et al. 1999). 
Both complexes allow for the acute bidirectional regulation of their cellular targets critical 
for the precise coordination of certain synaptic and cytoskeletal signaling events. 
Protein phosphatase 5 (PP5) was found to interact with Raf1 catalytic domain and 
ERK1/2 directly, and these interactions were additionally facilitated by the heat-shock 
protein Hsp90 (von Kriegsheim et al. 2006; Mazalouskas et al. 2014). Of note, in our own MS 
data, we observed SCP4 association with Hsp70, encoded by HSPA5 (Fig. 19C). Heat-shock 
proteins are molecular chaperones that catalyze appropriate protein folding and are often 
present in functional heterocomplexes. Identifying and disrupting Hsp70 binding surface 
could be informative on its functional role in SCP4 complexes formation, if any. PP5 
inhibited Raf1 by dephosphorylating pS338 outside of its activation loop, and its association 
with Raf1 kinases ERKs was reported to precisely regulate Raf1 phosphorylation output. 
One prominent example of a direct phosphatase/kinase complex was discovered at 
Cold Spring Harbor Laboratory in 1994 for the cyclin-dependent kinase 2 (CDK2) and 
kinase-associated phosphatase (KAP), encoded by CDKN3 gene (cyclin-dependent kinase 
inhibitor 3) (Hannon et al. 1994; Poon and Hunter 1995). The complex between KAP and 
CDK2 was, in fact, so robust that it allowed solving the crystal structure for these two 
proteins by the group of David Barford, who also was a Cold Spring Harbor Laboratory 
Fellow between 1991 and 1994 (Song et al. 2001). While the binding interface between KAP 
and CDK2 involved extensive interactions remote from the active sites of both enzymes, the 
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activation segment of CDK2 was reported to interact with the catalytic site of KAP via the 
phosphate group of the phosphorylated threonine residue (pT160) in the CDK2 activation 
loop. KAP inhibits CDK2 through dephosphorylation of its activating residue, thus 
promoting timely mitotic exit. 
Ca2+/CaM-dependent protein kinase IV (CaMKIV) forms a signaling complex with 
Bα- and Bδ-containing PP2A holoenzymes (Reece et al. 2009). This complex allows the 
characteristic transient nature of CaMKIV activation in response to its stimuli since PP2A 
rapidly dephosphorylates the pT200 residue within the CaMKIV activation loop and returns 
its activity to the baseline level within minutes upon activation (Westphal et al. 1998; 
Anderson et al. 2004). This case illustrates how the formation of multiprotein complexes 
regulates the timing of signaling events in addition to specificity (Pawson and Nash 2000; 
Hunter 2000). 
In yet another example of a stable phosphatase/kinase complex, mitogen-activated 
protein kinase ERK2 bears a docking domain composed of the negatively charged amino 
acids located opposite the kinase active site, which was shown to interact with the positively 
charged residues in the kinase interaction motives of the MAP kinase phosphatase MKP3. 
These interactions ensure exquisite specificity of ERK2 regulation by MKP3. MKP3 also 
deactivates ERK2 via dephosphorylation of pT183 and pY185 in its activation loop. 
Importantly, additional interactions between the ERK2 activation segment and MKP3 
facilitate MKP3 activation by realigning its catalytic residues. Single amino acid 
substitutions of the residues of MKP3 directly involved in ERK2 binding to alanines could 
disrupt the MKP3-ERK2 complex (Camps et al. 1998; Liu et al. 2006; Zhou et al. 2006). 
In contrast to the diminished interaction of SCP4D293A with the kinases (Fig. 21), 
catalytically inactive phosphatase MKP3C293S has a similar binding affinity with ERK2 to that 
of the wild type MKP3 (Zhou et al. 2001). In addition, the MKP3C293S mutant enhances ERK2 
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phosphorylation and limits its localization to the cytoplasm (Brunet et al. 1999). An 
important experiment would be to assess phosphorylation levels and any differences in 
expression or localization of STK35/PDIK1L upon the expression of the SCP4 inactive 
mutant. 
The SCP4D293A protein in our study may adopt an inactive conformation, which 
simultaneously impairs both catalysis and docking with STK35/PDIK1L. One piece of 
evidence in favor of this hypothesis could be that SCP4D293A catalytic mutant has its specific 
binding partners: FBXW11, BTRC, and CUL1 (Fig. 19C). FBXW11 and BTRC are paralogs, F-
box proteins, that together with CUL1 constitute two of the four subunits of the ubiquitin 
ligase complex called SCF (SKP1-CUL1-F-box protein). We have confirmed these MS results 
by IP-Western blot (Supplemental Fig. S2). Future structural studies of the SCP4-STK35/
PDIK1L complex coupled with mutagenesis could shed further light on the specific binding 
interactions between these catalytic domains. 
Lastly, the stable complex formation between an HAD-phosphatase SCP4 and either 
one of its macromolecular kinase partners could be synergistic, providing the resulting 
complex access to additional substrates not accessible for each enzyme separately. Given the 
disordered nature of SCP4 N-terminus (Fig. 14B), we can assume it belongs to the ‘capless’ 
C0-type HAD phosphatases (see Introduction §1.5.2). The capless HAD phosphatases are 
known to oligomerize to process low molecular weight substrates (Parsons et al. 2002; Wu 
and Woodard 2003; Lu et al. 2009; Biswas et al. 2009). Structural studies of SCP4 in the 
complex with STK35/PDIK1L are required to determine whether the unstructured N-
terminus adopts a new conformation or whether the kinase subunit of the complex could 
potentially serve as a “pseudocap” to sterically restrict the solvent access to the otherwise 
exposed HAD active site and hence allow SCP4 to act on low molecular weight substrates. 
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3.4. Phospho-regulation of eukaryotic kinases 
In each of the examples of phosphatase/kinase complexes discussed above, the 
docking interactions between phosphatases and kinases led to allosteric modulation of 
catalytic kinase activity (Remenyi et al. 2006). Our study provides evidence that a similar 
docking interaction and potential for allosteric regulation exist between SCP4 and STK35/
PDIK1L, leading to stabilization of the kinase substrates and positioning them for 
dephosphorylation. Our biochemical assays and mutational analyses implicate analogous 
serines at the activation loops of STK35 (pS385) and PDIK1L (pS194) as substrates of SCP4.  
In terms of kinases regulation, activating phosphorylation at conserved serine, 
threonine, or tyrosine residues of the activation segment is a well-described mechanism of 
activation for multiple kinases (Nolen et al. 2004; Ten Eyck et al. 2008). Interestingly, for 
STK35/PDIK1L, phosphorylations on the predicted activating S/T residues were likely 
dispensable since the kinases were functional when either residue was mutated one by one 
to alanines (Fig. 32C). However, for STK35, we showed that mutating both serines at the 
activating position to alanines at the same time renders a null mutant (STK35S413A-S414A in 
Fig. 32C). The latter suggests that either one of the adjacent S/T residues at the activating 
position could be required for the kinase activation, although additional mutagenesis 
experiments are required to prove that. Similar observations were made for the Aurora A 
kinase (Rowan et al. 2013). On the contrary, for the AMPKα, a mechanism is delineated 
where one of the S/T residues adjacent to the activating S/T is inhibitory (Djouder et al. 
2010). 
Of note, PDIK1L was more sensitive to mutations in the residues of its activation 
segment though only S194 exhibited a clear pattern of being a potential site for the 
inhibitory phosphorylation (Fig. 32C). Phyre2 predictions of three-dimensional structures 
for STK35 and PDIK1L sequences based on homology modeling (Kelley et al. 2015) revealed 
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that STK35, unlike PDIK1L, does not have a prospective β-turn in its activation loop 
(Supplemental Fig. S3). While there are conceivable limits to the accuracy of homology 
modeling for protein structures, if this prediction holds true in structural studies, it could 
explain why the STK35 structure would allow for more variation in the composition of its 
activation segment. In contrast, any perturbations around the activation loop of PDIK1L 
could peel its β-turn apart, distorting the kinase structure and disrupting its activity (Nolen 
et al. 2004). 
A lot less is known about inhibitory phosphorylation at the activating segment. For 
example, S/T residues at +4 position to the activating S/T residue were described as likely 
inhibitory in several studies. However, this position was also extremely sensitive to any 
substitutions, making it difficult to study via phosphomimetic/phosphomutant types of 
experiments (Timm et al. 2008; McCartney et al. 2016). For STK35/PDIK1L kinases, we did 
not confirm that analogous T221 in PDIK1L and S418 in STK35 residues were likely to act as 
sites for inhibitory phosphorylation (Fig. 32C).  
The conserved DFG motif of the activation loop in an active kinase conformation 
binds to a magnesium ion that interacts directly with ATP (usually reflected in the “DFG-in” 
structures of the kinases) (Modi and Dunbrack 2019; Xie et al. 2020). In an inactive 
conformation, the activation loop is often collapsed onto the surface of the kinase, blocking 
substrate binding, with the “DFG-out” position for the DFG motif also incompatible with 
binding magnesium ion and ATP. The structural differences in “DFG-in” and “DFG-out” 
states serve as the basis for developing specific kinase inhibitors, with type I inhibitors often 
targeting the active, “DFG-in” conformations, and type II — “DFG-out” state. While it was 
known that the DFG+2 serine residue was critical for the correct orientation of the “DFG-in“ 
state in the active kinase via a 3-turn and hydrogen bonds (Kornev et al. 2006; Xie et al. 
2013), our work for the first time to our knowledge provides genetic evidence that this 
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residue serves as a site for inhibitory phosphorylation. 
We hypothesize that incorporation of phosphorylation at the DFG+2 serine residue 
of STK35/PDIK1L locks the activation loop in an inactive conformation that is incompatible 
with the precise ATP-magnesium coordination (Fig. 37). However, this can only be 
determined by further structural studies of STK35/PDIK1L alone or in the complex with 
SCP4. Additionally, in vitro measurements of kinase activity with or without inhibitory 
phosphorylation would be essential evidence. One of the main caveats of most in vitro 
approaches is that the kinase that phosphorylates these residues on STK35/PDIK1L is 
unknown. Nevertheless, based on the publicly available phospho-proteomics data, we could 
speculate that the large portion of STK35/PDIK1L kinases in the cell are inactive and require 
SCP4 for their activation. 
3.5. AML metabolism 
One of the critical questions that our work proposes is what are the immediate 
effectors of the SCP4/kinases phospho-signaling cascade. Identifying substrates of SCP4/
kinases complex could potentially allow us to explain why AML cell lines show varying 
degrees of fitness defects upon SCP4 knockout or STK35/PDIK1L double knockout. While 
we ruled out the most apparent genetic explanations (such as differential gene expression, 
correlation with other known dependencies, cytogenetic and mutational background), there 
are many more potential causes for non-oncogene dependencies. For example, DNA 
hypermethylation and transcriptional silencing in AML can result in distinct synthetic lethal 
vulnerabilities (see Introduction §1.4.1.1).  
The neonatal viability of SCP4-/- mice can be extended from 20 to 42 hours by 
injecting glucose, which suggests a fundamental role of SCP4 in regulating metabolic 
pathways in vivo (Cao et al. 2018). In this prior study, SCP4 was found to positively regulate 
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FoxO1/3a transcriptional activity in hepatocytes, which promoted gluconeogenesis (for 
example, through the upregulation of phosphoenolpyruvate carboxykinase  PCK1  and 
glucose-6-phosphatase G6PC). While AML cells do not express PCK1 or G6PC at high levels, 
we did observe some downregulation in isoforms PCK2 and G6PC3 upon SCP4 knockout in 
MOLM-13 (Supplemental Fig. S4).  
Global transcriptional changes upon acute SCP4 knockout and STK35/PDIK1L 
double knockout showed consistent downregulation of multiple genes involved in amino 
acid biosynthesis and transport (Fig. 34B,C). We confirmed that most amino acid levels were 
indeed depleted upon SCP4 knockout and STK35/PDIK1L double knockout (Fig. 35). This 
nutrient deficiency was supported by the concurrent upregulation of genes involved in 
autophagy and catabolic pathways (Fig. 34B). 
AML cells drive complex metabolic reprogramming to rapidly generate energy and 
biosynthesis intermediates and hijack the nutrient-sensing signaling pathways operating in 
these pathological conditions (Castro et al. 2019). Amino acids are essential for this rewiring 
since they can be used as biosynthetic building blocks and as carbon sources for energy 
production, control mitochondrial OXPHOS, protect cells against ROS, and regulate major 
nutrient sensors such as mTOR (Kreitz et al. 2019; see Introduction §1.4.1.2). 
A 2018 study from Pereira et al. showed that different AML cell lines have different 
metabolic profiles (Pereira et al. 2018). Applying similar methods to the cell lines used in our 
study could be potentially informative if the differential dependency on SCP4 and STK35/
PDIK1L reflected the baseline relationship between the ratio of glycolytic and oxidative 
metabolism in these cell lines. The hypothesis would be that the cells heavily relying on 
OXPHOS for energy production would be more sensitive to SCP4/kinases complex 
perturbation since they are more dependent on high amino acid supplies to support their 
TCA cycle. In our metabolomics data, we contrasted the downregulation of TCA cycle 
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metabolites with a relatively unaffected urea cycle (Fig. 36).  
Another potential avenue for further research would be to investigate the mTOR 
kinase's biochemical response to the loss of SCP4/kinases since mTOR is a central node in 
nutrient sensing and transcriptional outputs of metabolic distress (Aramburu et al. 2014). 
mTORC1 also actively inhibits autophagy; hence upon amino acid starvation, autophagy is 
activated (Rothe et al. 2019). Watson et al. showed that autophagy induction limits glycolytic 
metabolism in the AML context (Watson et al. 2015). Additionally, many of the 
downregulated genes overlapping between SCP4 knockout and STK35/PDIK1L double 
knockout that are involved in amino acid biosynthesis and transport are some of the most 
sensitive targets of the stress-induced transcription factor ATF4 (Seo et al. 2009; Torrence et 
al. 2021). Characterizing the state of these proteins upon SCP4/kinases complex 
perturbation is essential to gain more insight into the nature of the following metabolic 
defects experienced by the cells. 
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Figure S1. Transcriptional downregulation of the myeloid protease cathepsin G in response to 
SCP4 knockout and STK35/PDIK1L double knockout.  
RNA-Seq transcripts per million (tpm) data for CTSG from MOLM-13 cells on day 5 post-infection 
with the indicated sgRNAs.  
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Figure S2. Catalytic mutants of SCP4, but not the wild-type SCP4, interact with FBXW11. 
Immunoprecipitation followed by Western blotting performed with the indicated antibodies. The 
nuclear lysates were prepared from the human MOLM-13 cells stably expressing empty vector 
(empty), FLAG-SCP4wt (wt), FLAG-SCP4236-466 (236-466), catalytic mutant FLAG-SCP4D293A (D293A). 
HA-FBXW11
FLAG-SCP4
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Figure S3. Predicted three-dimensional structures for the catalytic domains of PDIK1L and STK35. 
(A,B) Ribbon diagram of the predicted structure of (A) PDIK1L and (B) STK35 catalytic domains. 
(C,D) Activation segment of (C) PDIK1L and (D) STK35. (E) Alignment of activation segments 
residues of PDIK1L and STK35. Residues that are conserved among the kinases sequences are 
highlighted in light gray. Consensus sequence given; uppercase = conserved, lowercase = similar. The 
predicted structural elements of protein kinases are indicated below the consensus sequence. The 
secondary structure of PDIK1L is illustrated directly above the sequence alignment, arrows and boxes 
over PDIK1L sequence indicate β-strands. 
DFG motif is colored magenta, activation loop is colored green, P+1 loop is colored gray, APE motif is 
colored orange. Inhibitory serine residues are shown in (C) and (D) in red. The structures were 
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Figure S4. Gluconeogenesis genes upon SCP4 knockout and STK35/PDIK1L double knockout. 
RNA-Seq transcripts per million (tpm) data for G6PC3 and PCK2 from MOLM-13 cells on day 5 post-
infection with the indicated sgRNAs.  
















4. FUTURE DIRECTIONS 
4.1. Immediate degradation 
One of the major developments for understanding the functions of SCP4 and 
STK35/PDIK1L in the cell would be adopting and optimizing their specific and acute 
degradation strategy. An important caveat of depletion of SCP4 and STK35/PDIK1L at the 
DNA level that we have performed throughout this study via CRISPR-mediated knockout is 
the 5 days lag period between the infection of the cells with the sgRNAs and the sample 
collection, for example, for RNA-Seq or metabolomics experiments. Immediate SCP4 and 
STK35/PDIK1L protein degradation would allow us to discriminate between the direct 
consequences of their depletion and any confounding secondary effects.  
There are a few strategies that we could try and implement for our model systems, 
such as fusing constructs of interest to (1) a destabilizing FKBP12 mutant (Banaszynski et al. 
2006); (2) an auxin-inducible degron (AID) tag (Natsume et al. 2016); (3) an FKBP12F36V 
mutant that could be degraded via cell-permeable degraders called dTAGs (Nabet et al. 
2018). Destabilizing FKBP12 mutant fusion protein will be effectively degraded at baseline 
without the addition of stability-inducing ligand (conditional activation system). The other 
two approaches allow for conditional degradation of the protein of interest. Some of the 
caveats for all systems include cell line-specific degradation kinetics, incomplete target 
degradation, unconditional degradation due to ligand analogs in the media, potential ligand 
off-target effects, the requirement for co-expression of additional elements of the 
degradation system (for the AID approach). 
Ideally, we would knock-in the degradation system into the endogenous loci of the 
proteins of interest, for example, the N-terminus of SCP4, but initial validation of either 
approach could be performed with the exogenous expression of a construct and stable 
CRISPR-mediated knockout of the endogenous gene.  
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4.2. The role of SCP4 on chromatin 
Several studies, including ours, pointed out the remarkable affinity of SCP4 towards 
chromatin fraction. One possibility is that the biochemical properties of SCP4 mediate this 
association since chromatin is a highly charged biopolymer and upon cell lysis might bind 
proteins through nonspecific electrostatic interactions (Kustatscher et al. 2014). Interestingly, 
unlike endogenous protein, FLAG-tagged SCP4 in our study was equally distributed 
between the nuclear soluble and chromatin fractions (Fig. 17A,B). This can indicate that 
FLAG-tag somehow disrupts SCP4 loading on chromatin or that there is a competition 
between the exogenous and endogenous SCP4. A clarification experiment in this regard that 
could also point towards the specificity of SCP4 function on chromatin would be observing 
FLAG-SCP4 preferential chromatin localization upon the endogenous SCP4 knockout.  
Another necessary experiment is RNAse A treatment of the chromatin fraction prior 
to chromatin solubilization that would help us to determine whether SCP4 is anchored or 
bridged to chromatin via RNA (Hiragami-Hamada et al. 2018).  
Additional evidence could come from immunostaining experiments with specific 
antibodies against endogenous SCP4 and histone marks for transcriptional repression or 
activation. In this way, we could clarify whether SCP4 association with heterochromatin, 
described in the literature, is true for our model system (Wani et al. 2016). 
Our preliminary results suggested that at least HA-PDIK1L might be enriched in the 
chromatin fraction (data not shown) and less present in the other fractions with an obvious 
caveat of being exogenously expressed. These data were encouraging considering the tight 
association between PDIK1L and SCP4 and could suggest a model in which SCP4 attracts 
PDIK1L to chromatin for performing its downstream functions. Of note, HA-PDIK1L 
degradation in all fractions upon endogenous SCP4 knockout did not allow us to observe 
any relocalization of HA-PDIK1L. Going forward, the development of specific immune 
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reagents against endogenous proteins is crucial for providing an additional characterization 
of the SCP4-STK35/PDIK1L complex and its association to chromatin. 
Given SCP4 affinity with chromatin is functional, we could attempt to optimize 
ChIP-Seq protocols to preserve endogenous SCP4 via trouble-shooting fractionation, 
chromatin shearing, and triple knockout of myeloid proteases, if necessary. Depending on 
the mode of chromatin association, SCP4 ChIP-Seq could benefit from two-step crosslinking 
methods (Tian et al. 2012). Alternatives to ChIP-Seq could include Cut&Run or Cut&Tag, 
however, more evidence is needed to access the utility of these methods for the proteins not 
directly associated with DNA or for the heterochromatin regions.  
The development of protein depletion techniques from §4.1 would also allow us to 
perform ChIP-Seq with antibodies against histone epigenetic modifications of interest or Pol 
II upon acute SCP4 degradation. This could be informative in nominating immediate 
consequences of SCP4 loss on transcription factors and epigenetic modifiers or global 
transcription. Another experiment that could potentially help us to identify genes 
specifically affected by the acute SCP4 depletion would be ATAC-seq. 
4.3. Understanding the phenotype 
Competition-based proliferation assays are a powerful tool to detect cell fitness 
defects upon sgRNA mediated knockout of a gene of interest. However, additional 
experiments are required to understand the nature of the deleterious phenotype. Our cell 
cycle analysis upon SCP4 knockout and STK35/PDIK1L double knockout and apoptosis 
measurements showed both evidence for an increase in G1/G0 arrest and apoptosis (Fig. 8; 
Fig. 25). These effects were measured on day 5 post-infection with sgRNAs, and immediate 
protein degradation could help us distinguish primary from secondary effects of the 
essential genes knockout. 
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Various techniques have been developed to delineate the precise molecular mode of 
cell death (Galluzzi et al. 2018). As such, blocking the key cell death mediators via genetic 
means or with specific pharmacological inhibitors could be informative if the full or partial 
rescue of SCP4/kinases knockout phenotype was to be observed. Optimizing 
immunostaining methods for SCP4/kinases would also benefit our understanding of the 
knockout phenotype through various imaging and cytochemical techniques available for 
delineating the precise cell death phenotype (Taatjes et al. 2008). 
Another interesting question would be the relationship of SCP4/kinases complex 
with the cell cycle progression. The publicly available resource Cyclebase does not report 
any evidence for transcriptional regulation for STK35/PDIK1L dependency on the cell cycle, 
with their mRNAs expression measured in the high-throughput studies being non-periodic, 
unlike for the cell-cycle related proteins PCNA or AURKA (Santos et al. 2015). However, 
there is no expression data for SCP4 and no proteomics data available for either protein in 
relation to cell cycle measurements. 
While we have not observed any effects of SCP4 knockout on differentiation in 
human HSPCs, the top upregulated signature in our RNA-Seq studies was myeloid 
leukocyte activation (Fig. 11–13; Fig. 34). We could combine immediate SCP4/kinases 
depletion with immune activation markers flow-cytometry panels to gain further insights 
into this phenotype and any changes in cell morphology. Additionally, conditioned media 
experiments could be informative if SCP4/kinases loss phenotype induces some paracrine 
signaling in addition to its cell-autonomous effects.  
We also have to clarify the effect that SCP4 has on the stability of PDIK1L/STK35. 
Appreciating the full extent of this phenotype is difficult in the absence of specific 
antibodies against the endogenous proteins. Additional experiments using inhibitors of the 
ubiquitin-proteasome or lysosomal proteolysis pathways are required to differentiate 
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between these modes of protein degradation for cytoplasmic SCP4 and exogenous or 
endogenous STK35/PDIK1L upon the endogenous SCP4 knockout. The association with 
Hsp70 that we noticed in our MS data could potentially target proteins towards the 
autophagy pathway (Fernandez-Fernandez et al. 2017).  
4.4. Identifying and validating SCP4 substrates 
We have nominated STK35/PDIK1L as both interacting partners and potential 
substrates of SCP4 due to their stable interaction and the body of research on analogous 
phosphatase/kinase complexes (see Discussion §3.3–3.4). However, the question remains of 
whether these kinases are the only relevant substrates of SCP4 in AML and what are the 
immediate downstream effectors of the complex.  
Like ours, many studies started research into potential substrates of a given 
phosphatase through detecting protein-protein interactions in hypothesis-driven functional 
studies or through unbiased interactome analysis. For example, SCP1 over the last decade 
has been found to dephosphorylate and regulate the repressor element 1 (RE1) silencing 
transcription factor (REST) (Yeo et al. 2005; Nesti et al. 2014; Burkholder et al. 2018). In other 
cases, enzyme-substrate complexes tend to be transient and make substrate identification 
difficult (Fahs et al. 2016). One way to overcome this for protein tyrosine phosphatases has 
been the discovery of “substrate-trapping” mutants (Flint et al. 1997; Blanchetot et al. 2005). 
Nonetheless, “substrate-trapping” techniques for other families of phosphatases, including 
HAD-phosphatases, are yet to be described in the literature. 
Another standard method of discovering and validating physiological substrates of 
phosphatases is expression screening. It is not unbiased in the sense that specific antibodies 
against both phosphorylated residues and total protein levels of a prospective substrate 
have to be established. The following exogenous expression of a phosphatase versus its 
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catalytic mutant and the associated decrease in the specific phosphorylation versus total 
protein levels could indicate the potential enzyme-substrate relationship between them. 
Along these lines, antibodies against pS194 in PDIK1L and pS385 in STK35 are required to 
provide more evidence of these kinases being physiological SCP4 substrates in the cell. A 
more comprehensive way to look for additional substrates would be differential 
phosphoproteomics coupled with a labeling technique such as stable isotope labeling by 
amino acids in cell culture (SILAC) and recent advances in the differential tandem mass 
spectrometry proteomics, such as SAMPEI (Cifani et al. 2021), upon SCP4 acute depletion or 
the addition of the recombinant catalytically active versus mutant SCP4 into the cell lysates. 
4.5. Identifying kinases substrates 
Given our focus on the SCP4/kinases complex signaling outcome, a valid research 
path would be focusing on the substrates of the kinases. Similarly to identifying 
phosphatase substrates, the approaches here are limited to mapping kinase interactions and 
the indirect phosphoproteomics-based strategies (Jurcik et al. 2020). The caveats are also the 
same: transient enzyme-substrate interactions, high noise, secondary effects associated with 
a gain or a loss of a phospho-signaling enzyme. For all of these methods, it is essential to 
compare the kinases with their catalytically dead mutants and versions with 
phosphomutant or phosphomimetic residues at the sites of inhibitory phosphorylation we 
discovered. 
An alternative strategy recently described for kinase-substrates identification is 
employing their analog-sensitive (AS) mutants. AS mutants harbor several mutations in 
their ATP-binding pocket that allow them to accept in addition to ATP bulky ATP analogs, 
such as ATP with a γ-thiophosphate (Michowski et al. 2020). This approach could help us 
accomplish two goals: (1) identify direct kinase substrates that would be uniquely labeled 
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with a thiophosphate (labeling); and (2) selectively block the mutant kinase with the 
available specific bulky inhibitors (inhibition).  
Additionally, it would be interesting to compare the outputs for either substrate 
nomination approach upon disrupting the interaction between SCP4 and STK35/PDIK1L 
(see below). 
4.6. Structural and biochemical studies of purified proteins 
One of the main downstream developments for our research would be optimizing 
expression and purification strategies for STK35/PDIK1L alone or in the complex with 
SCP4. First, it is important to show that SCP4 dephosphorylates full-length STK35/PDIK1L 
in vitro. Among the challenges of this experiment would be making sure that the kinases 
were phosphorylated on the residues of interest. We can try purification strategies from 
insect or mammalian cell cultures to preserve naturally occurring phosphorylation. Again, 
phosphorylation-specific antibodies would be required. In our study, SCP4 additionally 
efficiently dephosphorylated pS216 residue that did not show a differential phenotype 
characteristic for potentially inhibitory phosphorylation upon phosphomimetic/
phosphomutant substitution experiments (Fig. 32, 33). It remains to be seen whether SCP4 
can also dephosphorylate this residue in the context of fully folded kinase substrates. 
SCP4/kinases complex purification is necessary to determine its stoichiometric 
composition. The analytical gel filtration step during purification would provide additional 
evidence for the integrity of this phosphatase/kinase complex. The purified complex would 
also allow us to map the interaction surfaces between them, for example using hydrogen/
deuterium exchange mass spectrometry. These data would allow us to design additional 
experiments involving interaction surface perturbations through genetic mutations and 
rationally designed peptides. 
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The co-IP experiments for SCP4 with different kinase mutants (catalytically dead, 
phosphomimetic/phosphomutant substitutions) would be informative for the model 
refinement and proposed structural studies. For example, any of the phosphomimetic/
phosphomutant kinase versions we used could have weakened or abolished the 
phosphatase/kinase association. This would require us to reevaluate the original 
conclusions from these experiments. Finally, structural studies of the purified SCP4 in the 
complex with STK35/PDIK1L wild type and with phosphomimetic/phosphomutant 
substitutions (as long as they do not disrupt the complex formation in co-IP studies) would 
be instrumental in supporting the model we propose. This could be the first tangible way to 
obtain the structures for these proteins, given that the previous attempts in SCP4 
crystallization have been unsuccessful (Zhang, personal communication). We would also be 
able to see the position of the DFG-loop relative to the SCP4 catalytic site for the active 
versus inactive kinase conformations, which would provide additional insight into the 
physiological regulation of eukaryotic kinases.  
4.7. Therapeutic implications 
All the experiments described above are important for deeper mechanistic insights 
into the role of SCP4/kinases complex in AML cells. It is likely that understanding the 
immediate effects of the complex perturbation, nominating downstream substrates, and 
characterizing the precise cell fitness defects will provide enough evidence to support or 
deny our current hypothesis that SCP4/kinases complex is implicated in supporting AML 
cell metabolism. The metabolomics MS analysis specifically requires acute protein 
degradation and careful labeling techniques to assess precise metabolic defects and their 
extent accurately. Additional validation for this hypothesis could come from a partial rescue 
of the SCP4/kinases loss phenotype upon adding the critical metabolites into the media.  
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Our findings that SCP4 is not required for normal HSPCs differentiation and thus 
could serve as a therapeutic opportunity in human AML were further supported by the 
published SCP4 knockout mouse model phenotype (Cao et al. 2018). However, Cao et al. did 
not methodically characterize the abnormalities in the embryonic development of 
homozygous SCP4-/- mice besides neonatal lethality and the glucose sensitivity. The mouse 
studies are a crucial next step for understanding the role of SCP4. Accurately describing the 
systematic SCP4 deficiency, specifically in the context of hematopoietic development, is 
essential for establishing its potential functional role in AML. Conditional knockout animal 
models are required, possibly with the simultaneous introduction of AML drivers, such as 
MLL-AF9, to characterize the AML onset and phenotypes. For the potential therapeutic 
implications, conditional knockdown in mice is required to access the target therapeutic 
potential. In this regard, our data concerning the mouse AML xenograft model are 
encouraging (Fig. 9). 
Several HAD family phosphatases have been successfully targeted using small-
molecule inhibitors (Freschauf et al. 2009; Zhang et al. 2011; Krueger et al. 2013; Krueger et 
al. 2014; Wang et al. 2016b). If the structural studies we propose are successful, virtual 
screening approaches could be exploited similarly to those described for the evolutionary 
close SCP1 (Park et al. 2017). Another option to explore would be developing STK35/
PDIK1L dual inhibitor using small molecules that compete with ATP binding to these 
targets. Mapping the interaction surface between SCP4 and the kinases would allow us to 
design allosteric peptide inhibition disrupting their interaction.  
Overall, our study justifies the development of such compounds targeting this 
phospho-catalytic signaling complex, which would be expected to suppress AML cells 
whereas having minimal effects on normal hematopoiesis, yield additional mechanistic 
insights into the SCP4/kinases cellular functions, and enrich our understanding of AML.  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5. MATERIALS AND METHODS 
5.1. Cell lines 
Human cell lines MOLM-13, NOMO-1, MV4-11, ML-2, HEL, SET-2, THP1, U937 
(acute myeloid leukemia, AML); K562 (chronic myelogenous leukemia, CML); PANC-1, 
MIAPaCa-2, SUIT-2, AsPC-1 (pancreatic ductal adenocarcinoma, PDAC); RH4, RH30 
(rhabdomyosarcoma, RMS); NCI-H1048 (small cell lung cancer, SCLC); and murine cell line 
RN2 (MLL-AF9/NRasG12D AML) (Zuber et al. 2011a) were cultured in RPMI-1640 
supplemented with 10% fetal bovine serum (FBS). Human cell line SEM (AML) was 
cultured in IMDM with 10% FBS. Human cell line OCI-AML3 (AML) was cultured in Alpha 
MEM with 20% FBS. Transformed human HSPC MLL-AF9 (MA9) cells (Mulloy et al. 2008; 
Wei et al. 2008) derivatives MA9-NRASG12D and MA9-FLT3ITD (AML) were cultured in 
IMDM with 20% FBS. Human cell line Kasumi-1 (AML) was cultured in RPMI with 20% 
FBS. Human cell lines RD (RMS), A549 (lung adenocarcinoma), and HEK293T were cultured 
in DMEM with 10% FBS. Murine cell line NIH3T3 was cultured in DMEM with 10% bovine 
calf serum (BCS). 1% penicillin/streptomycin was added to all media. All cell lines were 
cultured at 37°C with 5% CO2 and were regularly tested mycoplasma negative. 
5.2. Plasmid construction and sgRNA cloning 
The sgRNA lentiviral expression vector with optimized sgRNA scaffold backbone 
(LRG2.1, Addgene plasmid # 108098) was derived from a lentiviral U6-sgRNA-EFS-GFP 
expression vector (LRG, Addgene plasmid # 65656) by replacing the original wild-type 
sgRNA scaffold with our optimized version (Tarumoto et al. 2018). LRCherry2.1 was 
produced from LRG2.1 by replacing GFP with mCherry coding sequence. LRG2.1-Blast was 
generated by the introduction of the blasticidin resistance gene after GFP coding sequence 
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with a P2A linker. In this study, LRG2.1, LRG2.1-Blast, or LRCherry2.1 were used for 
introducing sgRNA into human cell lines, whereas the original LRG vector was used for 
sgRNA expression in murine cell lines. All the sgRNAs were cloned into the LRx2.1-
derivatives or LRG vectors using a BsmBI restriction site. Sequences of all sgRNAs used in 
this study are provided in the Appendix 6. 
LentiV_Neo vector was derived from LentiV_Cas9_puro vector (Addgene plasmid # 
108100) by removing Cas9 and replacing a puromycin resistance gene with a neomycin 
resistance gene. CTDSPL2 cDNA (Horizon Discovery, Clone ID: 5744745), partial STK35 
cDNA (Horizon Discovery, Clone ID: 9021751), and PDIK1L cDNA (Horizon Discovery, 
Clone ID: 4828997) were cloned into LentiV_Neo vector using In-Fusion cloning system 
(Takara Bio; Cat. No. 121416). The N-terminus of STK35 cDNA (4–296 bp from translation 
start site) was added to obtain STK35 cDNA corresponding to NM_080836. The N-terminal 
FLAG and HA-tags were added to the cDNAs in-frame. For the generation of all the 
mutants, the base substitutions were introduced into the cDNA via PCR mutagenesis. The 
list of all the primers used for the generation of mutants used in this study can be found in 
the Appendix 7. 
5.3. Construction of sgRNA libraries 
All the genes contained within the gene group “Phosphatases” reported by the 
HUGO Gene Nomenclature Committee (HGNC) were selected for designing the 
phosphatase domain-focused sgRNA library. The phosphatase domain information was 
retrieved from the NCBI Conserved Domains Database. 6 to 30 sgRNAs were designed 
against exons encoding phosphatase domains. For the CRISPR exon-scan library 85 sgRNAs 
were selected against every exon of SCP4. All sgRNAs were designed using https://
mojica.cshl.edu and filtered for the minimal predicted off-target effects (Hsu et al. 2013). 
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The domain targeting and positive/negative control sgRNAs oligonucleotides were 
synthesized in a pooled format on an array platform (Twist Bioscience) and then amplified 
by PCR, using Phusion® Hot Start Flex DNA Polymerase (NEB; Cat. No. M0535). The PCR 
products were cloned into the BsmBI-digested lentiviral vector LRG2.1 (Addgene plasmid # 
108098) using a Gibson Assembly® Cloning Kit (New England BioLabs; Cat. No. E2611). The 
library was produced in MegaX DH10B T1R Electrocomp Cells (Invitrogen; Cat. No. 
C640003). 
5.4. Lentivirus production and infection 
The lentivirus was packed in HEK293T cells by transfecting lentiviral expression 
vector plasmids together with the lentiviral packaging plasmid (psPAX2, Addgene plasmid 
# 12260) and the envelope protein expressing plasmid (VSV-G) using polyethylenimine (PEI 
25K™; Polysciences; Cat. No. 23966) transfection reagent. HEK293T cells were transfected 
when ~80–90% confluent.  
For the pooled sgRNA phosphatase library lentivirus production, five 10 cm plates of 
HEK293T were used. For one 10 cm plate of HEK293T cells, 5 μg of plasmid DNA, 5 μg of 
VSV-G, 7.5 μg psPAX2, and 64 μL of 1 mg/mL PEI were mixed with 1 mL of Opti-MEM®, 
incubated at room temperature for 20 minutes, and then added to the cells. The media was 
changed to 5 mL of fresh media 6–8 hours post-transfection. The lentivirus-containing media 
was collected at 24, 48, and 72 hours post-transfection, pooled together and filtered through 
a 0.45 μM non-pyrogenic filter. 
For lentivirus infection, target cells were mixed with the virus (volume empirically 
determined to result in the desired infection rate) and 4 μg/ml polybrene and then 
centrifuged at 600 x g for 30–45 minutes at room temperature. For adherent cell lines, media 
was changed at 24 hours post-infection. If selection was required for stable cell line 
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establishment, corresponding antibiotics (1 μg/mL puromycin, 1 μg/mL blasticidin, 1 mg/
mL G418) were added 24 hours post-infection. 
5.5. Pooled negative-selection CRISPR screening and data analysis 
Cas9-expressing stable cell lines were produced by infection with the lentivirus 
encoding human codon-optimized Streptococcus pyogenes Cas9 protein (LentiV_Cas9_puro, 
Addgene plasmid # 108100) and subsequent selection with 1 μg/mL puromycin. Lentivirus 
of pooled sgRNA phosphatase library titer was estimated by mixing the cells with the 
serially diluted virus and measuring GFP% on day three post-infection using a Guava® 
easyCyte™ Flow Cytometer (Merck Millipore). The cells were then infected with the volume 
of virus estimated to result in a 30–40% infection rate to increase the probability of a single 
sgRNA introduction event per cell. The number of cells was kept 1000 times more than the 
sgRNA number in the library to maintain the representation of sgRNAs during the screen. 
Cells were harvested at initial (day three post-infection) and final (10 or more population 
doublings after the initial) time points. Genomic DNA was extracted using the QIAamp 
DNA Mini Kit (QIAGEN; Cat. No. 51304). 
Sequencing libraries were prepared as described previously (Shi et al. 2015). Briefly, 
genomic DNA fragments (~200 bp) containing sgRNAs were amplified by PCR, using 
Phusion® Hot Start Flex DNA Polymerase (NEB; Cat. No. M0535). The PCR products were 
end-repaired with T4 DNA polymerase (NEB; Cat. No. B02025), DNA Polymerase I, Large 
(Klenow) fragment (NEB; Cat. No. M0210L), and T4 polynucleotide kinase (NEB; Cat. No. 
M0201L). The 3’ adenine overhangs were added to the blunt-end DNA fragments by 
Klenow Fragment (3’-5’ exo; NEB; Cat. No. M0212L). The DNA fragments were then ligated 
with diversity-increased custom barcodes (Shi et al. 2015), using Quick Ligation Kit (NEB; 
Cat. No. M2200L). The ligated DNA was PCR amplified with primers containing Illumina 
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paired-end sequencing adaptors, using Phusion Flash High-Fidelity PCR Master Mix 
(Thermo Fisher; Cat. No. F548S). The final libraries were quantified using Bioanalyzer 
Agilent DNA 1000 (Agilent 5067-1504) and were pooled together in an equimolar ratio for 
paired-end sequencing using MiSeq platform (Illumina) with MiSeq Reagent Kit V3 150-
cycle (Illumina). 
The sgRNA sequences were mapped to the reference sgRNA library to discard any 
mismatched sgRNA sequences. The read counts were calculated for each individual sgRNA. 
The following analysis was performed with a custom Python script: sgRNAs with read 
counts less than 50 in the initial time point were discarded; the total read counts were 
normalized between samples; the average log2 fold-change in the reads corresponding to 
sgRNAs targeting a given gene (CRISPR score) was calculated, as described (Wang et al. 
2015). AML-specific dependency was determined by subtracting the average of CRISPR 
scores in non-AML cell lines from the average of CRISPR scores in AML cell lines, and that 
score was ranked in ascending order. The phosphatase CRISPR screening data is provided in 
the Appendix 2. The SCP4 CRISPR exon scanning screening data is provided in the 
Appendix 3. 
5.6. Competition-based cell proliferation assays 
Cas9-expressing cell lines were infected with lentivirus encoding sgRNAs linked 
with either GFP or mCherry reporters at the infection rate of ~20–60% as described above. 
Percentage of GFP- or mCherry-positive cells was measured every three days from day 3 to 
day 18 post-infection using Guava® easyCyte™ Flow Cytometer (Merck Millipore). The 
percentage of fluorescent cells in the population on each day was divided by their 
percentage on day three to calculate fold-change corresponding to the effect of a given 
sgRNA on cell proliferation. 
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5.7. Western Blot 
For knockout experiments, cells were harvested on day 5 post-infection with sgRNA.  
For whole-cell lysates, a precise cell number was calculated before sample 
preparation for equal loading. Cells were washed 1X with ice-called PBS. Cell pellets were 
then resuspended in PBS and 2X Laemmli Sample Buffer (Bio-Rad, Cat. No. 1610737) 
containing β-mercaptoethanol (BME), boiled for 30 minutes, and cleared by centrifugation at 
room temperature at 13,000 rpm. 
For fractionation experiments, cell fractions were prepared as described below. The 
exact protein concentrations in the fractions were measured with the Pierce™ BCA Protein 
Assay Kit (Thermo Fischer, Cat. No. 23225). The cell fractionation samples were boiled for 5–
10 minutes with a 2X Laemmli Sample Buffer containing BME. 
The samples were separated by SDS-PAGE (NuPAGE 4-12% Bis-Tris Protein Gels, 
Thermofisher), followed by transfer to nitrocellulose membrane via wet transfer at 90 V for 
2–2.5 hours. Membranes were then blocked for 1 hour with 5% non-fat milk in TBST and 
incubated with primary antibodies overnight. On the next day, the membranes were washed 
3X with TBST followed by incubation with HRP-conjugated secondary antibodies (Rabbit 
Cytiva/Amersham NA934; Mouse Agilent/Dako P026002-2) for one hour at room 
temperature. After 3X washes with TBST, an enhanced chemiluminescence solution 
containing HRP substrate was added to the membranes, and the signal was visualized using 
the darkroom development techniques for chemiluminescence. Antibodies used in this 
study included SCP4 (CTDSPL2) (CST, # 6932, 1:500), FLAG (Sigma Aldrich, F1804, 
1:10,000), HA-HRP (Sigma Aldrich, clone 3F10, 1:10,000), H3K4me3 (Sigma Aldrich, 07-473, 
1:1,000), β-Actin-HRP (Sigma A3854-200UL; 1:50,000). 
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5.8. Cell cycle arrest and apoptosis analysis 
Cell cycle analysis was performed using the BrdU Flow Kit  according to the 
manufacturer protocol  (BD, FITC BrdU Flow Kit; Cat. No. 559619), with cells pulsed with 
BrdU for 1 hour at 37°C. Annexin V apoptosis staining was performed using the Apoptosis 
Detection Kit  according to the manufacturer protocol  (BD, FITC Annexin V Apoptosis 
Detection Kit; Cat. No. 556547). Cells were co-stained with 4ʹ,6-diamidino-2-phenylindole 
(DAPI) to measure DNA content and analyzed with a BD LSRFortessa flow cytometer (BD 
Biosciences) and FlowJo software (TreeStar).  
5.9. Editing and differentiation of human peripheral blood CD34+ cells 
Circulating G-CSF-mobilized human CD34+ cells were obtained from two de-
identified healthy donors (KeyBiologics). Enrichment of CD34+ cells was performed by 
immunomagnetic bead selection using an CliniMACS instrument (Miltenyi Biotec). After 
enrichment, the CD34+ cell fraction was 95% of the total, with <0.2% CD3+ cells and <2% 
CD19+ cells.  
Purified recombinant Cas9 protein was obtained from Berkeley Macrolabs. Two 
sgRNAs against SCP4 and one sgRNA against MYC were synthesized by TriLink 
BioTechnologies. The sgRNAs included 2ʹ-O-methyl 3ʹ-phosphorothioate (MS) 
modifications at 3 terminal nucleotides at both the 5ʹ and 3ʹ ends (Hendel et al. 2015).  
Editing in human CD34+ cells was performed as described before (Metais et al. 2019). 
Briefly, cryopreserved CD34+ cells were thawed and pre-stimulated for 48 hours in the 
maintenance medium (Appendix 8). The cells were then washed 1X in PBS, resuspended in 
T buffer included in kit (Thermo Fisher Scientific, MPK10025), mixed with RNP (described 
below), and electroporated with 1600 V, 3 pulses of 10 ms, using a Neon Transfection System 
(Thermo Fisher Scientific, Cat. No. MPK5000). As a control, cells were not electroporated or 
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electroporated with Cas9 and Non-targeting gRNA.  
Ribonucleoprotein complexes (RNPs) were formed by incubating 160 pmol of Cas9 
with 320 pmol sgRNA in 50 μL of 10 mM HEPES (Thermo Fisher Scientific, catalog # 
15630080), 150 mM NaCl (Thermo Fisher Scientific, catalog # 9759) for 35 minutes. 1 million 
CD34+ cells resuspended in 50 μL of T buffer were mixed with RNP complex in a final 
volume of 100 μL.  
After electroporation, cells were immediately added to the media with cytokines 
required for differentiation into erythroid, myeloid, or megakaryocyte lineages or to 
methylcellulose for the colony forming cell (CFC) assay (see below). Erythroid, myeloid, and 
megakaryocyte maturation were monitored by immune-flow cytometry for the appropriate 
cell surface markers (Appendix 8) on days 2, 5, 8, and 16 post-electroporation (final day for 
differentiation) using BD LSRFortessa Dual™ Flow Cytometer. The genomic DNA from each 
of the lineages was collected in parallel to the immune-flow cytometry, and Western blot 
samples were prepared on days 5 and 8.  
The on-target indel frequencies were quantified using QuantStudio™ 12K Flex Real-
time PCR System (Thermo Fisher Scientific) with Power SYBR Green Master Mix (Thermo 
Fisher). Two primer pairs were developed for each targeted region using Primer3 
(Untergasser et al. 2012). One primer in each pair was chosen to span the Cas9 cleavage site 
3-nt upstream of the PAM site, and the second primer was selected at a 100–150 bp distance. 
Primer sequences are provided in Appendix 8. Quantitative PCR was performed on 
genomic DNA from gene-edited cells or control cells. Based on the consistency of 
amplification, either chr10 or untargeted region of CTDSPL2 was used as an endogenous 
control for calculating ΔCT values. The percentage of editing in CD34+ cells electroporated 
with sgRNAs vs. Cas9 alone was approximated as 1 - 2^(-ΔΔCT). For the myeloid lineage, 
Surveyor nuclease assay was performed with primers in Appendix 8, according to the 
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manufacturer protocol (Integrated DNA Technologies, Cat. No. 706020) (Appendix 8. 
sgRNAs; media and cytokines; and antibodies used in flow cytometry panels in CD34+ 
experiments). 
For the CFC assay, ~800 CD34+ gene-edited and control cells were mixed with 1.0 mL 
of MethoCult™ SF H4636 methylcellulose (Stemcell Technologies, Cat. No. 04636) 
containing recombinant cytokines for human embryonic stem (ES) cell-derived 
hematopoietic progenitor cells. The cultures were incubated in 35-mm tissue culture dishes. 
After 14 days, single colonies were classified and quantified. 
All the reagents used in these experiments can be found in the Appendix 8. 
5.10. In vivo transplantation of MOLM-13 cells into NSG mice 
All animal procedures and studies were approved by the Cold Spring Harbor 
Laboratory Animal Care and Use Committee in accordance with the Institutional Animal 
Care and Use Committee. First, MOLM-13/Cas9+ cell line stably expressing luciferase was 
established via lentiviral infection with a Lenti-luciferase-P2A-Neo (Addgene # 105621) 
vector followed by G418 (1 mg/mL) selection. These cells were infected with lentivirus 
encoding GFP-linked sgRNAs either sgROSA (negative control) or sgSCP4. On day 3 post-
infection, the infection rate was checked by the percentage of GFP positive cells, and all 
samples had over 90% infection rate. 0.5 million cells were transplanted into sublethally 
(2.5Gy) irradiated NSG mice (Jax 005557) through tail vein injection. Mice were imaged with 
IVIS Spectrum system (Caliper Life Sciences) on days 12 and 15 post-injection for visualizing 
the disease progression. 
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5.11. Sub-cellular fractionation and Immunoprecipitation in MOLM-13 cells 
Subcellular protein fractionation was performed either by using Subcellular Protein 
Fractionation Kit for Cultured Cells (Thermo Scientific; Cat. No. 78840) according to the 
manufacturer protocol or following the protocol below.  
For subsequent mass spectrometry (MS) analysis, ~200 million cells were collected 
and the protocol below was used. For immunoprecipitation (IP) coupled with Western blot, 
40–60 million cells were collected and the protocol below was used. 
The cells were washed 2X with ice-cold PBS, then resuspended in 5X Packed Cell 
Volume (PCV) of Hypotonic cell lysis buffer (10 mM HEPES pH 7.9; 1.5 mM MgCl2; 10 mM 
KCl; 1 mM DTT; supplemented with proteinase inhibitors). Note: SCP4 might be a target of 
myeloid proteases in MOLM-13 cells (data not shown) (Zhong et al. 2018). Therefore, we 
found that the best protein preservation was achieved when avoiding the use of detergents 
in the protocol and thoroughly washing the nuclei pellet from any traces of the cytoplasm. 
After 15 minutes incubation at 4°C with rotation, the cells were pelleted and 
resuspended in 2X PCV of Hypotonic cell lysis buffer. The cell walls were disrupted using a 
glass tissue homogenizer on ice with 10 up-and-down strokes using a type B pestle. The 
disrupted cells in suspension were pelleted for 20 minutes at 11,000 x g at 4°C. The 
supernatant was saved as the cytoplasmic fraction. The pellet was thoroughly washed 4X with 
Hypotonic cell lysis buffer. The crude nuclei pellet was resuspended in 2/3X PCV of 
Extraction Buffer (20 mM HEPES pH 7.9; 1.5 mM MgCl2; 420 mM NaCl; 25% Glycerol; 1 
mM DTT; 1:1000 benzonase (Sigma E1014-25KU); supplemented with proteinase inhibitors). 
The nuclear lysates were incubated at room temperature for 1 hour on the rotor and 
centrifuged at 4°C for 10 minutes at 21,000 x g. The supernatant was diluted to 150 mM 
NaCl using No-salt dilution buffer (20 mM HEPES pH 7.9; 1.5 mM MgCl2; 0.31 mM EDTA; 1 
mM DTT; supplemented with proteinase inhibitors) and saved as the nuclear fraction.  
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The exact protein concentrations in the fractions were measured with the Pierce™ 
BCA Protein Assay Kit (Thermo Fischer, Cat. No. 23225).  
For immunoprecipitation, NP-40 was added up to 0.25%, and the nuclear fractions 
were incubated with anti-FLAG M2 agarose (Sigma A2220-10ML) or anti-HA agarose 
(Sigma E6779-1ML) or Pierce Anti-HA Magnetic Beads (Thermofisher 88837) at 4°C 
overnight. Next day, the beads were washed 5X with Wash buffer (20 mM HEPES pH 7.9; 
150 mM NaCl; 0.2 mM EDTA; 0.25% NP-40; 1 mM DTT; supplemented with proteinase 
inhibitors). For Western blot the beads were boiled for 10 minutes in 1X Laemmli Sample 
Buffer (Bio-Rad, Cat. No. 1610737) containing BME. For MS, the beads were send on ice to 
the Proteomics and Metabolomics Facility Center for Biotechnology at the University of 
Nebraska–Lincoln. 
5.12. Protein identification by mass spectrometry (MS)  
Bead samples were made up in 60μL 1x non-reducing LDS sample buffer and 
incubated at 95°C for 10 min prior to loading 50μL of sample onto a Bolt™ 12% Bis-Tris-Plus 
gel and running briefly into the top of the gel. The gel was fixed and stained with colloidal 
coomassie blue G250 stain. Gel containing the proteins was reduced and alkylated, then 
washed to remove SDS and stain before digestion with trypsin (500ng) overnight at 37°C. 
Peptides were extracted from the gel pieces, dried down, and samples were re-dissolved in 
30μL, 2.5% acetonitrile, 0.1% formic acid. 5μL of each digest was run by nanoLC-MS/MS 
using a 2h gradient on a 0.075 mm x 250 mm CSH C18 column feeding into a Q-Exactive HF 
mass spectrometer.  
All the samples were analyzed using Mascot (Matrix Science, London, UK; version 
2.6.2). Mascot was set up to search the cRAP_20150130.fasta (123 entries); uniprot-
human_20191024 database (selected for Homo sapiens, unknown version, 74,034 entries) 
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assuming the digestion enzyme trypsin. Mascot was searched with a fragment ion mass 
tolerance of 0.060 Da and a parent ion tolerance of 10.0 parts-per-million. Deamidation of 
asparagine and glutamine, oxidation of methionine, carbamidomethylation of cysteine, 
phosphorylation of serine, threonine and tyrosine were specified in Mascot as variable 
modifications.  
Scaffold (version Scaffold_4.8.9, Proteome Software Inc., Portland, OR) was used to 
validate MS/MS based peptide and protein identifications. Peptide identifications were 
accepted if they could be established at greater than 80.0% probability by the Peptide 
Prophet algorithm (Keller et al. 2002) with Scaffold delta-mass correction. Protein 
identifications were accepted if they could be established at greater than 99.0% probability 
and contained at least 2 identified peptides. Protein probabilities were assigned by the 
Protein Prophet algorithm (Nesvizhskii et al. 2003). Proteins that contained similar peptides 
and could not be differentiated based on MS/MS analysis alone were grouped to satisfy the 
principles of parsimony. Proteins sharing significant peptide evidence were grouped into 
clusters.  
5.13. Co-IP in HEK293T cells 
One 80% confluent 10-cm plate of 293T cells was transfected with 10 μg HA-PDIK1L 
and 10 μg of either Empty vector, or FLAG-SCP4, or FLAG-SCP4236-466, or FLAG-SCP4D293A. 
Total 20 μg DNA was mixed with 60 μL of 1 mg/mL PEI and 1 mL of Opti-MEM®, 
incubated at room temperature for 15 minutes, and then added to the cells. 24 hours post-
transfection the whole-cell lysates were prepared as follows.  
Collected cells by incubation for 5 minutes with 2 mL Trypsin, then neutralized with 
6 mL DMEM media. Washed cells 2X with ice-cold PBS. Resuspended cells in 500 μL of ice-
cold Cell Lysis Buffer (CST, #9803). Incubated on ice for 30 minutes. Centrifuged at 4°C for 
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10 minutes at 14,000 x g.  
The exact protein concentrations in the fractions were measured with the Pierce™ 
BCA Protein Assay Kit (Thermo Fischer, Cat. No. 23225).  
Whole-cell lysates were incubated with anti-FLAG M2 agarose (Sigma A2220-10ML) 
or anti-HA agarose (Sigma E6779-1ML). Next day, the beads were washed 5X with the Cell 
Lysis Buffer. Afterwards, the beads were boiled for 10 minutes in 1X Laemmli Sample Buffer 
(Bio-Rad, Cat. No. 1610737) containing BME, followed by Western blot analysis. 
5.14. RNA-Seq 
For knockout experiments, cells were harvested on day 5 post-infection with sgRNA. 
RNA was purified with the guanidinium thiocyanate-phenol-chloroform extraction method. 
Briefly, cells were washed 1X with PBS and lysed with 1 mL of TRIzol (Thermo Scientific; 
Cat. No. 15596018). The samples were vigorously mixed with 200 µL chloroform and 
incubated for 3 minutes at room temperature, followed by centrifugation at 10,000 x g for 15 
minutes at 4 °C. The aqueous phase containing RNA was added to the equal volume of 
isopropanol, and RNA was precipitated after incubation of 10 minutes at room temperature. 
Precipitated RNA was then pelleted by centrifugation at 10,000 x g for 10 minutes at 4 °C 
and washed 1X with 1 mL of 75% ethanol. After air-drying for 10 minutes, RNA was 
resuspended in 20 µL of DEPC-treated (RNase-free) water.  
RNA-seq libraries were prepared using TruSeq sample prep kit v2 (Illumina) 
according to the manufacturer protocol. Briefly, polyA RNA was enriched with oligo-dT 
beads and fragmented enzymatically. The cleaved RNA fragments were reverse transcribed 
into first strand cDNA using SuperScript II reverse transcriptase and random primers. The 
RNA template was then removed, and a replacement strand to generate double-stranded 
(ds) cDNA was synthesized. The ds cDNA was purified with AMPure XP beads, end-
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repaired, 3’-adenylated, and ligated with indexing adapters, preparing them for 
hybridization onto a flow cell. The DNA fragments that have adapter molecules on both 
ends were selectively enriched by PCR-amplification and purified with AMPure XP beads. 
RNA-seq libraries were pooled together in equimolar concentrations and analyzed by 
single-end sequencing using NextSeq (Illumina). Four independent biological replicates for 
control samples, samples from cells with SCP4 knockout, and cells with STK35-PDIK1L 
double knockout were sequenced in the same flow cell. 
5.15. RNA-Seq data analysis 
Sequencing reads were mapped into reference human genome hg19 using STAR v.
2.5.2b-1 (Dobin et al. 2013). The mapped reads were assigned to genes using HTSeq-Count v.
0.6.1p1 (Anders et al. 2015). The differential expression gene analysis was performed using 
DESeq2, with four replicates for each sample (Love et al. 2014).  
Genes were ranked by their log2 fold change multiplied by the adjusted p-value 
(corrected for multiple testing) as input for GSEAPreranked analysis with all available 
signatures in the Molecular Signature Database v.7.2, complemented with various signatures 
generated in our laboratory.  
Pseudo-alignment to the reference human transcriptome (gencode v.35), assignment 
of reads to genes, and TPM calculation were all performed using Salmon (v.1.0) (Patro et al. 
2017).  
For comparison with other RNA-Seq datasets, raw RNA-Seq files from GSE109491 
and GSE104308 datasets corresponding to the available replicates of negative controls, 
sgTAF12, sgMYB, sgSIK3, and sgMEF2C were downloaded. All the raw datasets, including 
ours, were re-aligned (pseudo-alignment) using Kallisto to hg38, bootstrap 100 (Bray et al. 
2016). The differential expression gene analysis was performed using DESeq2, with four 
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replicates for each sample (Love et al. 2014).  
Pearson's product-moment correlations between global log2 fold changes observed 
upon different knockouts in MOLM-13 cells were calculated using cor() function in R with 
default parameters. Transcripts Per Million (TPM) values were calculated using Kallisto 
(Bray et al. 2016). 
5.16. Protein Expression and Purification 
The SCP4 phosphatase domain (encoding residues 156–466) was sub-cloned into a 
pET28a (Novagene) derivative vector encoding a 6xHis-tag followed by a SUMO-tag and a 
TEV protease site. BL21 (DE3) cells expressing SCP4 were grown in one-liter cultures at 37°C 
in Luria-Bertani (LB) broth (Thermo) containing 50µg/ml kanamycin. Once the cultures 
reached an OD600 value of 0.6–0.8, the protein expression was induced with 0.2 M isopropyl-
β-D-thiogalactopyranoside (IPTG), and the cultures were grown an additional 16 hours at 
18°C.  
The cells were pelleted and resuspended in lysis buffer (50 mM Tris-HCl pH 8.0, 500 
mM NaCl, 15 mM imidazole, 10% glycerol, 0.1% Triton X-100, and 10 mM BME) and 
sonicated at 90 A for 2.5 minutes of 1 second on / 5 seconds off cycles on ice. The lysate was 
cleared by centrifugation at 15000 rpm for 45 min at 4°C. The supernatant was loaded over 3 
ml of Ni-NTA beads (Qiagen) equilibrated in lysis buffer, then washed through with wash 
buffer containing 50 mM Tris-HCl pH 8.0, 500 mM NaCl, 30 mM imidazole, and 10 mM 
BME. The recombinant SCP4 was finally eluted with elution buffer containing 50 mM Tris-
HCl pH 8.0, 500 mM NaCl, 300 mM imidazole, and 10 mM BME. Protein fractions were 
pooled and dialyzed overnight at 4°C in a 10.0 kDa dialysis membrane (Thermo) against 
dialysis buffer (50 mM Tris HCl pH 7.5, 100 mM NaCl, and 10 mM BME) supplemented 
with 0.5 mg of TEV protease to remove the 6xHis and SUMO-tag.  
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The protein was then loaded onto a DEAE anion exchange column (GE) equilibrated 
with Buffer A (50 mM Tris-HCl pH 7.5, 10 M NaCl, 10 mM BME) and eluted with a 0-100% 
gradient of Buffer A to Buffer B (50 mM Tris-HCl pH 7.5, 500 mM NaCl, and 10 mM BME). 
Peak fractions were analyzed by SDS-PAGE before the fractions containing SCP4 were 
pooled and dialyzed overnight in gel filtration buffer containing 25 mM Tris HCl pH 8.0, 200 
mM NaCl, and 10 mM BME. The protein was finally polished using gel filtration 
chromatography with a Superdex 75 size exclusion column. Fractions containing SCP4 were 
pooled, concentrated, and flash-frozen at -80°C. 
5.17. Phosphatase activity assay 
Initial rates of phosphatase activity were determined by incubating SCP4 (1µM) with 
various concentrations of phosphopeptide (0–100 µM) in SCP4 assay buffer (50 mM Tris-
acetate pH 5.0, 10 mM MgCl2) in a 40µl reaction volume for 10 minutes at 37°C. 20µl of the 
reaction was then quenched with 40µl of BIOMOL Green reagent (Enzo Life Sciences) within 
a clear, flat-bottom 96-well plate. The mixtures were allowed to sit at room temperature for 
30 minutes for color development before reading the absorbance signal at A620 in a Tecan 
Plate reader 200. The A620 values were corrected by subtracting the A620 values of substrate 
only reactions at each substrate concentration. The readings obtained were converted to the 
amount of phosphate released through a Phosphate standard curve determined using the 
BIOMOL Green assay following the manufacturer instructions. The reaction rate was plotted 
for kinetic fitting to derive kcat/KM. Biological triplicates were prepared and analyzed 
independently to guarantee replication of experiments.  
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5.18. Metabolomics analysis by liquid chromatography coupled to mass 
spectrometry (LC-MS) 
Cells (0.6 mln cells/well) were seeded in 6 well plates after lentiviral infection with 
sgRNAs. On Day 5 post-infection, cells were quickly washed in PBS before adding 1 mL of 
ice-cold extraction solution (50% methanol, 30% acetonitrile, 20% H2O) per million cells. The 
cell suspension was snap frozen in liquid nitrogen. Samples were agitated using a tube 
rotator at 4°C for 15 minutes followed by incubation at -80°C overnight. Samples were then 
centrifuged at 15,000 rpm, 4°C for 10 minutes. The supernatants were collected and stored in 
autosampler vials at -80°C until analysis.  
Intracellular extracts from five independent cell cultures were analyzed for each 
condition. Samples were randomized in order to avoid bias due to machine drift and 
processed blindly. LC-MS analysis was performed using a Vanquish Horizon UHPLC 
system coupled with a Q Exactive HF mass spectrometer (both Thermo Fisher Scientific). 
Sample extracts (8 µL) were injected onto a Sequant ZIC-pHILC column (150 mm × 2.1 mm, 
5 µm) and guard column (20 mm × 2.1 mm, 5 µm) from Merck Millipore kept at 45°C. The 
mobile phase was composed of 20 mM ammonium carbonate with 0.1% ammonium 
hydroxide in water (solvent A), and acetonitrile (solvent B). The flow rate was set at 200 μl/
min with the previously described gradient (Mackay et al. 2015). The mass spectrometer was 
operated in full MS and polarity switching mode. The acquired spectra were analyzed using 
XCalibur Qual Browser and XCalibur Quan Browser software (Thermo Fisher Scientific) by 
referencing to an internal library of compounds.  
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5.19. Quantification and statistical analysis 
All statistical analysis and graphical representation of data was performed using 
GraphPad PRISM5 software. Error bars represent the mean plus or minus standard error of 
the mean, unless otherwise stated. 
5.20. Data and software availability 
The RNA-seq data from this study have been uploaded to GEO database with 
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Appendix 1. Categorization of human phosphatases targeted by 























CDC14A, CDC14B, DUSP1, DUSP10, DUSP11, DUSP12, 
DUSP13, DUSP14, DUSP15, DUSP16, DUSP18, DUSP19, 
DUSP2, DUSP21, DUSP22, DUSP23, DUSP26, DUSP28, 
DUSP29, DUSP3, DUSP4, DUSP5, DUSP6, DUSP7, 
DUSP8, DUSP9, EPM2A, PTEN, PTP4A3, PTPDC1, 









13 CTDP1, CTDSP1, CTDSP2, CTDSPL, CTDSPL2, EYA1, 










11 ENOPH1, EPHX2, LHPP, NANP, PHOSPHO1, 
PHOSPHO2, PMM1, PMM2, PNKP, PSPH, PUDP
Lipid phosphatases 3 LPIN1, LPIN2, LPIN3
Lipid 
phosphatases 46 Lipid phosphatases 46
BPNT1, DOLPP1, FIG4, IMPA1, IMPA2, INPP1, INPP4B, 
INPP5A, INPP5B, INPP5D, INPP5E, INPP5F, INPP5J, 
INPP5K, INPPL1, MINPP1, MTM1, MTMR1, MTMR10, 
MTMR11, MTMR12, MTMR13, MTMR14, MTMR2, 
MTMR3, MTMR4, MTMR5, MTMR6, MTMR7, MTMR8, 
MTMR9, OCRL, PIP4P1, PIP4P2, PLPP1, PLPP2, PLPP3, 





phosphatases 3 CDC25A, CDC25B, CDC25C
Protein 







PGAM5, SSU72, ILKAP, PDP1, PDP2, PHLPP1, PHLPP2, 
PPEF1, PPEF2, PPM1A, PPM1B, PPM1D, PPM1E, PPM1F, 
PPM1G, PPM1H, PPM1J, PPM1K, PPM1L, PPM1M, 
PPM1N, PPP1CA, PPP1CB, PPP1CC, PPP2CA, PPP2CB, 
PPP3CA, PPP3CB, PPP3CC, PPP4C, PPP5C, PPP6C
Sugar 
phosphatases 13 Sugar phosphatases 13
BPGM, FBP1, FBP2, G6PC1, G6PC2, G6PC3, PFKFB1, 







PTPN1, PTPN11, PTPN12, PTPN13, PTPN14, PTPN18, 
PTPN2, PTPN21, PTPN22, PTPN23, PTPN3, PTPN4, 
PTPN5, PTPN6, PTPN7, PTPN9, PTPRA, PTPRB, PTPRC, 
PTPRD, PTPRE, PTPRF, PTPRG, PTPRH, PTPRJ, PTPRK, 
PTPRM, PTPRN, PTPRN2, PTPRO, PTPRQ, PTPRR, 



















































































Appendix 2. Average log2 FC in phosphatase domain-focused screen (7/7)
APPENDICES 
Appendix 3. Average log2FC in SCP4 CRISPR exon 
scanning screen in MOLM-13 
Cut Site Cut Codon sgRNA Sequence log2FC
53 17 CTCTGGCAGTGCGTTGTGTT 0.48
66 22 AACGCACTGCCAGAGCAAAG -2.02
70 23 TGAATATTTCCTCTTTGCTC -0.88
79 26 AGCAAAGAGGAAATATTCAG 0.26
101 33 GTTGATGATAGCCTGCCTTC -0.47
104 34 GATGATAGCCTGCCTTCAGG -1.53
107 35 GTTTTTCTCCTCCTGAAGGC 0.83
111 37 GATGGTTTTTCTCCTCCTGA 0.44
129 43 AAGCCGGTTTCATTCTTCGA 0.34
131 43 AAACCATCGAAGAATGAAAC 0.51
145 48 TTTAATTGAAGACAACAAGC 0.62
164 54 TCAATTAAAAAATTTATTAA 2.75
204 68 AGAGAGAAAATCCTTCAAAA -0.77
210 70 TCAATTCTACTCCGTTTTGA 2.21
260 86 ATCACGTCAACACCAAGAGC -0.42
267 89 TTAGGTTTTTCTCCTGCTCT 0.77
285 95 ACTCGAGATATCTGTTTGTT 0.74
297 99 AACAGATATCTCGAGTAAGA -0.23
314 104 AGACGGAAAAGTCAAGTAAA -0.01
362 120 AATCAACATGTAAAACAAAA 2.28
386 128 TTAGAAGATAATCCTTCCTC 0.34
393 131 CTTGGAGGACTGCCAGAGGA 0.56
397 132 AGTCCTTGGAGGACTGCCAG 0.74
402 134 CTTCCTCTGGCAGTCCTCCA -1.47
408 136 CCCAACAAAGTAGTCCTTGG 0.84
413 137 CCTCCAAGGACTACTTTGTT 0.52
414 138 GTCCCCAACAAAGTAGTCCT 1.34
415 138 TCCTCCAAGGACTACTTTGT 1.80
417 139 CTCCAAGGACTACTTTGTTG 1.33
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436 145 GTTGAAGACAGGTGAAAATA 1.18
444 148 GGTGAAAAAAAGTTGAAGAC 0.30
488 162 ACGTCAGGATCAGATTCTCC 0.90
493 164 AGGATCAGATTCTCCAGGAC -0.23
499 166 AGATTCTCCAGGACAGGCTG 0.15
501 167 TCAGCTTCCACAGCCTGTCC -0.36
535 178 AATAGTAAAACAACTTGATA 0.52
541 180 ACAACTTGATATGGAACAGG 1.05
541 180 AAAACAACTTGATATGGAAC 1.07
571 190 ATTAGTTGATGTAGTAGTAC 1.26
578 192 AGTACTACTACATCAACTAA 0.56
629 209 GTGAGACCATCACTAAACAA 0.94
633 211 TCTAAACCATTGTTTAGTGA 0.76
699 233 TAACCACTATCTGGAGTTAC 0.08
708 236 GCTGATGAATAACCACTATC -0.13
721 240 TGGTTATTCATCAGCCCACG -0.11
727 242 TTATTCATCAGCCCACGCGG -2.04
731 243 CTTCATAGGTGGCCTCCGCG -1.32
733 244 TTCATAGGTGGCCTCCGCGT -0.68
745 248 TACTTCCCAGTCTTCTTCAT -1.88
745 248 TTCCCAGTCTTCTTCATAGG -0.67
745 248 GGCCACCTATGAAGAAGACT 0.29
747 249 AGGCCACCTATGAAGAAGAC 0.19
797 265 GTTGTTCTTCTGTCAGTGGC -0.06
801 267 AGTTGTTCTTCTGTCAGTGG -3.02
804 268 TTTAGTTGTTCTTCTGTCAG 2.16
810 270 TGACAGAAGAACAACTAAAT -3.88
834 278 CTTGTTTTCAACGGAAGAGC -2.03
840 280 GGTGTGCTTCTTGTTTTCAA -1.27
850 283 GTTGAAAACAAGAAGCACAC -3.61
945 315 ATGACATCTTGGAAAAGGAC -0.78
Cut Site Cut Codon sgRNA Sequence log2FC
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950 316 GATAAATGACATCTTGGAAA -3.02
989 329 ATTTCTTCTTTGCCAGTAGA 0.78
991 330 GAGATTAAGACCATTTTTCA -1.78
990 330 TGAGATTAAGACCATTTTTC 1.49
993 331 TCCAGGAATTCCCTGAAAAA -3.04
997 332 ACCATTTTTCAGGGAATTCC -3.36
1004 334 GCAAAGAAGAAATATACACA 1.50
1005 335 CAAAGAAGAAATATACACAA 2.46
1051 350 TCTTTTTACTGCTTCTAAGA 0.78
1099 366 ACTAGACCCTAAAAAGCAAC -1.42
1124 374 CACAATGTTCACGGAAAAGC -2.71
1130 376 GTACACAAACACAATGTTCA -2.81
1142 380 GAACATTGTGTTTGTGTACA 0.94
1156 385 TGTACAAGGAAACTATATAA -5.40
1260 420 ATGGAATCCCTATAGAAAGT -3.91
1260 420 TCCATAAACCAACTTTCTAT -3.79
1262 420 CCATAAACCAACTTTCTATA -2.41
1267 422 CCCTATAGAAAGTTGGTTTA -1.06
1301 433 CCAGGAATGGAATCAATTTT 1.20
1309 436 CCTAAAATTGATTCCATTCC -2.85
1356 452 CGAAATCTGTCTCTGATGTG -1.06
Cut Site Cut Codon sgRNA Sequence log2FC
222
APPENDICES 
Appendix 4. Genes downregulated upon SCP4 knockout 
sgSCP4_dn_MOLM13_spolyans
ACOT7 CHRNA6 HSD11B1 NPM2 SERF1A
ADAM11 COCH HSD11B2 NR1I2 SFXN2
ADAMTS13 COPZ2 HYAL3 NRARP SH2D2A
ADSSL1 CPNE5 IGFBP2 NRTN SHISA2
ALDH5A1 CPNE7 IGLL1 OBSL1 SKA3
ALS2CL CSPG5 IL2RB OIP5 SKIDA1
ANGPT1 CST7 IQSEC3 ONECUT2 SLC16A13
ANK2 CTDSPL2 IRX3 OPRL1 SLC22A31
ANKRD34A CTSG IRX5 ORM2 SLC25A10
ANO7 CUX2 ITGA11 OSBP2 SLC29A1
ANXA8 DDN JCAD OSM SLC29A4
ARHGAP23 DLEC1 KAZALD1 PACSIN3 SLC2A5
ARHGEF39 DLG5 KCNQ4 PALM SLC46A1
ASIC1 DMPK KDELC2 PAQR4 SLCO4A1
ATP1A3 DMWD KHK PIF1 SMIM10
ATP6V1C2 DOCK6 KIRREL2 PIMREG SMKR1
BSN DOK4 KLHL35 PKMYT1 SPRY4
C19orf57 DRP2 KRT86 PLS1 SYNPO2
C21orf58 DZIP1L LBHD1 PLXND1 TEDC2
C2orf48 EMID1 LDHD PNMA6A TERT
C3orf18 EMILIN1 LGALS12 PPM1E TLN2
CACNB3 EPDR1 LOC112268013 PRRT4 TMEM229B
CAMSAP2 ETV4 LRP11 PTK2 TMEM45A
CASKIN2 FAM57B LZTS1 PTPRN2 TNXB
CBSL FAM69B MAP2K6 PTPRS TP53I11
CBX2 FAM83H MAPK11 PYCR3 TRIM7
CCDC136 FAM86B1 MESP1 RAB26 TRNP1
CCDC142 FCGBP MINOS1-NBL1 RAD54L TSPAN32
CCDC182 FHL1 MLC1 RASIP1 TTC30A
CCDC85C FIBCD1 MORN1 RCOR2 TUBB4A
CCND1 FLRT1 MS4A3 RHEX TUSC1
CDC14B GAL MT1G RHOV TYRO3
CDC45 GATA2 MT1H RIBC2 ULBP2
CDCA7 GATM MTSS1L RIMBP3C VAT1L
CDH24 GINS1 MYH6 ROBO3 ZBTB16
CDK18 GOLGA7B MYL5 ROS1 ZBTB47
CDT1 GPR153 NFIX RPL22L1 ZDHHC11
CELSR2 GPT NOTUM RTN4R ZNF367
CENPM HES7 NOV SEMA3F ZNF469
CHRNA5 HIP1R NOXA1 SEPT5 ZP3
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Appendix 5. Genes upregulated upon SCP4 knockout 
sgSCP4_up_MOLM13_spolyans
A2M CST3 GSN MILR1 SAMD8
ABHD4 CTSZ HBEGF MPEG1 SAMHD1
ABTB1 CXCL8 HECA MS4A6A SCPEP1
ACPP CYBB HIST1H1C MTMR11 SDCBP
ADA2 CYP27A1 HMOX1 MTURN SEMA6B
ADAP2 CYSLTR1 HTR7 MVP SHTN1
ADCY6 CYTH4 IFI30 MYBPH SIGLEC7
AFDN CYTIP IGSF6 MYO1E SIPA1L2
ALOX5 DAPP1 IL10RA MYOF SKAP2
AOAH DPYD IL13RA1 NAIP SLAMF7
APOC1 DSC2 IL1A NATD1 SLC25A20
ARHGEF10L EEPD1 IL1B NBPF19 SLC37A2
ARHGEF3 EPB41L3 IPCEF1 NCF1 SLC43A2
ARPC4-TTLL3 EVI2A IQCN NEFM SLCO3A1
ARRDC3 EVI2B ISG20 NFXL1 SLFN5
ARTN FAM20C ITGB7 NLRC4 SNX18
BCL3 FAM210B JAK2 NTNG1 SORT1
BMF FAM214B JAML OR52K2 SQSTM1
BTG2 FAM49A KCNE3 PDK4 SRC
C1orf162 FCAR KCTD12 PELI2 STX11
C1orf54 FCGR2B KCTD7 PHLDA1 SULF2
C6orf226 FCGR3A KIAA0513 PIGR TCEAL4
CA2 FCGRT KIAA1551 PIK3IP1 TFEC
CALCOCO1 FCMR KLHDC8B PITPNM1 TGFBR2
CAMK2D FGL2 LACTB PKD2L1 THEMIS2
CCDC144NL FIG4 LIPA PLD3 TLR1
CCM2 FILIP1L LOC101059949 PLEKHO1 TLR2
CD101 FRY LOC102725035 PLIN2 TLR8
CD109 FTH1 LOC112268354 PLK2 TMEM176B
CD180 FUCA1 LOC441155 PPP1R15A TNFAIP2
CD36 GABARAP LOC643802 PRDM1 TP53INP1
CD82 GABARAPL1 LPAR6 PRKCA TSHZ3
CD84 GAPT LPXN PSAP TYROBP
CDKN1A GAS7 LRRK2 PTPRO VSIG4
CHST15 GDF15 LSP1 RAB43 VSIR
CLEC10A GLIPR1 LYZ RBM47 YPEL3
CNTN4 GPR137B MAP3K3 RCBTB2 YPEL5
COLQ GPR141 MCOLN1 RHOC ZFYVE16
CPEB4 GPR183 METTL7A RTL5 ZNF257
CREBRF GPR34 MFSD14C S100A6 ZNF366
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Appendix 7. Primers for the generation of CRISPR-resistant constructs 























































Appendix 8. sgRNAs; media and cytokines; and antibodies used in 
flow cytometry panels in CD34+ experiments 
Antibodies used in flow cytometry panels
Lineage Antibody Clone Manufacturer Catalog #





GA-R2 (HIR2) (RUO) BD Pharmingen™ 559943
APC Anti-Human 
Band3
New York Blood Center Gift from X. An
Myeloid PECy7 CD11b ICRF44 Biolegend 301322
BV421 CD33 clone HIM3-4 BD Bioscience 744350
Megakaryocyte PECy7 CD41a clone HIP8 BD Bioscience 561424
BV421 Anti-Human 
CD42b
Clone HIP1 BD Bioscience 740075
Media and cytokines








Human Stem Cell 
Factor (hSCF)
R&D systems rhSCF, 255-SC/CF 100 ng/mL
Thrombopoietin (TPO) R&D systems rhTPO # 288-TP/CF 100 ng/mL
FLT3-Ligand (FLT3-L) R&D systems rhFlt-3 # 3088-FK/
CF)
100 ng/mL
Penicillin-Streptomycin Thermo Fisher 
Scientific





























(Common to all 
phases)
IMDM (base) Thermo Fisher 
Scientific
12440061
Human Male AB 
Plasma
SeraCare 1810-0001 2%
Human AB Serum Atlanta Biologicals S40110 3%
Heparin Sagent Pharmaceuticals NDC # 25021-401-02 3 UI/mL
Insulin Lilly Humulin® R U-100, 
NDC # 0002-8215-17
10 μg/mL






Medium Component Manufacturer Catalog #
Final 
Concentration
Penicillin-Streptomycin Thermo Fisher 
Scientific





(phase I): Add 





Millipore Sigma T0665 200 μg/mL
Human Stem Cell 
Factor (hSCF)
R&D systems rhSCF, 255-SC/CF 10 ng/mL
Human IL-3 R&D systems rhIL-3, 203-IL/CF 1 ng/mL
Erythroid 
Differentiation 
(phase II): Add 





Millipore Sigma T0665 200 μg/mL
Human Stem Cell 
Factor (hSCF)
R&D systems rhSCF, 255-SC/CF 10 ng/mL
Erythroid 
differentiation 
(phase III): Add 





Millipore Sigma T0665 1 mg/mL
The sequences of sgRNAs and primers
Assay Name Sequence (5ʹ to 3ʹ)
Single guide RNAs e’ refers to the exon # that is targeted by each sgRNA. Underlined 



















* 2’-O-methyl modification and phosphorothioate internucleotide 
linkage.  
Chemically modified versions of sgRNA-1 contained 2’-O-methyl 
modifications and phosphorothioate linkages in the first and last 3 
nucleotides. gRNAs were synthesized by Trilink.
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The sequences of sgRNAs and primers
Assay Name Sequence (5ʹ to 3ʹ)
Indels by RT-qPCR









chr10_fwd (negative control) TTAATTTTGGTTCAGGTGGTTGA
chr10_rev (negative control) ACCAACACTCTTCCCTCAGC
Indels by Surveyor
SCP4e7_Surv_fwd AGGTATTTGAAACTTTTAATGGGGC
SCP4e7_Surv_rev AAGAAAAGGGTTATGGTCTTGCATA
SCP4e12_Surv_fwd TGAATGGGAGATATGGTCACTGTAT
SCP4e12_Surv_rev CAGTACACACAAAGCAAAGACATTT
230
